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” Tell people what it 
is like this Motor 
Neurone Disease. Then 
maybe someone will find 
a cure. Then it won’t 







CON A : Concanavalin A
PHA : Phytohaemagglutinin
PWM : Pokeweed Mitogen
PBS : Phosphate Buffered Saline
TBS : Tris Buffered Saline
FCS : Fetal Calf Serum
DHS : Donor Horse Serum
LCM : Lymphocyte Culture Medium
SFM : Serum Free Medium
SSM : Serum Supplemented Medium
MEM : Minimal Essential Medium
DMEM : Dulbecco’s Modified Essential Medium
HAT : Hypoxanthine, Aminopterin, Thymidine
HT : Hypoxanthine, Thymidine
DNA : Deoxyribonucleic Acid
RNA : Ribonucleic Acid
AP : Alkaline Phosphatase
HRPO : Horse Radish Peroxidase
ELISA : Enzyme Linked Immunoabsorbent Assay
CELIA : Competitive Enzyme Linked Immunoabsorbent Assay
MND : Motor Neurone Disease
MS : Multiple Sclerosis
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SUMMARY
1) Conditions for the stimulation of peripheral blood lymphocytes 
with Con A, PHA, and PWM have been developed for 5 assay systems. 
Sub-optimal mitogen concentrations were established for the
3 3 3
incorporation of [ H]-thymidine, [ H]-leucine, and [ H]-uridine , 
into DNA, protein and RNA respectively, and for assays based on 
the release of lactate and glucose uptake. Stimulation of 
lymphocytes from MND patients by either Con A or PHA was found to 
be significantly depressed relative to normal age-matched
3 3
controls as shown by the incorporation of [ H]-thymidine or [ H]- 
leucine or by glucose uptake. Stimulation of lymphocytes from MS 
patients by either Con A and PHA was also found to be 
significantly depressed compared to age-matched healthy controls.
3 3
The incorporation of [ H]-thymidine, [ H]-leucine, the uptake of 
glucose and the release of lactate were all found to be 
significantly depressed.
2) Neurone-rich cultures from rat spinal cord cells were 
established. The cells were cultured in serum-supplemented 
medium for the first 3 days and subsequently in serum-free 
medium. The neuronal cells matured up to day 15-20 with large 
cell clusters and thick processes. These clusters and processes 
were labelled clearly with tetanus toxin which is a neurone cell 
marker. Membranes were prepared from 15-day old rat spinal cord 
cell cultures and used to stimulate peripheral blood lymphocytes
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from MND patients and normal age-matched controls. There were 4 
out of 14 MND patients that showed a blastogenic response 
compared with 0 out of 9 normal controls.
3) Peripheral blood lymphocytes from healthy donors were 
stimulated with Con A, PHA or PWM in serum-free medium. 
Stimulation with Con A and PHA was not significant with all 5 
assays (previously described). However, with PWM, stimulation 
indices were significant (p < 0.01).
Lymphocytes from MND patients and normal healthy controls 
were cultured with rat spinal cord. Lymphocytes from 3 out of 3 
MND patients were significantly stimulated compared with those of 
0 out of 3 controls.
4) An ELISA was established for detecting anti-neural 
membrane antibody-producing hybridomas from MND lymphocytes. It 
involved coating individual wells with rat spinal cord membrane 
fragments. A similar assay for monoclonal anti-myelin basic 
protein antibodies was developed for MS-derived hybridomas.
5) Lymphocytes from MND, MS and normal individuals were fused 
with the mouse myeloma cell line P3. X63“Ag8-653• Normal and MND
lymphocytes yieded hybridomas in 50% of the wells whereas the 
corresponding figure for MS lymphocytes was only 11$. 9% of the
MND colonies and 2% of the MS colonies were found to be positive 
for their respective antibodies. These remained stable after 
recloning for 3 months. The principal immunoglobulin secreted was
8
of the IgG class.
Stimulation of MND, MS and normal lymphocytes with PWM for 5 
days prior to fusion. Stimulation increased the number of cells 
for fusion by approximately 20%. However, this did not alter the 
percentage of hybridomas formed, except in the MS samples where 
the percentage rose from 11% to 50%. Similar numbers of hybrids 
secreted IgG and were positive for their respective antibodies. 
The colonies were recloned by limiting dilution and remained 
stable for over 3 months.
Lymphocytes from MND, MS and normal donors were initially 
stimulated with PWM for 5 days and then transformed with Epstein- 
Barr virus. It was found that 90% of wells contained colonies, 
which grew quickly and equal numbers of colonies secreted IgG or 
IgM. The number of positive colonies was 9% in MND and MS 
patients. The clones remained positive for over 3 months.
The culture supernatants which were positive with the ELISA 
were tested for binding to cultured rat spinal cord cells by 
immunofluorescence. There was no detectable binding of 
immunoglobulin to the cultures by immunofluoresence even after 
concentrating the culture supernatants by salt fractionation.
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SECTION 1 THE IMMUNE SYSTEM
Section 1 The Immune System
The essential function of the immune system is defence against 
infection and the complexity of the system derives from an 
intricate communications network capable of exerting multiple 
effects based on relatively few distinct cell types. A normally 
functioning immune system is an effective defence against foreign 
agents such as bacteria, and against native cells which transform 
into tumour cells. The system produces a specific reaction to 
each infectious agent which prevents reinfection later.
The immune system comprises a variety of molecules and cells 
which are distributed throughout the body.
1.1. Components of the Immune System
1.1.1. Cellular Components
The differentiated cells of the lymphoid system, macrophages 
and lymphocytes, have their origin in pluripotent stem cells 
present in bone marrow. Lymphoid cells that undergo 
differentiation and acquire immunocompetence in the thymus give 
rise to re-circulating populations of mature T-cells. T-cells 
take part in a wide range of cell-mediated immune reactions which 
include protection from infection by fungi and viruses, graft 
rejection, and immune surveilance (Gupta, 1980). They comprise 
10% of peripheral lymphocytes (Gupta & Good, 1980) and can be 
recognised by their capacity to form rosettes with sheep red 
blood cells (Aiuti et al, 1975; Taylor et al, 1977) and by the
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presence on their membranes of targets for specific monoclonal 
antibodies (Haynes, 1981). They are concerned with the regulation 
of other lymphoid cells in the immune system and can be divided 
into effector and regulatory cells.
Effector T-lymphocytes are responsible for such functions as 
cytotoxicity and lymphokine production. Cytotoxic T-cells are 
produced, for example, when the host cells are infected with 
virus, or when a foreign tissue graft is introduced. Surface
receptors of cytotoxic cells recognise transplantation antigens 
on the target cell, bind to the latter, and within a matter of 
minutes, bring about cytolysis (Cosimi, 1981; Ellis et al, 1982). 
Lymphokines are biologically active soluble factors some of which 
influence the movement and activity of macrophages.
Regulatory T-cells are divided into two major subclasses. T- 
helper (Th) and T-suppressor (Ts) which are involved in the
regulation of antibody production by B-cells. Ts cells represent 
about 35# of the peripheral T-cells in a normal individual and
inhibit the differentiation of B-cells into antibody-secreting 
plasma cells. Antigen-specific suppressor T-cells regulate the 
clonal expansion of B-cells by sending an inhibitory signal
(Roitt et al, 1985) as shown in Figure 1. All T-cells recognise 
antigen but secrete only mediator substances. Th cells represent 
about 65# of peripheral T-cells and can also induce T suppressor 
or cytotoxic cell function (Reinherz and Schlossman, 1980). This
20
is shown in Figure 2. T helper and T suppressor can be identified 
by monoclonal antibodies (Table 1.)






Anti-T3, Anti-Leu 4 55_80
Anti-Til, Anti-Leu 5 60-85

















Macrophages Pre-killer Cells B-cells
Helper T-cells 
Suppressor T-cells 
Figure 1. Negative Feedback of Suppressor T Cells
Maturation of lymphoid cells in the bone marrow produces B- 
cells, a fundamentally different class of immunocompetent 
lymphocytes which can be recognised by their membrane bound 
immunoglobulin (Ig) (Baran, 1985)• When triggered by the 
appropriate antigen, the B-cells differentiate further into 
memory cells, antibody-producing plasma cells, and regulatory B 
lymphocytes, which also secrete antibody. This lymphocyte 
population represents 10-20 % of peripheral blood lymphocytes in 
a normal individual. Antibodies secreted by the B-cells serve as 
protection against bacterial, and some viral infections ( Gupta & 
Good, 1980).
None of these functionally distinct populations act in 
isolation but must cooperate with macrophages, antibody and each 
other to regulate the immune response (Figure 2).
1.1.2. Humoral Components of the immune system
1.1.2.(a) Antibodies 
Antibodies are the best characterised molecules of the immune 












A cell "presents" the antigen plus the major histocompatibility 
complex M.H.C. (a). This activates a helper T cell with a suitable 
receptor. The helper T cell sees the same antigen-MHC combination 
on a B cell (b). Here the antigen is held by surface antibody, and 
the interaction triggers the B cell to produce lots of antibody 
thus neutralizing circulating antigen.
into plasma cells. Five classes of heavy chains are found in 
human sera (IgG, IgM, IgA, IgD, IgE) and two light chain classes 
(kappa and lambda) Table 2 lists some of the characteristics of 
the immunoglobulins.
TABLE 2 CHARACTERISTICS OF IMMUNOGLOBULIN
IgGl IgG2 IgG3 IgG4 IgM IgAl IgA2 IgD IgE
















4 4 4 4 5 4 4 4 5
Carbohydrate
{%) 2-3 12 7-11 9 12
Antibody molecules have three main functions, complement-mediated 
cell lysis, antibody-mediated cell cytotoxicity, (via killer 
cells), and direct agglutination of particular antigens (e.g. 
bacteria) followed by removal of the complex by macrophages. 
Immune complexes are formed when antibody cross-links with 


















Classical Pathway Alternative Pathway
FIGURE 3 The Pathways of Complement
1.1.2.(b) Complement
Complement consists of a complex series of proteins many of which 
are proteinases. These proteins form two interrelated enzyme 
cascades termed the classical and alternative pathways (see 
Figure 3«). both providing different routes to the cleavage of 
C3. The enzyme cascades are generated by the activation of enzyme 
precursors which are, in turn, fixed to the membrane surface. 
Each enzyme precursor is activated by the previous component of 
complement which proteolytically converts the precursor to its 
catalytically active form. Each step is amplified as each enzyme 
activates many enzyme precursors. The complement system performs 
three main functions: cell activation: cytolysis: and
opsonisation for phagocytosis.
1.1.2.(c) Lymphokines
Antigen-activated T-cells release mediators known as lymphokines. 
These are also released by B-cells, although more is known about 
those released from T-cells . There are many lymphokines with 
different functions. These are summarised in Table 3*
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TABLE ^ FUNCTIONS OF LYMPHOKINES
FUNCTIONS OF LYMPHOKINES : LYMPHOKINE





: T-cell replacing factor
2) Regulation of other lymphocytes : Assorted antigen specific
helper factors
: Assorted antigen specific
suppressor factors
3) Induction of Inflammation : Skin reactive factor





5) Regulation of other tissues : Colony stimulating factor
: Osteoclast activating factor
6) Destruction of non-leucocyte cells : Lymphotoxins
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1.2. The Immune System and the Central Nervous System
1.2.1. CNS; an immunologically privileged site
For many years the brain was regarded as being inert 
immunologically. These ideas stemmed from experiments carried out 
early in this century with transplantations and viruses. Grafts 
in the brain were found to be more successful (Murphy and Slurm, 
1923), even cross species, and viruses were able to proliferate 
unhindered in brain tissue (Theiler,1930).This led to the idea 
that the brain was not under immune surveillance with the rest of 
the body but was surrounded by a barrier preventing the entry of 
antibody and immunocompetent cells.
These views have now been modified. It is now known that the 
brain is only partially privileged and that most of the effector 
cells involved in the immune response are present in low numbers 
within the CNS (Traugott et al, 1981; Aarli, 1983). Pluripotent 
stem cells have even been reported (Bartlett, 1982; Phillips et 
al, 1982). However, the proportions of different immunocompetent 
cells in the brain are not the same as in the peripheral blood or 
lymphoid organs (Circolo et al, 1982). The brain can reject 
grafts (Scheinberg et al, 1964) and can elicit immune responses 
(De Micco et al, 1986). There is no organised lymphatic system in 
the brain indicating that the brain is not normally exposed to 
antigenic attack (Darling et al, 1981). The brain is a partially 
immunologically privileged site with the tissue being sequestered
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during the development allowing only a few cells to reach the 
brain through a barrier : the blood brain barrier which controls
the passage of fluids and cells into and out of the brain (Moser 
et al, 1976; Lisak and Zweiman, 1977; De Micco et al, 1986).
1.2.2. Blood Brain Barrier
The neural tissues are surrounded by a series of functional 
barriers regulating the entry of fluids, electrolytes, small 
molecules and protein from the blood into the extravascular space 
(Bradbury, 1979)(See Diagram 4.).
The passage of the above components into the brain takes 
place by a variety of methods including diffusion, active- 
transport, and pinocytosis. The rate of entry is regulated by the 
cerebral capillary cells and the glial cells. Neural tissue is 
very closely packed together, being derived from ectoderm, and 
the cells are like the epidermal layer of the skin forcing fluid 
to pass through rather than around the cells. The brain and 
spinal cord are bathed in cerebral spinal fluid (CSF) which is 
derived from the plasma . It has a very low concentration of 
protein which is prevented from entering by the tight junctions 
of the cuboidal cells forming the choroidal epithelium and the 
endothelium of the cerebral arteries. The arachnoidal cells 
prevent proteins from diffusing into the CSF from the outer 
layers of the arachnoid. Even with all these barriers there are 
still discrete areas of the brain where protein molecules and 














FIGURE 4 The Blood Brain Barrier
The isolation of the brain from all other tissues can be 
easily demonstrated by injecting trypan blue or Evan’s blue 
intravenously. The dye soon equlibriates and diffuses out of the 
blood into surrounding tissue. If the tissue is then examined for 
dye the only tissues not stained are those of the brain and 
spinal cord. A similar experiment can be repeated by injecting 
the dye into the brain when only the brain and spinal cord are 
stained (Leibowitz and Hughes, 1983)•
(c) The local immune response in the CNS
Immunoglobulin enters the CNS by diffusion depending on the 
levels of immunoglobulin in the serum. IgG and IgA occur in low 
but measurable amounts, whereas only traces of the other 
immunoglobulins are present. The levels are low compared to those 
in the serum. Small molecules are able to pass into the brain 
more easily which explains why IgM, with a high molecular weight, 
is only present in trace amounts in the CSF. Albumin, a 
relatively low molecular weight protein, is the most abundant 
protein in the CSF and can be used to measure how intact the 
blood brain barrier is.
Complement components C1-C4 are present but only in very low 
amounts, whereas the C5-C9 have not as yet been detected in the 
CNS (Bradbury, 1979)*
The brain is partially isolated from the normal lymphatic 
system of the body, has no organised lymphoid tissue of its own
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and is without lymph nodes (Darling et al, 1981). There are 
permanent populations within the CNS of native immunocompetent 
cells including macrophages (Circolo et al, 1982), T and B 
lymphocytes (Traugott et al, 1981; Kreth et al, 1982) and 
haemopoietic stem cells (Bartlett et al, 1982) capable of 
initiating an immune response. Accordingly only a few B and T 
lymphocytes in the CNS.
Inflammation can cause any of the barriers previously 
described to break down (Vandenbark et al, 1985), allowing plasma 
proteins, immunoglobulins and complement components into the CNS. 
The increase in cerebral vascular permeability can be shown by 
measuring the albumin in the CSF and the serum. If the ratio of 
the two is raised then this indicate some breakdown of the blood 
brain barrier.
As part of the inflammatory process B and T lymphocytes 
enter the CNS and immunoglobulin is synthesised intrathecally. 
Local production of antibody is most pronounced in chronic 
inflammatory disorders such as syphilis. An increase in CSF IgG 






Autoimmunity is that state where the immunological response is 
directed at the organism’s own antigens. It may be transient and 
reversible or persistent and life threatening. There is an entire 
area in clinical medicine concerned with illnesses in which 
autoimmunity plays a dominant pathogenic role; in many of these 
the detailed pathogenesis and etiology have not been eludicated. 
There are autoimmune diseases which are mediated by attack on a 
target organ and are known as organ specific. An autoimmune
disease where the effect is widespread is known as a non-organ 
specific disease.
Normally the immune system reacts against foreign antigens 
without attacking 'self' components. Such self tolerance is 
essential for health and when it breaks down autoimmune diseases
occur (Ehrlich, 1900). However, the immune system displays a
complexity, which includes a requirement for self recognition. 
Internal regulation involves certain cell-cell interactions 
which do not occur efficiently unless there is a recognition by 
one cell of self determinants on the other. Aurameas et al (1984) 
demonstrated the abundance of autoantibodies in serum of normal 
individuals. Autoantibodies are consistent with health ( Holmberg 
et al, 1984; Prabhaker et al, 1984; Dighiero et al, 1985) yet
their uncontrolled production may lead to disease.
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The original hypothesis of Burnet and Fenner (1959) that all 
anti-self lymphocytes are eliminated before being allowed to 
mature, is now not acceptable because anti-self B-cells are 
present in adults. Yet the immune system regulates the production 
of autoantibodies and remains unresponsive to self-antigens 
(tolerant). There are three main possibilities of how this 
tolerance is achieved. The first of these involves clonal 
elimination during the development of the immune system. During 
their differentiation B and T cells go through a phase where 
contact with antigen (self or foreign) induces tolerance. In some 
way the cells receive a signal which makes them tolerant, either 
by elimination or by causing functional inactivation without cell 
death (Roitt et al, 1985) suggest the deletion of anti-self T 
helper cells making the B-cell clones unable to respond to 
antigen. Lymphocytes are rapidly replaced so this form of 
tolerance must be an active continual process (Ryan et al, 1984).
The second mechanism involves compartmentation and exclusion 
from the immune system. Certain antigens such as lens proteins, 
brain antigens and spermatazoa become sequestered in avascular 
sites during development, making them antigenic to the host. 
Their release would then induce autoantibody formation. Yet many 
autoantibodies are found in normal individuals and they are often 
not destructive. If the sequestation theory is correct, then 
lymphocytes would have to be under some form of active continuous 
control (Teale et al, 1980; Heshmati et al, 1984)
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The third idea is that of active suppression which proposes 
the continuous suppression of the T helper and B-cell functions 
by the enhancement of T suppressor cells. This role of T
suppressor cells is still unproven (Green et al, 1983)•
Autoimmunity defines a state where self tolerance
terminates, and the disease occurs as a result of antibodies or 
cells reacting with self constituents. There are three major 
effector mechanisms which induce tissue damage, more than one of 
which can operate in one individual with the disease. This helps 
to explain the variability amongst patients with the same
syndrome even those who are closely related. The tissue deimage is 
mediated either by the action of autoantibodies, the action of 
immune complexes or by sensitized T lymphocytes (Senitzer et al,
1984).
Autoantibodies cause destruction to tissues by binding to
the cell surface and initiating complement activation and lysis. 
Myasthenic sera cause complement mediated cell lysis to cultured 
muscle cells.(Childs et al, 1985)• However damage can also occur 
as a result of antibody dependent cell-mediated cytotoxity, when 
cells with a cytotoxic potential and possessing Fc receptors for 
immunoglobulin bind and lyse target cells already coated with 
antibody. This happens in Multiple sclerosis (Baumhefner et al,
1985). In addition to these mechanisms, antibodies can induce 
disease by binding to functional receptors so inhibiting (e.g. 
pernicious anaemia), blocking ( myasthenia gravis) or
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stimulating (Grave’s disease) functions without actually killing 
the cells .
Another factor to cause damage is the formation of immune 
complexes which are deposited in many tissues of the body. These 
complexes are believed to be formed in the circulation or 
intercellular fluids being usually deposited in tissues with 
large filtering membranes. The kidney, skin, brain and joints are 
therefore most affected by the damage which usually arises from 
complement, and the attraction of macrophages and granulocytes 
(Koffler et al, 1982).
Cell-mediated immunity also gives rise to tissue damage 
through cell-mediated cytotoxcity. This involves many cell types 
which, when they become closely bound to the target cell, give 
”the kiss of death” ie they lyse the target cell. Such cells are 
usually T-cells and are known as cytotoxic T-cells. Cytotoxic T- 
cells bind to the target cell via the major histocompatability 
antigen; a specific antigen but no antibody is required. After 
binding, the membrane permeability of the target cell is altered, 
followed by swelling, disruption and lysis. The T-cell survives 
to go and lyse more cells. In autoimmunity, cytotoxic T-cells 
are sensitised to self antigens and either cause tissue lesion 
themselves, attract macrophages via lymphokines or secrete 
destructive lymphokines. In multiple sclerosis (MS), the 
cytotoxic T-cells outnumber T helper cells by 5:1 in the cerebral 
spinal fluid compared to healthy controls. There is also
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migration of the T helper cell from the peripheral blood into the 
CNS of MS patients where further destruction occurs (Booss et al,
1983).
Autoimmunity develops in individuals either through a 
genetic defect or a defect in the immune system. There is 
undoubted familial incidence of autoimmunity e.g. thyroid 
autoantibodies are linked with abnormalities of the X chromosome. 
These genetically linked autoimmune diseases are more often 
specific for one organ, (e.g. Hashimoto’s disease) and patients’ 
relatives often have a high titre of thyroid autoantibodies 
(Roitt et al, 1985). Further evidence for the operation of 
genetic factors in autoimmune diseases is given by the fact that 
they tend to show associations with particular HLA specificities 
(e,g B8, Dr4 in Rheumatoid arthritis, B8, Dr3 in Myasthenia 
Gravis and Addison’s disease)(Harrison and Behan, 1986).
Immunological control mechanisms operate in the normal 
individuals who possess both self-reactive lymphocytes and 
autoantibodies. These must be suppressed to prevent autoimmunity 
occurring. Autoimmunity may arise by direct activation of T 
helper cells or activation of another cell which renders T helper 
cells resistant to suppression. Autoantigens could also by-pass 
the T helper cells to directly stimulate the T effectors and B- 
cells. Also defects in antigen specificity can inactivate T 
suppressor cells, non-specific T suppressors or idiotypic T 
suppressors.
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Some clones of self reactive B-cells show an innate ability 
to respond without the requirement for T-cell help and the 
primary defect may lie in these cells. B-cells can be triggered 
directly to produce autoantibodies by polyclonal activators such 
as Epstein Barr virus or bacterial polysaccharides. These 
autoantibodies are however only of the weakly binding IgM class 
which cause little damage so are unlikely to be of primary 
importance. However in genetically predisposed hosts they may act 
as accelerators of the disease ( Jyonovchi et al, 1981).
Also cross-reactivity of exogenous agents with host antigens 
can lead to autoimmunity. A severe infection with hemolytic 
streptococcus which causes acute rheumatic fever can often elicit 
an immune response where the antibodies cross react with self 
cardiac muscle antigens (Kaplan et al, 1964).
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2.2. Examples of Autoimmune Diseases
2.2.1. Myasthenia Gravis
Myasthenia Gravis (MG) is an organ specific autoimmune 
disease affecting predominantly young women. The disease is 
characterised by extreme muscle weakness associated with 
antibodies to the acetylcholine receptor (ACHR) present on the 
surface of the muscle membranes. The ACHRs are localised at the 
motor end plate where the nerve impulse is transmitted by the 
release of acetylcholine from the nerve terminal to the muscle. 
In MG the ability to synthesise or release acetylcholine is not 
affected. Examination of the motor end plates by 
immunocytochemical techniques demonstrates IgG, C3 and C9 
deposited on the post-synaptic folds of the muscle (Sahashi et 
al, 1980). Few cells infiltrate the MG end plates, so effector 
cells are rarely involved. The means by which loss of ACHR occurs 
is still unclear but the anti-ACHR antibody probably consitutes 
the primary agent. Autoantibodies could act via one or more of 
three mechanisms, namely: the direct blockade of the receptor by 
antibody; complement-mediated lysis of the post synaptic membrane 
and the accelerated degradation of the post-synaptic membrane 
(antigenic modulation).
Workers have sought for abnormalities in the cellular immune 
system in MG (Lisak et al, 1982; 1985) For the regulation of the 
immune response, normal functioning of distinct lymphocyte
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subsets is necessary. The total number of B and T lymphocytes 
reported in MG compared to normal controls have been determined 
by many groups of workers with no clear conclusions. The overall 
indications are of increased B-cells and decreased T-cell 
populations in both the thymus and peripheral blood (Harrison and 
Behan, 1986).
An idea of Miller and Schwartz (1982) that defective 
suppressor T-cell activity could result in the elevated levels of 
anti-acetylcholine receptor antibodies found in MG was supported 
by demonstrations in such patients of elevated levels of other 
autoantibodies (Huang et al, 1981; Limburg et al,1983; Smith et 
al, 1984). However, if one removes the suppressor T-cell 
population from normal individuals, anti-acetylcholine receptor 
antibodies are not synthesised (Lisak et al, 1984). The relative 
proportions of T-cell helper and T-cell suppressor populations of 
MG patients have been compared to normal controls. The results 
are conflicting and inconclusive (Harrison and Behan, 1986).
Studies of the in vitro responses of peripheral blood 
lymphocytes to non-specific mitogens have been shown to be normal 
(Housley and Oppenheim, 1967; Abdou et al, 1974; Tronconi et al, 
1979; Wijermans et al, 1980; Trotter et al, 1982) and impaired 
(Simpson et al, 1976; Huang et al, 1977; Zilko et al, 1979; Sagar 
et al, 1980; Berrih et al, 1981; Koethe et al, 1981; Dropcho et 
al, 1982) in MG patients. However the proliferative response to 
acetyl choline receptor has been consistently reported to be
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increased (Harrison and Behan, 1936).
Multiple Sclerosis
Multiple Sclerosis (MS) usually occurs in young adult life with 
symptoms developing over a period of years. The characteristic 
lesions of MS are sharply demarcated plaques of demyelination in 
the CNS (Lumsden, 1972). They are present in the brainstem, 
cerebellum, spinal cord and optic nerves. In histological 
sections stained for myelin the sheath is seen to cease abruptly 
at the margin of the plaque, the neurones and axis cylinders 
survive but may disappear in time.
The most widely held theory about the aetiology and 
pathogenesis of MS invokes autoimmunity (Leibowitz, 1983)*
Blood lymphocyte numbers have been found to be normal in MS 
(Weiner et al, 1979; Hauser et al, 1981; Brinkman et al, 1982) 
yet there are a few reports of reduced numbers (Reddy et al, 
1976; Sagar et al, 1979)* The lymphocyte count does not seem to 
vary with MS disease activity (Hauser et al, 1981) or duration 
(Brinkman etal, 1982). The majority of data indicate that the 
percentage of T lymphocytes in the blood of MS patients is not 
significantly different from normal controls or patients with 
other neurological disease, although a number of studies report a 
decrease in T-cell number in the blood of MS patients when the 
disease is clinically active. T-cell suppressor activity has been 
reported to be defective when the disease is active and normal 
when the disease is stable (Antel, 1978; Huddleson and Bloom, 
1979)• However a concensus on the results of lymphocyte sub-
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1979). However a concensus on the results of lymphocyte sub­
populations in MS as compared to normal controls has not been 
achieved by different groups of workers. Several studies showed 
an elevated number of B-cells especially with a decrease in T- 
cells (Reddy et al, 1976; Lisak et al, 1975; Schauf et al ,1977; 
Sagar et al, 1979)* There is one report however of a decreased 
number of B-cells in the blood of MS patients (Kam-Hansen et al, 
1978 ). T suppressor cells have been reported to increase with
exacerbations (Antel et al ,1978; Antel et al, 1979)•
In a number of reports MS blood lymphocyte proliferative 
responses to various mitogens were found not to differ from those 
of normal controls (Weiner et al, 1979; Goust et al, 1980; Schauf 
et al, 1981;Brinkman et al, 1982; Haahr et al, 1983;) or of 
patients with other neurological diseases (Hughes et al, 1977; 
Brinkman et al, 1982). Reactions to phytohaemagglutinin (Hughes 
et al, 1977; Weiner et al, 1979; Goust et al, 1980; Schauf et al, 
1981), Concanavalin A (Knight et al, 1975; Weiner et al, 1978; 
Sheremata et al, 1979) and Pokeweed mitogen (Knight et al, 1975; 
Weiner et al, 1978; Goust et al, 1980; Brinkman et al, 1982) 
were all investigated. Some studies however have shown a decrease 
in response to several mitogens in MS (Antel et al, 1978; Nordal 
et al, 1978; Dropcho et al, 1979; Walker et al, 1979; Honen et 
al, 1981).
The percentage of T-cells increases and the percentage of B- 
cells decreases in the CNS of MS patients but this is generally 
seen in patients with a variety of neurological diseases. Both
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significant depressions of T suppressor cells during active 
disease followed by a significant increase in these cells during 
recovery have been recorded in the CSF. (Huddleston and Bloom,
1979)
Antimyelin antibodies have been demonstrated in MS (Lisak et 
al, 1975; Wolfgram et al, 1976). There is a considerable evidence 
that demyelination in MS is immunologically mediated (Lisak, 
1980; Raine, 1984) but the target antigen is still unknown. The 
myelin-associated glycoprotein (MAG) has been found to be 
preferentially depleted in myelinating plaques. However the 
detection of anti-MAG antibodies has not been successful in the 
blood by RIA (Nobile-Orazio, 1985) or the CSF (Nobile-Orazio,
1986) of MS patients.
The recent report by Koprowski et al (1985) that human T- 
cell lymphotrophic retroviruses (HTLV) may be involved in the 
development of MS has aroused interest. A study by Hauser et al 
(1986) investigated the presence of HTLV-like sequences in 
tissues from the CNS of MS patients and Karpas et al (1986) 
investigated the presence of antibodies against these 
retroviruses in the serum amd CSF of MS patients with no success. 
On the whole the results are very contradictory with no clear 
idea as to the cause of the disease.
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SECTION 2 MOTOR NEURONE DISEASE
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Section 3. Motor Neurone Disease 
3»1» Introduction
The clinical components of motor neurone disease (MND) were 
described over a century ago by Aran (I85O), Duchenne (i860), and 
Charcot (1869). This fatally progressive neurological disorder of 
adult life is characterised by clinical evidence of widespread 
damage to motor neurones, resulting in wasting, weakness, and 
fasciculation of skeletal muscles. Almost invariably pyramidal 
tract signs appear at some stage of the illness. The clinical 
features are attributable to the degeneration of the motor 
neurones at the spinal and brain stem levels, or at both levels, 
usually with some involvement of the Betz cells of the cortex and 
demyelination of the corticobulbar and corticospinal (pyramidal) 
tracts.
Several variants of the disease are recognised, progressive 
muscular atrophy (Aran, I85O) occurs when the disease is confined 
to the anterior horn cells of the spinal cord where the limb 
motor neurones are predominantly affected; progressive bulbar 
palsy (Duchenne, i860) when the cranial motor nuclei are 
involved; and amyotrophic lateral sclerosis (Charcot, 1869) when 
there is pyrimidal tract involvement causing degeneration of the 
corticospinal pathway. The clinical differentiations are 
indistinct and it is common in a clinical series to class them as 
a variants of one disorder ~ motor neurone disease (Friedman et 
al,1950; Mulder,1957; Mackay,1963; Bonduelle et al,1970). However
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in the United States, the generic name amyotrophic lateral 
sclerosis is preferred to motor neurone disease.
The diagnosis of MND is sometimes difficult at the early 
stages of the disease. This is so because of the similarity of 
symptoms to those of other neurological disorders. In general, 
diagnosis is based on electro-myography which involves measuring 
the electrical activity of muscles using microelectrodes. Muscles 
which have lost their nerve supply will have impaired response to 
stimuli.
MND is usually a fatal condition with death occuring within 
3”5 years of onset (Clifford-Rose, 1984) although 20 per cent of 
patients survive upto 5 years and 10 per cent survive up to 10 
years (Mulder and Howard,1976). It is an uncommon but ubiquitous 
disease with a prevalence of 2.7~7 per 100,000 population 
(Kurland et al,1958,1969)* although pockets of high prevalence 
exist in certain tribal communities of the Western Pacific 
Islands, especially on Guam. The Chamorro people of Guam have an 
annual incidence rate of 32.3 per 100,000 (Brody et al,1972).
The mean age of onset is about 52 years, with 98 per cent 
between the age range 35“84 years. A remarkable feature of all 
types of motor neurone diseases is that, throughout the world, 
the male rate is from 1.2-2.5 times higher than the female rate. 
A familial form has a 1:1 male to female ratio, as is usual with 
autosomal traits (Hawkes et al, 1984). There are no well 
documented racial differences for the susceptibility of MND, with
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the exceptions of Guam and Japan. However, there are reports of a 
slight increase in rate among Japanese in the United States and a 
suggestion of an elevated rate among Filipinos in Hawaii 
(Matsumoto et al, 1972).
Despite the apparent simplicity of the pathological process 
in MND there is an almost complete lack of knowledge of its 
cause, or of possible therapies.
3.2. Aetiology
Many possible factors have been considered as being involved in 
the aetiology of MND. Some of these will be briefly discussed 
here.
3.2.1. Carbohydrate Metabolism
A number of studies have shown impaired glucose metabolism in 
patients with ALS, (Gotoh et al, 1972; Gustafson and 
Stortebecker, 1972; Koerner, 1976; Nagano et al, 1979)• Recently 
Murai et al (1983) confirmed that serum glucose levels were 
significantly higher in MND than in healthy controls although the 
insulin response to glucose loading was normal. These results 
contradict those of Gotoh et al, (1972) and Nagano et al, (1979) 
who found impaired pancreatic secretion of insulin which may 
result in the abnormal glucose metabolism.
It is now generally accepted that glucose intolerance is a 
common finding in MND, although the pathophysiological mechanisms 
involved in the carbohydrate abnormality are still disputed.
3.2.2. Lipoprotein Metabolism
Only a few reports have been published on lipid and lipoprotein 
metabolism in MND. Mueller et al, (1970) showed significantly 
elevated fasting concentrations of serum free fatty acids and 
cholesterol while Gustafson and Stortebecker (1972) found an 
increased incidence of type II hyperlipoproteinemia in ALS. Huang 
et al, (1978) found an abnormal composition of high density
lipoprotein (HDL) with reduced levels in familial ataxia and 
Friedeich's ataxia. Recently, Murai et al, (1983) found lowered 
HDL cholesterol levels and increased triglyceride levels in ALS 
patients as compared with healthy controls.
In patients with MND, skeletal muscle fibres are 
progressively denervated resulting in striking changes in their 
metabolic capabilities. It may be that the abnormalities 
observed in denervation have no particular pathogenic 
significance for MND but rather result from general metabolic 
derangement.
3.2.3. DNA
It has been suggested that certain neurological disorders arise 
from abnormalities in DNA and its function (Bradley et al, 1982; 
Mims et al, 1983 )• Such defects may occur in several ways e.g., 
as an error in the DNA code during semi conservative replication 
or a defect in the DNA repair mechanism. Neurones are in post 
mitotic phase and mutation may not be corrected because of the 
low repair activity (Scudiero et al, 1976). Neurones may even be 
more prone to mutations due to virus infection (Doolittle et 
al, 198*0* Severe damage to motor neurone nuceli is commonly 
observed in MND. Mann and Yates (197*0 found shrinkage of the 
nucleus and hyperchromatic condensation of the nuclear chromatin 
followed by loss of basophilia of the nucleolus and a reduction 
of the cytoplasmic RNA content . Davidson and Hartmann (1981)
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found a 30-40# reduction in RNA content of patients with ALS, 
and they presented evidence to suggest that it was restricted to 
the motor system. This reduced RNA content was not a function of 
age or cellular loss. The base composition of RNA from motor 
neurones of ALS patients differed in that it had a low percentage 
of adenine, and a low adenine to uridine ratio. Auto-antibodies 
to single-stranded and double-stranded DNA are elevated in some 
autoimmune disorders and infectious diseases (Tang et al, 1979)* 
The presence of DNA in circulating immune complexes in MND sera 
was recently investigated (Unger et al,1985). The ratio of 
single-stranded : double-stranded DNA was found to be
significantly increased with respect to normal controls. Bradley 
et al (1982) suggested that ALS is due to a deficiency in the 
normal DNA repair mechanisms with resultant accumulation of 
damaged DNA, which causes the abnormal transcription of RNA and 
thus translation of abnormal protein or absence of synthesis of 
specific proteins.
3*2.4. Mineral and Metal Metabolism
Calcium metabolism in ALS was found to be abnormal in 
approximatly 20 per cent of cases compared with normal controls. 
The patients were found to be hypocalcaemic with elevated levels 
of parathyroid hormone (PTH), indicating secondary 
hyperparathyroidism (Patten, 1984).
Plasma levels of 25-hydroxy-vitamin D were found to be low
48
in ALS patients with abnormal calcium metabolism. This mild 
vitamin D deficency, could have caused the hypocalcaemia, as 
calcium metabolism was returned to normal by administering a 
vitamin D analogue. However, even though calcium metabolism was 
corrected there was no reinnervation of the motor neurones 
(Patten, 1984).
There is a significantly increased incidence of congenital 
abnormalities in ALS (Campbell et al, 1970). The relationship 
between calcium metabolism, and vertebral structure in MND is 
unclear.
Yase (1980) noted that when there is severe calcium 
deficiency calcium in the form of hydroxyapatites is deposited in 
soft tissues, including the brain. These may be caused by 
secondary hyperparathyroidism in infancy and childhood (chronic 
deficiency). The accumulation of the hydroxyapatites in motor 
neurones could eventually destroy the cells (Yase, 1968; 1973;
1979*1980) as in MND. Long term calcium deficiency also affects 
metal toxicity rendering metals such as aluminium, iron, and 
manganese toxic because of increased absorption from the gut, 
decreased renal excretion and decreased bone deposition of these 
metals in bone. Instead the metals are deposited in soft tissues 
such as the brain where they are a poison becoming chronically 
toxic to the motor neurones and are thought to lead to the 
premature appearance of neurofibrillary tangles seen in ALS and 
Parkinson’s Dementia (Gajusek, 1984).
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Patten (1984) found that exposure to lead and mercury are 
antecedent events in motor neurone disease. Lead has several 
types of toxic effects on the nervous system (Simpson et al, 
1964). Lead intoxicated patients have been documented with 
weakness and wasting of muscles with some pyramidal tract disease 
and fasciculations (Wilson, 190?) thus mimicking MND. Lead levels 
in plasma (Conradi et al, 1978) and cerebral spinal fluid 
(Conradi et al, 1980) were increased in MND, compared to normal 
controls, and increased levels of lead in tissues, including the 
anterior horns, have been reported by Kurlander et al (1979)* 
There are also reports of high incidences of exposure of ALS and 
MND patients to lead before disease onset (Felmus et al, 1976; 
Pierce-Ruhland et al, 1981). Lead exposure usually results in 
lead storage in bone, the major mechanism of detoxification 
(Barry, 1975)• Demineralisation of the skeleton in aging, 
fracture, cancer, or serious trauma or infection can result in 
the transfer of lead from bone to soft tissues where it is a 
poison. This could explain the increased incidence of fractures 
(Felmus et al, 1976; Kurtzke et al, 1980), bone disease 
(Campbell, 1970; Patten, 1982), trauma (Kurtzke, 1980) and cancer 
in MND patients.
Chelating agents are used to mobilise lead from the nervous 
system of patients with MND preventing further damage. Remission 
of ALS can result, and this remains the only real evidence for 
the toxic origin of MND (Patten, 1984).
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3.2.5. Enzyme Defects
MND results in damage to the neuromuscular system leading to 
eventual failure. Nerves contact muscle at the muscle end 
plates, and these structures control the information transfer 
from the muscle to the nerve and vice versa. 
Acetylcholinesterase (AChE) is an essential consituent of the end 
plate and contains a collagen-like tail which may interact with 
fibronectin. It was suggested by Festoff et al (1980) that the 
continuous degeneration of the motor system results from the 
steady decrease in adherence of AChE to the basement membrane 
because of the activation of a latent collagenase which allows 
collagen to be resorbed.
3.2.6. Neurotransmitters and aminoacids
Spinal motor neurones are metabolically highly active and are 
subject to a number of neural influences from the descending 
cortical and brain stem tracts, as well as from segmental spinal 
afferents and local inhibitor and excitatory interneurones, such 
as Renshaw cells (Belleroche et al, 1984). The excitory 
transmitters, aspartate and glutamate, and the inhibitory amino 
acids glycine, taurine, and gamma aminobutyric acid (GABA) have 
a direct effect on spinal motor neurones (Davidson, 1976). Many 
other transmitters are present and could possibly contribute to 
the regulation of the motor neurone activity e.g. Noradrenalin, 
dopamine, enkephalin, 5"hydroxytryptamine and substance P
(Belleroche et al, 1984).
Abnormalities in the metabolism of these neurotransmitters 
may contribute to the mechanism of the disease. Studies of 
neurotransmitters in MND are of two types. Firstly there are
those dealing with the measurement of levels, and changes in 
their rates of biosynthesis and degradation. Secondly, those 
concerned with measurement of neurotransmitter receptors. 
Biochemical analysis is usually carried out on serum and CSF
samples, and spinal cord and brain post mortem tissue.
Yoshino et al (1976) found diverse changes in amino acids in 
the ALS spinal cord, with an increase in the taurine content. 
They also found (Yoshino et al, 1979) seven amino acids that 
showed statistically significant changes, (taurine was the only
one which increased constantly) in the motor cortex of ALS
patients compared with normals.
Patten and coworkers (1978) found elevated levels of amino 
acids in the CSF and serum of MND patients compared with 
neurological controls and observed an increase in the levels of 
ammonia and ornithine in anterior horn spinal cord tissue of ALS 
patients (Patten et al, 1982). Belleroche et al (1984) measured 
the levels of a number of amino acids in the CSF of MND and age 
matched controls and showed that marked abnormalities do occur. 
Large increases (upto 60$) were observed among both essential and 
non-essential amino acids. The most marked increase was in the 
level of glycine. The changes in amino acid levels, particularly 
in glycine, alanine and taurine showed correlations with disease
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severity and duration.
In summary, a number of amino acids are significantly 
elevated in MND when compared with age matched controls. However, 
it is not clear yet whether this results from enhanced catabolism 
and\or reduced efficiency of amino acid uptake from the CSF.
3.2.7. Receptor Defect
Androgen receptors have been demonstrated in both the cranial 
nerve, and spinal motor neurones (Sar and Stumpf, 1977). However, 
cranial nerves III, IV, and VI and the dorsal root motor nuclei 
of cranial nerve X have very few androgen receptors, and these 
structures are invariably spared in motor neurone disease. Weiner 
(1980) suggested that MND may be a disease where androgen 
receptors are lost from motor neurones or are not functioning. In 
ageing men oestrogen levels increase and testosterone levels 
decrease possibly because testosterone binding globulin removes 
free testosterone from the circulation. In normal people axons 
can be repaired with the anabolic help of androgens. However, in 
MND , androgen receptors are lost and the axonal changes result 
in the death of the motor neurone (Weiner, 1980).
Hayashi et al (1981) reported that compared to normal spinal 
cord taken from ALS patients showed a significant loss in the
3
number of glycine receptors as measured by H-strychnine binding 
to the anterior grey areas of the spinal cord taken from ALS 
patients compared to controls. Whitehouse et al (1983) found that 
muscarinic, cholinergic, benzodiazepine, and glycine receptor 
concentrations were all diminished in cervical, thoracic, and
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lumber spinal cords of MND patients, and that the distribution of 
these receptors within MND spinal cord differed from normal.
Recently, infusions of thyrotropin-releasing hormone (TRH) 
have been claimed to alleviate the weakness of MND patients 
(Engel et al, 1983). Receptors for TRH are present on motor 
neurones and their density and distribution in the MND spinal 
cord have been investigated. Reduced density and altered 
distribution of TRH receptors in MND spinal cord have been found 
(Mitsuma et al,1984; Manaker et al, 1985).
The reduction in receptor distribution can be explained by 
destruction and loss of motor neurones in MND. However, the 
altered pattern of distribution particularly in those areas of 
the spinal cord where motor neurones are not damaged could 
suggest some kind of defect in receptors.
3.2.8. Genetic Defects
Motor neurone disease can be inherited within families, in which 
case it is called familial MND. Inheritance is mainly autosomal 
dominant (Engel et al, 1959) and gives rise to a progressive 
illness affecting predominantly the lower motor neurones leading 
to death within an average of 4 to 7 months. Post mortem studies 
reveal severe cell loss in the anterior horns and occasional 
degeneration of the pyramidal tract. The mean age of onset is 
45.8 years with nearly equal sex incidence. According to Alter 
and Schaumann (1976) familial cases comprise 2-15 P®1* cent of 
motor neurone diseases.
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Histocompatibility antigens have been measured for the A, B, 
and C loci in various populations of MND. Antel et al (1976)
reported an increased incidence of HLA-A3 in a group of 44
patients when compared to 200 controls. Terasaki and Mickey 
(1975) found the overall incidence of HLA-A3 in ALS was also 
increased but not significantly. However, Pederson et al (1976) 
found no such changes. Hoffman et al (1977) found an increase in 
Bw-l6 in Guamanian patients but it was not significant. Hoffman 
et al (1978) reported that cell mediated immunity was
decreased, and that all the hyporesponsive patients had Bw-35« 
Behan et al (1976) only found an increased incidence when HLA-A2 
and A28 were combined . Kott et al (1976) found cellular immunity 
to polio virus in two thirds of patients with ALS, with an
increased incidence of A3 and Bw 35• Most recently Bartfeld et al 
(1982) found a slight increase in HLA-B17 and B8 and a slight 
decrease in the frequency of HLA-A9 in patients with ALS. Knott
et al (1976) reported that HLA-Bw 35 was increased in Israeli
patients. Bartfeld et al (1982) analysed their results taking 
the report by Kott et al (1982) into consideration, and separated 
the patients by race. They found that non-Jewish patients with 
ALS had a significant increase in Bw 35 compared with controls.
Zaiwalla et al (1984) on the other hand reported no relationship
between HL antigen and MND.
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3.2.9. Polio Virus
Polio virus has the capacity to produce paralysis in the absence 
of other neurological signs and has prompted speculation that it 
may be a causative factor in MND. Polio virus has been implicated 
in virtually all types of motor neurone disease.The most commonly 
reported syndrome has been poliomyelitis followed by delayed 
muscular atrophy. There are now over a hundred cases reported in 
the literature (Campbell et al, 1969; Mulder et al, 1972) most of 
which are males who experienced severly disabling poliomyelitis 
in early childhood and then neurological improvement and 
stabilisation.In general paralysis begins after 35“^0 years, and 
lacks any pyramidal tract signs. In 193^ Alajouanine described a 
woman (40 y) who had a lower motor neurone disorder having had 
polio. There was notable chromatolysis of the motor neurones. 
Fragments of her brain stem were injected intracerebrally into a 
rabbit which developed hind and then fore limb paralysis, 
resulting in death within six months.Pathological findings in the 
rabbit closely resembled those of the patient.
Zilkha (1962), Poskanzer et al (1969), and Norris (1975) all 
reported an increased incidence of prior poliomyelitis in 
patients with classical MND.
There have been many investigations, virological and 
immunological, seeking evidence to support the involvement of 
polio virus in MND. Humoral immunity to polio has been sought in 
MND patients by measuring neutralising or complement-fixing anti
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polio titres without success (Cramer et al, 1973; Lehrich et al, 
197^; Jokelainen et al, 1977; Kurent et al, 1979; Kascsak et al, 
1982). However the possibility of an antibody-mediated 
abnormality in MND has been supported by reports of immune 
complexes in tissue sections of kidney (Oldstone et al, 1976),
skin (Palo et al, 1978), and jejunum (Pertschuk et al, 1979).
but without evidence of polio antigens.
A variety of techniques including, cell fusion, indirect 
immunofluorescence for viral antigens, electron microscopy, and 
haemadsorption has failed to recover polio virus from tissues of 
ALS patients (Miller et al, 1980).
It has also been postulated that, like retroviruses, polio
virus inserts non-infectious RNA into host cells. The RNA retains
the ability to produce injurious proteins or defective particles 
but remains undetectable by conventional infectivity studies. 
Roos et al (1980) and Miller et al (1980) have looked at 
molecular hybridisation (The DNA from MND patients is hybridised 
with polio virus RNA), but no polio virus has been detected.
Kott (1976) reported that in vitro cultures of MND 
lymphocytes showed production of a migration inhibition factor 
after challenge with polio vaccine in ALS. Studies of cellular 
immunity in classical and post polio motor neurone diseased 
patients by Behan (1977) however found no abnormalities in 
response to skin test challenge with polio virus although he did 
observe reduced responses of T lymphocytes to PHA in both groups
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of patients compared with normals and normals with a prior 
history of polio.
As already mentioned HLA-A3 was found to be abnormally 
prevalent (Antel et al, 1976; Kott et al, 1979) in MND. HLA-A3 
and A7 are reported to be increased in polio patients (Pietsch et 
al, 1973). but this has not been confirmed. HLA antigens serve as 
genetic markers for immune responsiveness, particularly in viral 
and autoallergic diseases. It has been suggested that MND is a 
persistant slow viral infection thus leading to the study of HLA 
antigens.
Virally-initiated immunological attack on motor neurones 
could start in a number of ways. An obvious possibility is that 
of fortuitous cross-reactivity between a viral antigen and one on 
the motor neurone membrane. Alternatively anti-idiotypic 
antibodies to anti-viral antibodies might interact with virus
receptor sites on neuronal cells.
However, evidence implicating polio virus in the 
pathogenesis of MND is inconclusive.
3.2.10. Immunological Involvement in MND
Motor neurone disease is a highly specific disease causing 
degeneration only of the motor neurones. This specificity has the 
nature of an antigen-antibody reaction, and an autoimmune 
disorder. This possibility has been debated for years without any
clear evidence which could prove or disprove the idea.
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3.2,10,(a) Immune Complexes
The usual laboratory indices of abnormality in the immune system, 
serum immunoglobulin and complement levels, and peripheral white 
blood cell counts have been reported to be normal (Whitaker, 
1973; Behan, 1979; Antel et al, 1982). The CSF is usually normal 
in these respects although electrophoretic studies show minor 
alterations in protein levels, consistent with blood brain 
damage. Increased concentrations of immunoglobulin in the CSF 
have been reported (Behan, 1979; Leonard! etal, 1984). Positive 
evidence in favour of an immune system involvement in MND is 
provided by the detection of immune complexes in renal tissues 
(Oldstone et al, 1976; Norris, 1979). spinal cord and motor 
cortex (Donnenfeld et al, 1984) and of elevated levels of such 
complexes in sera (Hoffman et al, 1978). A more recent study by 
Bartfeld et al (1982) found an increase in serum immune complexes 
over normals but no greater than in neurological controls. In 
these studies, the circulating immune complexes were determined 
by Clq binding assays. The Raji cell binding assay has led to 
reports of both slightly elevated (Antel et al, 1979) and normal 
(Tachousky et al, 1976) levels of immune complexes in MND sera. 
Characterisation of DNA in circulating immune complexes in MND 
sera showed a significantly higher ratio of single -stranded : 
double-stranded DNA with respect to control (Unger et al, 1985)•
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3.2.10. (b) Cells
Immune cell abnormalities in MND have been sought with mixed 
success. The cutaneous response to common antigens was found to 
be decreased in some MND patients (Kott et al, 1976; Hoffman et 
al, 1978; Behan, 1979)• The percentages of immunoregulatory T 
cells measured using monoclonal antibodies was found to be normal 
in MND patients (Bartfeld et al, 1985). In vitro responses to 
non- specific mitogens such as PHA and ConA have been reported to 
be abnormally low (Hoffman et al, 1978; Behan, 1979). However, 
Antel et al (1979) and Bartfeld et al (1982) were unable to 
demonstrate any differences. T-cell counts were found to be 
normal as were the B-cell counts (Antel et al, 1979)* The T-cell 
subsets measured by the expression of receptor however were 
significantly different. The Fc^ i subset was decreased relative to 
the Fc / subset (Westall et al, 1983).
3.2.10. (c) Autoantibodies
Studies of potential autoantibodies in MND have 
sometimes given positive results, but are rather controversial. 
Both serum and spinal fluid gammaglobulin levels have been
reported to be relatively high in some MND cases compared to
normals, but not to neurological controls (Roboz et al, 1969; 
Tavolate et al, 1975). The high gamma globulin levels may
indicate a high incidence of infectious complications in MND
patients. Hoffman et al (1981) reported high levels of IgA and 
IgG in Guamanian MND patients.
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Serum samples from patients with MND were used as controls in 
early studies of myelintoxic antibodies in Multiple sclerosis 
(MS), and were found to cause demyelination in myelinating 
cultures just as frequently as the MS sera (Bornstein et al, 
1965; Field et al, 1969). The presence of auto antibodies to 
myelin has also been shown by immunofluoresence (Edgington et al, 
1970; Lisak et al, 1975)* Schauf et al (1980) reported that serum 
from MND patients reduces the electrical response from the 
central roots of a frog spinal cord preparation when the dorsal 
root was stimulated. The blocking activity seemed to correlate 
with disease activity and could reflect the presence of a 
neurally-directed antibody (Schauf et al, 1978). While such serum 
factors would be interesting in a primary demyelinating disease, 
in MND the actual relevance is obscure because there is primary 
neuronal degeneration and only secondary demyelination.
There have been reports of elevated levels of serum 
antibodies to neurofilament antigens in neurological disorders 
(Bahymanyar et al, 1983; Bahymanyar et al, 1984; Toh et al, 1985; 
Jehanli et al, 1986).
An initial report of Wolfgram and Myers (1973) of a serum 
borne neurotoxic factor in MND has been recently confirmed by 
Roissen et al (1982) but there have been contradictory reports 
(Horwich et al, 1974; Liveston et al, 1975; Obatak et al, 1976). 
However, Digby et al (1982; 1983; 1984; 1985) have reported that 
MND sera contain immunoglobulins that bind specifically to foetal
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rat spinal cord cells in culture. Antibodies in MND sera which 
bind to antigens present in homogenates of motor neurones and 
dorsal root ganglia have been recently found (Brown et al, 1984; 
Kletfi et al, 1984).
Gurney and Apatoff (1984) demonstrated that antisera against 
components of conditioned medium from cultures of denervated rat 
diaphragms are capable of suppressing terminal axon sprouting and 
that such polyclonal sera recognised a 56K protein secreted from 
muscle into the medium. In addition, it was shown that sera from 
MND patients block terminal axon sprouting, and also have an 
antibody against a 56K antigen (Gurney et al, 1984). There are 
also reports of antibody activity against a protein in the motor 
neurones (Apatoff et al, 1984) and to a "survival factor" for 
cultured spinal cord neurones (Kletti et al, 1984). Gurney et al
(1984) observed that sera found to supress sprouting in vivo 
have been shown to block the activity of a muscle-derived 
survival factor, and have produced a monoclonal antibody that 
blocks the survival factor for cultured rat spinal cord neurones. 
Factors from denervated muscle which lead to motor neurone 
survival and neuritic extension have been reported by others 
(Eagleson et al, 1983; Slack et al, 1983; Nurscombe et al, 1984), 
but this report by Gurney et al (1984) has still to be confirmed.
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3*2.11. Other Suggested Pathogenic Factors
Many other factors have been reported in association with 
MND, but usually in small numbers of cases. These include milk 
ingestion (Patten, 1984), bone fracture (Pierce-Ruland et al, 
1981), heavy labour (Breland et al, 1967), pneumatic drilling 
(Alpers et al, 1949), mechanical injuries (Campbell et al, 1970; 
Kurtze et al, 1980; Kondo et al, 1981), electrical shock (Haynal 
et al, 1964), spinal anaesthesia (Ask-Upmark et al, 1961) and 
various diseases, including malignant neoplasia (Norris et al,
1965).
Environmental factors may have a significant effect on the 
occurance of ALS. There are three foci of high incidence of ALS 
in the Western Pacific area. In all three foci a syndrome of 
Parkinsonism Dementia (PD) and associated Parkinson Syndromes 
have been seen with a high incidence paralleling ALS. To date, an 
extensive search for the cause in a slower virus infection (Gibbs 
et al, 1972), genetic (Reed et al, 1975) or immunological defect 
(Hoffman et al, 1978; 1981) or a neurotoxic item in the diet
(Whiting 1963; 1964; Kurland, 1972) has been unsuccessful. There
are recent reports that the incidence of the disease is declining 
and has been over the past three decades. Garruto et al, 1985 
report that the high incidence rates of ALS and PD occuring 
amoung the Chamorros of Guam have declined to rates only slightly 
higher than those observed in the continental United States. This 
decline has occured among males especially those born after 1920
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and living in areas where calcium and magnesium levels are low in 
the soil, and drinking water. The male ratio now approaches 
unity, compared with the ratio 2:1 in ALS and 3:1 in PD three 
decades ago. These changes suggest that the high incidence 
resulted from defects in mineral metabolism, provoked by calcium 
and magnesium deficiencies, resulting in deposition of calcium 
and aluminium in neurones. Essentially, however the results 
indicate very clearly that an evironmental variable has been 
responsible for the disease (Garruto et al, 1981; Gajudusek, 
1984).
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SECTION 4 LYMPHOCYTE ACTIVATION
Section 4 Lymphocyte Activation
Lymphocyte proliferation occurs when specific clones of cells 
reactive against foreign antigens are amplified in vivo (Clonal 
selection). Cultured B and T lymphocytes can be induced to 
proliferate in vitro in response to antigens, including those on 
allogeneic cells (Robbins, 1964). However studies of the 
proliferative mechanisms are difficult to follow because of the 
small population of cells that actually respond to specific 
antigen (Ada, 1970). These problems may be avoided by using 
polyclonal activators that are able to stimulate lymphocytes 
irrespective of their antigen specificity.(Wedner and Parker, 
1976) 70 - 80 per cent of cells in a given lymphocyte population
may be so stimulated (Andersson et al, 1972). The polyclonal 
activation caused by the non-specific mitogens can sometimes occur 
in specific lymphoctye subsets. Hence they can be used to study 
mechanisms of proliferation or immune competence of particular 
lymphocyte types (Baran,1985).
4.1. Polyclonal Activators
The most commonly used polyclonal mitogens are the lectins, a 
group of carbohydrate-binding proteins. Lectins bind to the 
oligosaccharide residues on the cell membrane, and being 
multivalent, cross link surface molecules as the first step in 
lymphocyte activation. Lectins were initially characterised by 
their ability to agglutinate red blood cells, and during these
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studies their mitogenic properties were discovered.
Phytohaemagglutinin (PHA) comes from the red kidney bean, 
Phaseolus vulgaris. The exact concentration of PHA required for 
lymphocyte activation depends very much on the precise 
experimental conditions used, but, for human lymphocytes in medium 
containing 10% (w/v) serum, the best PHA preparations are
generally most active when present at 1-5 ^ g/ml (Ling,1978). PHA 
transforms a major proportion of the T lymphocyte population. It 
also appears to affect some B cells, although their response seems 
to be T-cell dependent (Waxdal & Wilson, 1975)* It is thought 
that PHA-stimulated lymphocytes are preferentially the helper T- 
cell population (Ramagnani et al, 1977)*
Concanavalin A, (Con A) is the best characterised of all the 
plant lectins. It may account for up to Z% of the protein of the 
Jackbean (Canavalia ensiformis) and was first obtained in a 
crystalline form many years ago (Summer 1919)• It binds 
glycoconjugates containing cl -D glucopyranosides, and tC - D - 
mannopyranosides, binding specifically with C3, C4 and C6 hydroxyl 
positions of the pyranoside ring. Con A also agglutinates 
erythrocytes, although not as powerfully as PHA. It preferentially 
stimulates the suppressor T cell population (Roitt et al,1985).
Pokeweed Mitogen (PWM) is extracted from several parts of 
the pokeweed (Phytolacca americana), and differs from Con A and 
PHA in that it has little erythroagglutinating activity. It 
stimulates both T and B cells (Greaves & Janossy, 1972; Douglas,
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1972) and, in view of the fact that only one B cell in ten 
thousand responds to specific antigen, PWM has become important in 
in vitro studies of B cells (Chiorazzi et al, 1982).
Other compounds, apart from the lectins, have mitogenic 
properties. Protein A has been claimed to be a highly efficient 
mitogen for human peripheral B lymphocytes with no detectable 
activity for T lymphocytes (Forsgren et al, 1976). However, 
Sakane & Green (1978) found that it was a mitogen for both B and T 
lymphocytes.
Dextran sulphate has been shown to activate lymphocytes 
(Ruhl et al, 197*0. and is a B-cell polyclonal activator 
(Gronowicz et al, 197*0* Tuberculin PPD at low concentrations acts 
as a specific antigen, stimulating only lymphocytes of sensitized 
animals. However when used in high concentration it acts as a 
polyclonal B-cell activator (Gronowicz et al, 197*+)*
Lipopolysaccharides (LPS) from Gram negative bacteria, 
stimulate T and B cells in humans and only B cells in mouse. They 
induce differentiation of antibody-producing plasma cells. The 
lipid, rather than the polysaccharide moiety of the LPS, has been 
demonstrated to be responsible for mitogen activity (Andersson et 
al, 1973; Peavy et al, 1973; Rosenstreich et al, 1973)*
It has been postulated that lymphocyte proliferation can be 
induced by the Fc-fragment of immunoglobulin (Berman et al, 1979) 
and by a wide range of other substances including periodate ions 
(Novagrodsky & Katchalski 1973). zinc ions ( Ruhl et al, 1971;
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Berger and Skinner, 197*0. mercury ions (Ruhl et al; 1971). 
proteolytic enzymes and extract of polymorphonuclear lymphocytes 
(Mazzei et al, 1966).
Although plant lectin-induced mitogenesis is a rather 
artificial event, there is no doubt that it has enormous practical 
usefulness. Polyclonally-activated lymphocyte subpopulations 
express differentiated functions, and polyclonal activation only 
amplifies the changes associated with proliferation and permits 
their detection.
4.2. General Mechanism of Activation
There are many changes in metabolic activities of lymphocytes 
between initial stimulation by mitogens and the start of DNA 
synthesis. Biochemical studies have shown that there are 
alterations in the activities of almost every metabolic pathway, 
some of which occur more rapidly than others. Metabolic changes 
result in the enlargement of the cell (in particular in the 
cytoplasm), in the conversion of much of the nuclear 
heterochromatin to euchromatin and in the appearance of prominent 
nuclei (Ling, 1978).
4.3. Receptor - Membrane Interaction
The response of lymphocytes is initiated by binding of mitogen to 
receptors on the surface of the responsive cell. The response 
does not require passage of the stimulatory agent into the 
cytoplasm but depends upon the transmembrane transmission of
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information and possibly on the generation of a "second 
messenger". Responses at the plasma membrane itself may be 
related to mitogen-receptor interaction (Wedner and Parker, 
1976).
Two basic parameters determine the ability of an individual 
cell to respond to an external stimulus: the concentration of the 
external ligand in the extracellular fluid and the concentration 
of high affinity receptors for that ligand on the cell surface. 
It is now well established that cells have the ability to 
regulate the density of their plasma membrane receptors and 
thereby to alter their sensitivity to particular ligands. "Down 
regulation" describes the cells1 response to high doses of 
ligand by reducing the density of its receptors; "Up regulation" 
denotes the acquistion of new receptor specificities as a 
consequence of cell activation e.g. Insulin receptors, which are 
normally absent, or present in very low concentrations on T 
cells, can be accquired (Helderman et al, 1977)•
Mitogenicity depends upon the multivalency of the inducing 
ligand, and its ability to cross link the membrane components 
(Prujanski et al, 1978). This is the generally accepted view, 
although a number of monovalent agents having mitogenic 
properties have been reported. Fraser et al 1976 prepared a 
monovalent derivative of Con A which retained its mitogenic 
activity. Sela et al (1976) suggested that mitogens which are 
monovalent can become effectively multivalent when concentrated
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DNA synthesis is not a continuous process even in cells which 
are undergoing rapid division (Wedner and Parker, 1976). It is, 
confined to one period of the cell cycle, the S-phase. In a
normal cell cycle, mitosis is followed by a growth phase, Gl, when 
no DNA is synthesised. The next stage is the S-phase, then the G2 
phase where DNA synthesis has been completed, and the cell again 
prepares for mitosis. As DNA synthesising cells are rare in many 
populations of lymphocytes, the initiation of DNA synthesis has 
proved a sensitive low background assay that has become a standard 
method of determining lymphocyte transformation. The
incorporation and transport of thymidine into DNA of lymphocytes 
stimulated by PHA is virtually confined to those cells which have 
DNA contents between the diploid (GI) and tetraploid (G2) values. 
Peters and Hausen (1971) showed that thymidine enters the cell by 
carrier-mediated diffusion, with the response occurring after a 
24 hour lag. Feulgen-stained smears, and isotope incorporation 
determined by autoradiography showed that DNA synthesis was 
continuous throughout S phase only.
The most frequently used radioactive precursors for the study 
of DNA synthesis induced by mitogen stimulation are those
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3 14
containing H and C isotopes of thymidine. The main differences
3
between these are that H-thymidine is available at a much high 
specific activity and is significantly cheaper. Other nucleotides 
such as deoxycytidine, deoxyuridine and iodo-deoxyuridine have 
been used (Ling, 1974). The increase in DNA synthesis resulting 
from the proliferation is assessed by measuring the incorporation 
of radio-labelled nucleotide into acid-precipitable material.
The rate of thymidine incorporation depends upon the 
concentration of thymidine added. Saturation occurs at a thymidine 
concentration of about 20ug/ml(Sample & Chretien, 1971)• Most 
workers use lower concentrations (0.lug/ml) because high thymidine 
levels inhibit DNA synthesis (Hartog et al, 1967). However, 
short pulses (4h) of high concentrations of thymidine produce 
reliable results for the synthesis of DNA. DNA synthesis after 
addition of PHA begins after a lag of 24 h and is usually found to 
be maximal after 72 h, dying away at later times (Hardy & Ling,
1973).
An enzyme immunoassay has been used by Porstmann et al
(1985) to measure lymphocyte proliferation. They used an analogue 
of thymidine, 5"bromo-2-deoxyuridine (BUdR) which is incorporated 
into DNA and measured by using an anti-BUdR antibody. The results
3
obtained were as sensitive as [ H]-thymidine incorporation.
Many factors can affect the onset, extent and duration of 
DNA synthesis. These include the nature, concentration and 
metabolism of the stimulant used, the source and prior history of 
the responding cells and the culture conditions.
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4.4.2. RNA synthesis
Lymphocytes have a large stable pool of inactive mRNA (Wettenhall 
et al, 1976). Liver and muscle cells also have a similar pool of 
mRNA (Wool & Cavicchi, 1966). This stored mRNA has very low 
template activity which increases rapidly following the addition 
of mitogen, which is (Wettenhall et al, 1976) responsible for the 
adenylation of mRNA (Hauser et al, 1976) promoting transport of 
RNA from the nucleus to the cytoplasm (Mitchell et al, 1976). 
Both these increases reflect an overall increase in the rate at 
which mRNA is processed.
Free ribosomes, present in large numbers in unstimulated 
lymphocytes, rapidly form clusters and polysomes during 
transformation (Cooper, 1977; Harms - Ringdahl & Cooper, 1978). 
This ribosome aggregation may be related to the phosphorylation of 
a specific ribosomal protein that occurs within 20 minutes of Con 
A addition (Wettenhall et al, 1979)* A similar response is 
observed as chick embryo fibroblasts enter G1 in response to the 
addition of insulin or growth factors (Haselbacher et al, 1979)•
In stimulated lymphocytes the pattern and extent of 
methylation of tRNA is significantly altered. Methylation of tRNA 
may be necessary as a preliminary step in the acceptance of amino 
acids by transfer RNA, in the binding of aminoacyl tRNA to 
ribosomes and in the codon response.
Most living lymphocytes are engaged in RNA synthesis. If
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highly sensitive autoradiographic methods are used, a high 
proportion of cells can be shown to incorporate the pyrimidine 
nucleosides, tritiated uridine, and tritiated cytidine. Torelli 
et al (1964) showed that different morphological classes of human 
blood lymphocytes may have different rates of incorporation.
When lymphocytes are stimulated with PHA, the rate at which
3 3
they incorporate H-uridine, and H-cytidine into RNA is greatly 
increased. The nucleosides enter by carrier mediated facilitated 
diffusion. This begins soon after stimulation and becomes very 
prominent well before the initiation of DNA synthesis (Epstein & 
Stohlman, 1964). Similar increases have been reported with many 
other mitogens and seem to be a universal feature of activation. 
There have been no reports of DNA synthesis in lymphocytes not 
preceded by a stimulation of incorporation of pyrimidine 
nucleosides into RNA.
3
Most workers observed an increase in the rate of H-uridine 
incorporation into RNA within one hour of the addition of PHA. In 
some cases the increase has been small, and in others as much as 
four fold (Cooper & Rubin, 1965; Kay & Cooper, 1965)- The 
explanation is probably that the optimum concentration of PHA 
required for DNA synthesis may be lower than that required to 
initiate RNA synthesis.
The incorporation of other precursors into RNA has been
32
studied less intensively. PHA increases the rate of P-phosphate 
incorporation into RNA, although the stimulation is smaller than
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3
that seen with H-uridine (Ebaugh, 1962). The stimulation of the
incorporation of purine nucleosides, adenosine and guanosine into
3
RNA is of the same order as that of H-uridine but unstimulated 
lymphocytes incorporate the adenine into RNA much more readily 
than the adenosine, and the incorporation of adenine was 
stimulated much less by PHA. When cycloheximide inhibits RNA 
synthesis, uridine is still taken up, indicating that the uptake 
does not depend upon RNA or protein synthesis. Therefore, 
increases in uridine labelling at various times after stimulation 
should take into account uridine transport and phosphorylation. 
The availability of intracellular nucleosides or nucleotides may 
limit the RNA synthesis.
*1.4.3. Protein synthesis
A sharp increase in the transport of amino acids across the plasma 
membrane is a universal feature of the response of mammalian cells 
to growth stimuli (Cunningham and Pardee et al, 1978; Dubrow et 
al, 1978). The carrier systems that transport amino acids are 
termed the A system and the L systems. The former, but not the 
latter, utilises the plasma membrane Na(+) gradient to drive 
uptake against a concentration gradient (Van den Berg and Betel, 
1972). The omission of amino acids from the medium results in the 
inhibition of mitogenesis (Van den Berg, 1972) suggesting an 
important requirement for exogenous amino acids at one or more 
stages of transformation.
The rate of turnover of protein may also be affected. Tanaka
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& Ichihara (1976) found a three fold increase in the half lives of 
several proteins that are rapidly turned over in stimulated L - 
cells. The increase correlated with an increase in the activity 
of a lysosomal enzyme involved in protein degradation. This 
possibility may apply to lymphocytes and is consistent with 
increased lysosomal activity actually observed in PHA stimulated 
lymphocytes (Alison & Mallucci, 1964).
The addition of mitogens to lymphocytes is followed rapidly
by the stimulation of radioactive amino acid incorporation into
protein. The reported time courses of amino acid conversion into
14
protein varies with different authors. Incorporation of C- 
leucine into acid-precipitable material has been observed within 
five minutes of addition of Con A to rat thymocytes (Yasmeen et 
al, 1977)* Pogo et al (1966) found the incorporation of radio- 
labeled alanine after 15 minutes exposure to PHA of human 
peripheral blood lymphocytes. Hausen et al (1969) studied the 
uptake of radiolabelled amino acids into intracellular protein of 
PHA-stimulated peripheral blood lymphocytes, and observed an 
increase in incorporation of radiolabel within two hours of PHA 
addition. Levy et al (1973) could only detect the incorporation 
of other radiolabelled amino acids into protein after two to 
three hours. However, the majority of workers observed increases 
after two hours continuing after forty-eight hours. Facilitation 
of ribosome processing has been observed as early as one hour 
after PHA addition to lymphocytes. This movement of protein and
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RNA in and out of the nucleus in stimulated lymphocytes suggests
that the nuclear membrane may have an important regulatory
function. The rate of incorporation of amino acids seems a
reasonably accurate index of the rate of protein synthesis
(Schechter et al, 1973) at least when the amino acids leucine or
3
phenylalanine are used (Kay et al, 1971)* H-leucine 
incorporation in particular has been used (Levy & Kaplan, 197*0 
and recommended as a more sensitive indicator of lymphocyte
3
abnormality than the more common H - thymidine uptake assay 
(Behan, 1979).
The variation in results obtained from different 
laboratories possibly reflects the use of different culture 
media, PHA concentration, labelling protocols and labelled amino 
acid chosen.
*1.4.4. Carbohydrate Metabolism
Only glucose or closely related molecules can supply the energy 
needed to support long term cell multiplication in culture (Fodge 
& Rubin, 1973)• Moreover, glucose is a source of many 
intermediates needed for nucleic acid, carbohydrate and protein 
synthesis as well as providing the reducing power needed in lipid 
synthesis. Because all of these processes are required for 
multiplication, glucose might be expected to play a key role in 
co-ordinating these activities.
Apart from an overall stimulatory effect of cell metabolism,
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glucose could have a more selective function in providing energy 
or substrate required in the synthesis of a critical regulatory 
molecule e.g. in the thermocytes, glucose has been shown to be 
required for maximum incorporation of radiolabelled amino acids 
into proteins in the nucleus (Giddings & Young, 197*0.
D-glucose enters the lymphocyte by carrier-mediated 
facilitated transport. In their studies of the effect of PHA on 
the transport of a non-metabolisable analogue of glucose, 3“0 MG, 
Peters & Hausen (1971) found an increase in the rate in influx 
after two minutes, and a five fold increase after thirty minutes 
suggested that PHA acts by making more carrier molecules available 
to the glucose.
Most mammalian tissues do not produce large amounts of 
lactate when they are incubated under normal aerobic conditions. 
Otto Warburg (1926) was the first to report high rates of lactate 
production by rapidly proliferating cells. He observed that white 
blood cells oxidising glucose under aerobic conditions, showed 
high rates of lactate production. It has been suggested that the 
glycolytic capacity of growing cells may be regulated by the co­
ordinated control of the expression of glycolytic enzymes. Lactate 
production by lymphocytes increases to four times the initial rate 
after 2k hours following PHA addition (Packman, 1968). The effect 
of PHA increases with time, and early changes in carbohydrate 
metabolism include the accumulation of lactate, pyruvate,
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does occur and as much as 83% of ATP synthesized may result from
oxidative phosphorylation. (Roos &. Loos, 1973)* From 30 to 120
min there were increases in parameters of carbohydrate metabolism
(Peters and Hausen, 1971)* Early metabolic changes can be measured
by assays of glucose consumption (De Cock et al,1980) or lactate
production (Cordiali - Fei et al, 1980; Polgar et al, 1968; Roos &
Loos,1970; Parkes & Howells, 1975)* Do Cock et al (1980) found
3
that glucose consumption correlated well with H-thymidine 
incorporation into DNA, and morphological studies of transformed 
cells. Their test was highly reproducible registering the whole
3
event of transformation, unlike H-thymidine incorporation or
morphological studies. The rate of glucose uptake doubles within
I5-3O minutes of PHA addition and increases further with time
(Peters & Hausen, 1971).
Lactate release can also be monitored Cordiali - Fei et al
(1980) found significant levels of lactate released after three
hours of stimulation with PHA of peripheral blood lymphocytes.
3
The results were reproducible and correlated well with H -




The increase of Ca influx appears to be one of the earliest 
events which takes place following contact with stimulating agents 
(Kennes et al, 1981) and uptake of radiolabelled calcium was found 
after 30 min. Kennes et al, (1981) and Freedman et al (1979) both
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used the assay and found it was variable but correlated quite well
3
with H-thymidine incorporation.
The insulin receptor can also be used as a marker for
activation. It is not normally present on T and B cells but
appears on the membrane as a consequence of activation. The
insulin receptors appeared after three days of culture with the
125
stimulant, and are easily monitored with I- insulin,
(Helderman et al, 1978)• The insulin receptor has been shown on 
lymphocytes from man, mouse and rat upon activation, and is 
therefore a general marker of cellular activation.
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Section 5» Human Monoclonal Antibody Production
Section fj Human monoclonal Antibody Production
5.1. Introduction
The theory of monoclonal antibody production is based on the
clonal selection hypothesis of Macfarlane Burnet (Burnet, 1959).
Each mammalian B cell has the potential to make a monospecific 
antibody. The constant region of the antibody chain may alter but 
the variable region retains its singular specificty.
The first report of hybridoma production was in 1970 when 
Sincovirs et al, (1970) fused virus specific lymphocytes with 
tumour cells. However, the full potential of the monoclonal
technology was developed in a now famous paper by Kohler and
Milstein in 1975.
5.2. Monoclonal Antibodies by Cell Hybridisation
5.2.1. Theory
The experimental problem encountered in the production of 
monospecific antibody relates to the fact that antibody secreting 
plasma cells are terminally differentiated lymphocytes with a 
finite life span, and cannot be grown in culture. However, tumours 
of such cells can be found in animals, and can be readily induced 
in mice with the aid of mineral oils (Kohler and Milstein, 1975* 
1976; Campbell, 1984). These tumour cells secrete antibody of a 
single specificity yet can be grown indefinitely in culture. If 
such tumour cells can be fused with a lymphocyte making antibody
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of a required specificity some hybrids will have the eternal 
growth of one parent, and specific antibody production of the 
other (Kohler & Milstein, 1975* 1976). There are two key
refinements of the technique; firstly, the selection of a tumour 
parent line which does not itself secrete antibody, so the hybrid 
antibody is necessarily that of the required specificity and 
secondly selection of a cell line that is vunerable to the cell 
culture conditions so that it cannot survive unless it has 
participated in the fusion. The most frequently used way of 
achieving the latter condition is to use a parent tumour line 
which lacks either the enzyme thymidine kinase (TK) or 
hypoxanthine phosphoribosyl transferase (HPRT). These enzymes are 
from the salvage pathway of nucleic acid metabolism and are 
essential for cells growing in the presence of aminopterin which 
blocks the major pathway of nucleotide synthesis. The cells after 
fusion are cultured in media containing Hypoxanthine, 
Aminopterin, and Thymidine (HAT) (Littlefield, 1964) so that the 
parent tumour cells die; hybrid cells possess the salvage enzymes 
of the non-tumour parent and survive. Methods Figure 2.1 shows a 
schematic representation of the fusion procedure. The hybrid 
cells are grown in culture plates and assayed for production of 
the required antibody. The suitable clones are then selected for 
expansion and subcloning so that eventually the required antibody 
can be produced in large amounts.
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5.2.2. Fusion Partner 
Both mouse and rat systems are widely used and the choice between 
the two is fairly open. The human hybridomas are harder to make 
than are the rodent ones and are only produced when the other 
systems cannot be utilised.
The mouse system was historically the first to be developed 
as a method of production of monoclonal antibodies of predefined 
specificity (Kohler & Milstein, 1975) and the majority of 
hybridomas to date are of mouse origin. Table 1 lists some of the 
mouse cell lines currently available as fusion partners. All the 
cell lines originated in Balb/c mice. The most obvious choice of 
mouse species for immunisation would be Balb/c as this is 
compatible with the myeloma cell lines, and the hybridomas
produced can be grown in ascites fluid.
The rat system has been reported to have definite
advantages. The rate of reversion of cell lines to non-secreting 
forms is lower than in presently available mouse cell lines, and 
this is obviously a valuable characteristic if it is retained in 
the progeny. An additional advantage is that 90% of the growing 
hybrids express spleen immunoglobulins compared with only 60% in 
the mouse system (Clark et al, 1983). Rats are larger and yield
approximately ten times more ascitic fluid in the production
stages (Galfre et al; 1979)*
Additional advantages of the rat system may lie in the high 
frequency of antibodies able to fix human complement. If
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therapeutic applications are envisaged then this property may be 
significant.The rat system was originally developed by Bazin 
(Bazin et al, 1972,1973;)* Rat myelomas are comparatively rare.
Human hybridomas present more difficulties and their use is 
only really justified if the final application of the monoclonal 
antibody precludes the use of mouse or rat (Edwards & O'Hare, 
1984). There are few non-secreting human myeloma, or 
lymphoblastoid cell line presently available and this leads to 
mixed and diluted antibody production. Only a few papers have 
reported the production of human-human hybridomas(Croce et al, 
1980; Olsson and Kaplan, I98O; Shoenfeld et al, 1982; Sikora et 
al, 1982) and relatively few deal with technical details (Olsson 
et al, 1983). Shoenfeld et al (1982) stimulated mononuclear cells 
from the spleen or peripheral blood with PWM, favouring 
autoantibody producing B-cells. Their human-human fusions gave low 
frequency of hybridomas but the frequency of autoantibody 
producing hybrids was comparable to that of mouse-mouse hybrids. 
The results of Olsson et al (1983) confirmed the low hybridoma 
frequency but this was found to be comparable with that from 
fusions of mouse peripheral blood lymphocytes with a corresponding 
mouse myeloma cell line. They also studied the use of PWM over a 
period of days before fusion and observed that, if the peripheral 
blood lymphocytes were stimulated for 5-7 days, the number of 
hybrids was significantly increased. The reasons for this probably 
stems from the fact that when PEG is used to fuse the cells it
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only mediates the fusion of the cell membranes, whereas the fusion 
of the karyons occurs spontaneously when the two nuclei 
synchronously enter mitosis. However, human peripheral blood 
lymphocytes are not normally in active cell cycle and the fusion 
of such cells with a human myeloma/lymphoma cell line results in 
very few successful hybrids as very few are actually in mitosis. 
The number of hybrids was increased with PWM because more cells 
are actively dividing when fused. The number of Ig-secreting 
clones tended to be higher with PWM-PBL but not significantly. 
While hybrids of the appropriate specificity are sometimes 
obtained after the initial fusion, subcloning is necessary to 
maintain secretion, and hybrids present many technical 
difficulties.
Clearly,humans are not generally immunised for monoclonal 
antibody production and human hybridomas are of interest more for 
the study of autoimmune or malignant disease.
Many early fusion experiments were often carried out with 
mouse cell lines. These interspecies fusions were first reported 
in 1973 (Schwaber and Cohen, 1973) when the mouse myeloma cell 
line TEPC-15 was fused with human PBL and the heteromyeloma 
secreted both human and mouse immunoglobulin. Similar fusions have 
been performed since (Schwaber and Rosen, 1978; Croce et al, 1979; 
Astaldi et al, 1980; Nowinski et al, 1980; Sclom,Wunderlich and 
Teramoto, 1980; Lane et al, 1982; Bron et al, 1984; Foung et al,
1984). Many of these were generated from spleen cells, lymph nodes
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and PBL.
Mixed human-human and human-mouse hybrids tend to lose human 
chromosomes preferentially although human chromosome 14 (carries 
the heavy chain locus) and 22 (which carries the lamba chain 
locus) are frequently retained (Croce et al, 1980). Loss of 
secretion has occured even when the relevant chromosomes have been 
retained (Raison et al, 1982). The loss of antibody production was 
found not to be due to the overgrowth of the secreting clones by 
the non-secreting clones, but rather by a loss or inactivation of 
antibody-producing chromosomes (Westerwould et al, 1983). The 
greatest loss in secretion results in the first three weeks after 
fusion and then stabilises. This unstability in mouse-human 
hybrids has made them unpopular as a method of human monoclonal 
antibody production. Despite all these findings, Cote et al (1983) 
have shown that if early and repeated subcloning is carried out, 
the mouse - human system can yield hybridomas with stability 
comparable to that of human - human fusions. The use of the mouse 
system enables one to employ non-secreting cell lines, not yet 
possible with human hybridomas. To date only a limited number of 
human monoclonal antibodies have been reported (Lagace et al,
1985). There are four main cell lines available for use in human 
- human fusions (Edwards & O’Hare 1984) SK0-007, GM1500, LICR-LON- 
HYM2, UC729.
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5.2.3. The Selection of Cell Lines 
There are several factors to consider when choosing a cell line. 
As mentioned already it is preferable to choose a myeloma cell 
line that does not secrete antibody. If a myeloma makes only light 
chains then the amount of irrelevant antibody is limited and at 
least 25% will be the immunoglobulin of the desired specificity. 
However, if both heavy and light chains are secreted then specific 
antibody is more diluted. Generally ,most fusions are mouse-mouse 
and the most common myelomas used are P3X63.Ag8-653 and NS1 Ag4-1, 
of which NS1 produces intracellular light chains. Since these can 
combine with heavy chains produced in a hybridoma and then 
secreted, the preferred myeloma is Ag8. Another line that is 
often used is SP2. However, SP2 is not a true myeloma but a non- 
producing hybridoma and as such, in theory, less stable. Table 1 
gives a summary of the cell lines available for fusion and their 
properties.
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Table 1. A Summary of the Plasmacytoma Cell Lines used for 
Hybridisation
Cell Myeloma Drug Immunoglobulin










P3+spleen 8-Ag - -
F0 Sp2 = Sp2 8-Ag - -
P3x63-Ag8.653 P3 8-Ag - -
MOPC-315LK MOPC 315 none a L2
4T00.1 MPOC 11 6-TG + 
oubain
y2B k
P326BU4 MOPC 21 Brdu + yi k
PB00.1 P326BU4 BrdU + 
oubain
yi k
Cl.3 X5563 none y2A k
lOkE MOPC 104E none u L
45.6TG1.7 MOPC 11 6-TG y2B k
4T0.2 MOPC 11 6-TG + 
oubain
Y2B k
P1BU1 Adej.PC5 BrdU Y2A k
PIBUl-Ou P1BU1 BrdU + 
oubain
Y2A k




TEPC-15 TEPC-15 none a
210.RC43.Agl Rat 8-Ag -
Y3-Agl.2.3 Rat 8-Ag -
UM.l-6TGr UM-1 6-TG u
Um-21-5 UM-21 citrullinemic -
GM 1500 6TG-A12 GM 1500 6-TG Y2
U-266AR1 U-226 8-Ag E
From J. Imm Methods 53 (1982) pp.261-291
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5.2.4. The Fusion Procedure 
The basic theory behind monoclonal antibodies revolves around two 
important discoveries. The first was to select an agent that 
would cause the fusion of two cells (the myeloma and the spleen 
cell), and the second was to develop a selection method to 
separate those cells that had fused to give a hybrid from unfused 
spleen and myeloma cells.
In their original paper Kohler & Milstein 1975(Nature 256:495) 
used Sendai virus as the fusion agent. This virus has the ability 
to cause the two membranes to fuse. It was found that polyethylene 
glycol would do the same thing but was much easier to handle and 
so has been the fusion agent of choice ever since (Pontecorvo, 
1976; Lane, 1985; Roitt et al,1985).
The most common cells used in the fusion are spleen cells. 
However, peripheral blood lymphocytes can also be used. The latter 
are separated on ficol-hypaque gradients to remove the red blood 
cell contamination. The spleen cells naturally die in culture 
after 1-2 weeks;the myloma cells die in HAT, but the fused cells 
survive having the immortality of the myeloma and the metabolic 
by-pass of the spleen cells.After the inital 1-2 weeks in HAT the 
cells are then transferred to HT medium, which lacks the powerful 
toxin Aminopterin, for 1 week and then finally to culture medium.
5.2.5. Screening
When screening, it is essential to identify desirable hybrids
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quickly, as the labour of maintaining and characterising them is 
greater than that needed to perform another fusion. The screening 
assay must be sensitive to about lug of antibody /ml.
Antibodies are commonly detected by ELISA or RIA based on 
immobilised antigen (Williams et al, 1967; Goding, 1980). 
However, the antibody should be tested in the way that is is to be 
used. e.g. immune precipitation of antigen has been used for 
screening after a preliminary rapid test for abundant antibody 
binding to protein A of Staphylococcus aureus (Brown et al, 1980). 
Staining of tissue sections, or cells by immunofluorescence 
(Goding, 1980) or immunocytochemical methods (Schlom et al, 1980) 
are suitable screening methods for antibodies that mark particular 
cells or special structures such as intermediate filaments.
5.2.6. Plating and Cloning
Hybridomas are commonly lost between detection of postitive 
clones and cloning. The fused cells carry a tetraploid number of 
chromosomes making them unstable and therefore have to expend 
large amounts of energy in order to replicate. Cells which lose 
chromosomes can divide more quickly, but the chromosome lost may 
be the one required for immunoglobulin secretion. Hence the non- 
secreting clones will overgrow the desired hybridomas. Cells 
secreting immunoglobulin also use substantial amounts of energy 
for protein synthesis and therefore have less energy for cell
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division. Early cloning is essential for maintaining 
immunoglobulin secretion.
Cloning a single hybrid under adverse conditions is time 
consuming. If one is screening for an antibody that discriminates 
between 2 antigens, a specific clone may be missed if it is mixed 
with a clone that produces non-specific antibodies. Hence fusion 
protocols should be designed to generate clonal hybrids from the 
outset, hybridomas are enhanced in both cell growth and antibody 
production by various specific growth factors (Astaldi et al, 
1981; Pintus et al, 1983; Westerwould et al, 1983)• These 
observations have led to the extensive use of feeder layers 
(macrophages or thermocytes, non-dividing cells that provide a 
suitable environment, Goding et al, (1980)) during hybrid 
production (Goldsby et al, 1978; Kennett et al, 1978; Brodin et 
al, 1983; Teng et al, 1983; Strike et al, 1984). The feeder cells 
presumably condition the medium and optimise it for hybridoma cell 
growth and survival. Long et al (1986) found that irradiated human 
diploid cells were highly effective in the establishment and 
propagation of new hybridomas and in maintaining viable hybridomas 
during limiting dilution. Human-human fusions always have feeder 
cells present (preferably human) as this gives the hybrids the 
most possible help. Only 10# of wells should contain hybrids 
after limiting dilution (Fazekas de St. Groth et al, 1980). An 
alternative is to plate the hybrid cells in agar so that they grow 
as clones (Sharon et al, 1979; Edwards et al,
9^
1980). Individual positive clones are picked from wells and 
retested after isolation (Edwards, I98O). Hybrids should be 
recloned by limiting dilution, rather than in agar which gives a 
lower cloning efficiency and may select for unwanted cells that 
are more vigorous than the desired hybrids.
Pokeweed Mitogen Stimulation of B Lymphocytes 
Mitogenic stimulation of B-cells results in a greater chance of 
obtaining antibody-secreting hybrids after fusion or 
transformation. A number of reports (Astaldi et al, 1980; Olsson 
et al, 1983) suggest stimulation with PWM. This mitogen is known 
to induce human peripheral blood lymphocytes to enter S phase and 
also to induce B lymphocytes to differentiate into plasma cells 
(Janossy et al, 1975; Ginsburg et al,1978; Tosato & Blaese, 1985). 
While differentiation of plasma cells usually reaches a maximum 
after 6-7 days, stimulation with PWM reduces the period to only 4 
days (Yen et al, 1981). PWM-induced polyclonal B-cell activation 
requires the participation of helper T-cells ( Keightly et 
al,1976; Fauci et al,1976; Hirano et al, 1977; Saxon et al, 1977) 
or their secreted products (Insel et al,1977) while suppressor T- 
cells can modulate generation of immunoglobulin synthesising cells 
(Moretta et al,1977; Lipsky et al, 1978). This mitogenic 
stimulation of B-cells results in a greater chance of obtaining 
antibody secreting hybrids after fusion or transformation.
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5.2. The Production of Human Monoclonal Antibodies by
EBV Trans formation 
Epstein-Barr is a ubiquitous virus that infects the majority 
of human adult normal individuals worldwide (Tosato and 
Blaese,1985). Primary infection with the Herpes virus is generally 
asymptomatic, particularly in childhood, but may result in acute 
infectious mononucleosis in adults (Henle and Henle,1979)* One of 
the main characteristics of the virus is that it induces normal 
human B lymphocytes to proliferate and secrete antibody,and to 
become activated into long term cell lines that can be propagated 
in vitro for years (Sugden,1982; Nilsson and Klein,1982). That is, 
EB virus is a polyclonal B cell activator. The induction of the 
indefinite cellular proliferation in vitro by EBV is 
termed "transformation”.
EBV transformation offers an alternative method of obtaining 
monoclonal human B-cells that secrete human monoclonal antibodies 
of defined specificity. The great advantage of this method is that 
a very high percentage of antibody producing cells may be 
immortalised and no chemical selection is required. This technique 
has been used to obtain human monoclonal antibodies to tetanus 
toxin (Kozbor et al,1982), red blood cells, rheumatoid factors, 
and anti-nuclear antibodies in SLE.
Infection of lymphocytes with the virus represents a 
necessary step to achieve B-cell activation and immunoglobulin 
production. Culture supernatant of a Burkitt lymphoma cell line,
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marmaset B95“B, is the most commonly used source of the virus 
(Tosato and Blaese,1985). The continuous presence of the virus is 
not necessary for transformation and a 1-9 hour exposure is
usually sufficient (Yarchoan et al,1983). In contrast to other B- 
cell polyclonal activators, EBV does not require cooperation from 
other cells e.g. T-cell or macrophages (Kirchner et al,1979)* 
During the first 8 days in culture the B-cell response to EBV in 
vitro is not significantly different from the response to other B- 
cell activators such as PWM. All the major classes and subclasses 
of immunoglobulin (Andersson et al,198l) are produced and
production can increase exponentially over a 14 day culture 
period. However, in most cases B-cell response is inhibited after 
8 days because most individuals produce cytotoxic T-cells which 
attack and destroy the virus infected B-cells (Tosato et al, 
1982). Hence for successful transformation, removal of this 
cytotoxic effect is necessary. This can be achieved in a number of 
different ways. T lymphocytes can be removed by E-rosetting with 
sheep red blood cells (Roitt et al, 1985). by killing them with 
drugs, e.g. cyclosporin A (Tosato et al, 1984a) or, better still, 
the B-cells may be positivly selected. Positive selection is 
readily performed with soluble antigens which are attached to SRBC 
and then separated on percoll gradients.The relevant lymphocytes
are then located in the pellet (Kozbar & Roder,198l).
There are several disadvantages in this technique. One is 
that B-cell immortalisation by EBV is not synonymous with
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immunoglobulin production. In fact, most (approximately 95#) of 13- 
cells infected with EBV secrete immunoglobulin but only 60 %
become immortalised (Tosato et al, 1983). Immunoglobulin 
production by EBV-activated cells that do not give rise to long­
term antibody production could be due to a phenomenon of abortive 
transformation (Tosato & Blaese,1981). The other disadvantage is 
the very low level of immunoglobulin secretion of EBV transformed 
cells which is rarely above ljig/ml of culture supernatant ( most 
commonly 10-100ng/ml). Both problems may be overcome by early 
cloning of the transformed cell or much better by fusion with a 
myloma cell line (Kozbor et al, 1982 used KR-4 cell line).
5.3» Monoclonal Antibodies and Autoimmune Disease
Current concepts of autoimmunity emphasize the role of antibodies 
in the development and maintenance of most autoimmune disorders 
(Allison, 1977) including SLE, RA, MG, autoimmune thyroiditis, 
autoimmune haemolytic anemia and several experimental and drug 
induced autoimmune diseases. With the exception of a few 
monoclonal rheumatoid factors, the majority of autoantibodies are 
polyclonal.
Consequently, the detailed investigations of the structure, 
specificity and pathogenic role of these antibodies has been very 
difficult. Hybridoma technology presents the opportunity of 
studying autoantibodies in more detail.
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5.3.1. Antigen Specificity of Autoantibodies 
A precise characterisation of antigens involved in an autoimmune 
syndrome may help in understanding its etiology and pathogenesis 
with eventual diagnostic and prognostic applications. Autoantigens 
have been identified in a number of autoimmune diseases, including 
the acetylcholine receptor in MG, (Lindstrom,1979)» IgG in RA 
(Zvaifler, 1977)* and nuclear antigens in SLE (Stoller,1973)• It 
should be borne in mind however, that the ability to find 
autoantibody does not necessarily identify the true initiating 
autoantigen (Moller et al, 1981). In SLE, the putative autoantigen 
is DNA which possesses many antigenic determinants. Autoantibodies 
that bind to DNA could be directed against any number of 
determinants.
The presence of autoantibody-producing B-cells in healthy 
mammals is supported by the existence of animal models. Also 
administration of polyclonal B-cell activators to normal animals 
gives rise to detectable antibodies to DNA, and poly A ( Fourie et 
al, 197^; Fischbach et al, 1978).
There are many problems concerning the role of 
autoantibodies in mediating disease. A given autoantibody could be 
an essential part of a pathological mechanism which leads to 
tissue damage and organ dysfunction, or it may appear as a 
product of the disease.
Monoclonal antibodies, when isolated and purified in 
sufficient quantities, may contribute to the eludication of a
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pathogenic mechanism. The production of several monoclonal 
antibodies that possess the same antigenic specificity, but differ 
with respect to antibody class, and subclass, antibody valence, 
degree of polymerisation and complement-fixing properties may help 
to determine the relative importance of each of these parameters 
in mediating autoimmune disease in experimental animals. Also the 
special characteristics of the interactions between autoantibodies 
and their antigens is important in the expression of pathological 
manifestations, particularly in autimmune diseases which are 
classified as immune complex diseases.
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CHAPTER 2 MATERIALS AND METHODS




2 Materials and Methods
2.1 Materials
2.1.1. Radiochemicals
[Thy-methyl-3H] (specific activity 25 Ci/mmol); [Leu-4,5-3H]
3
(specific activity 64 Ci/mmol); [Urid-5,6- H] (specific activity 
40 Ci/mmol); were purchased from the Radiochemical Centre, 
Amersham, Bucks; U.K.
2.1.2. Enzymes
Deoxyribonuclease I (bovine pancreas), trypsin (bovine pancreas), 
horseradish peroxidase and alkaline phosphatase-conjugated 
antisera were purchased from Sigma Chemical Company, Poole, 
Dorset, U. K.
2.1.3* Mitogens
Concanavalin A, and Phytohaemagglutinin were obtained from 
Pharmacia, Uppsala, Sweden. Pokeweed Mitogen was obtained from 
Sigma Chemical Company, Poole, Dorset, U.K.
2.1.4. Cell Lines
P3.X63-Ag8-653 a non-immunoglobulin secretor mouse myeloma B-cell 
line was obtained from Flow Laboratories, Irvine, Scotland 
2.1.5* General Reagents
The following items were obtained from Flow Laboratories: fetal
calf serum; donor horse serum; L-glutamine; penicillin- 
streptomycin; RPMI 1640; leucine-free minimal essential medium; 
phosphate-buffered saline; sodium pyruvate; sodium bicarbonate;
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Lymphocyte Separation Medium; HAT; HT; and 10-spot multi test 
slide.
Dulbecco’s Minimum Essential Medium (DMEM); high binding 
microtitre plates, and all sterile plastic ware were purchased 
from Gibco-Nunc, Paisley, Scotland.
The following items were purchased from BDH, Poole, Dorset, U.K.: 
Trypan blue; acetic acid; perchloric acid; trichloroacetic acid; 
eosin; Delafeld’s haematoxylin; microscope slides; coverslips; n- 
propyl gallate; polyethylene glycol. Di-nitrophenyl phosphate 
(DNPP) and all other chemicals were Analar grade.
The assay kits, for glucose and lactate determination and uranyl 





i) Lymphocyte Culture Medium 
Components Final Concentration




RPMI 1640 85# (v/v)
ii) Leucine-free Lymphocyte Culture Medium 
Components Final Concentration




MEM (Eagles)(Leucine free) 85# (v/v)















PH adjusted to 7*4-7*6 with sterile IN NaOH
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2.1.6. (b) Neuronal Cell Culture Medium
i) Serum Supplemented Medium (SSM)
Components Final Concentration
Fetal calf serum (heat inactivated) 10# (v/v)

























This medium also contains all the components of SSM except the
sera.
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PH was adjusted to 7*3"7*4 with IN NaOH
2.1.6 (c) Media for Monoclonal Antibody Production
i) Cloning Medium
Components 
















This medium contains all the components of the cloning medium plus 
Hypoxanthine (O.lmM) and Thymidine (l6pM).
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iii) HAT Supplemented Medium
This is as the HT medium plus Aminopterin (0.4jjM).
iv) Polyetheylene Glycol Solution (50$ w/v)
Components Final Concentration
Polyethelene glycol 4000 (MERCK) lOg
PBS 10ml
Dimethyl suphoxide (DMS0) 1ml
The PEG and PBS were measured into a glass container and then 
autoclaved , after which the DMS0 was added.
2.1.7» Patients and Controls
Blood samples from patients with Motor Neurone Disease (MND) and 
Multiple Sclerosis (MS) were obtained from Dr. M. Campbell 
Consultant Neurologist at the Bristol Royal Infirmary. The 





2.2.1. (a) Lymphocyte Preparation
All the following procedures were carried out under aseptic
conditions. Peripheral blood lymphocytes were isolated from whole
blood by a modification of the method of Boyum (1968). Fresh
venous blood (20ml) was collected into a sterile syringe, and
expelled into a 30ml universal flask containing an anticoagulant,
Heparin (20U/ml). The blood was diluted with an equal volume of
phosphate buffered saline (PBS). This dilution with the PBS is
carried out to control the degree of aggregation of the red blood
cells so that they sediment easily with the minimum of lymphocyte
entrapment. The diluted blood was carefully layered onto a
gradient of lymphocyte separation medium in a 10ml polycarbonate
centrifuge tube. After centrifugation at bOOxg for ^0 min at room
temperature, the mononuclear cell layer was clearly visible at the
interface as a white band. It was carefully removed with a 1ml
Pasteur pipette, washed three times with PBS (20ml each wash), and
6
finally resuspended at 2x10 /ml in lymphocyte culture medium
3
(LCM). Cells used for the [ H]-Leucine incorporation studies were 
resuspended in leucine-free lymphocyte culture medium.
2.2.2. Cell Viability
Lymphocyte viability was tested by the cells’ ability to exclude 
trypan blue. Equal volumes of the cell suspension and 0.2% (w/v) 
trypan blue in saline were mixed, and the cells were counted using
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a haemocytometer. The lymphocytes were counted in PBS rather than 
lymphocyte culture medium as the FCS in this medium could lead to 
false results because of the great affinity for trypan blue of 
proteins (Kruse et al, 1973)* Counting was performed within 3 
minutes after the addition of trypan blue. After this time viable 
cells also take up the dye.
2.2.3* Mitogen Stimulation
5
Samples (100/ul, 2x10 cells) of the lymphocyte suspension were
placed in the wells of U-bottomed microtitre tissue culture
plates. An equal volume of Concanavalin A (Con A),
Phytohaemagglutinin (PHA), Pokeweed Mitogen (PWM), or membrane
fragments (see Section 2.2.8.) at the appropriate concentration
was added. Control cultures received the lymphocyte culture medium
only. The cultures were then incubated in a humidified atmosphere
o
of 3% CO in air at 37 C for 72 h. All the experiments were
2
carried out in triplicate.
2.2.4. Lymphocyte Trans formation Assays
2.2.4.1. Glucose Consumption Test
This was carried out according to De Cock et al (1980). At the
appropriate time, samples (lOOpl) of the supernatant from both
control and stimulated cultures were deproteinised with uranyl 
acetate (1ml) and centrifuged at 10,000xg for 5 min. The 
supernatants were then assayed for glucose within 24 h with a 




Glucose + 0  + H 0
2 2
> gluconate + H 0 
2 2
H O  + ABTS* 
2 2





*ABTS = diammonium 2,2’-azino-bis (3-ethylbenzothiazoline-6- 
sulfonate
GOD = Glucose Oxidase 
POD = Peroxidase
Lymphocyte stimulation was expressed as the difference between 
glucose used by the control and stimulated cells.
2.2.4.2. Lactate Release
This procedure is very similar to that of the glucose assay. At
the appropriate time, samples (200jil) of the supernatant from the
stimulated and control cultures were deproteinised with ice cold
perchloric acid (0.6M, 1ml), and centrifuged at lOOOxg for 10 min
o
at 4 C. The lactate content of the samples was measured by using 
the Lactate Test Combination Kit.
Test Principle
L-Lactate + NAD(+) ------^ Pyruvate + NADH + H(+)
Stimulation was expressed as the difference in lactate content of 
the supernatants from the stimulated and control cells.
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2.2.*1.3 Incorporation of Radioisotopes
At the appropriate time, radiolabelled precursors (0.2/uCi) were 
added to the cells in the lymphocyte culture medium (10/ul) for a
3
period of 18 h. [ H]-thymidine was added to measure the increase
3
in DNA synthesis, [ H]-uridine was used to follow RNA synthesis
3
and [ H]-leucine gave a measure of protein synthesis. The cells
were then harvested by using a cell harvester (Flow Laboratories,
Irvine, Scotland) and the radioactivity precipitated by 10# (w/v)
trichloroacetic acid was measured in a liquid scintillation
spectrophotometer (Packard Tri-Carb, Packard Instrument Ltd;
Reading, England).
The lymphocyte stimulation was expressed as log (CPM
(stimulated) - CPM (control)) or as the Stimulation Index
(CPM (stimulated)).
CPM (control)
The control refers to the test sample incubated without mitogen.
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2.2.5. Rat Spinal Cord Cell Culture
2.2.5.1. Preparation of Collagen-Coated Plates
The plates were coated with photopolymerised rat tail collagen
according to the method of Masurousky and Peterson (1976). Culture
dishes (3.5cm petri dishes, 2k well trays, and 10 well multi-spot
slides) were coated with a collagen (lmg/ml)-riboflavin (0.03%
2
w/v) mixture (ratio k:l) which was spread evenly (lOjil/cm ) and
o
then placed in an incubator at 37 C overnight, and rinsed twice
with sterile water to remove excess riboflavin. 30 min prior to
the addition of the cells, the plates were incubated with Serum
o
Supplemented Medium at 37 C in an atmosphere of 10# CO , 90# air.
2
2.2.5.2. Preparation of a Single Cell Suspension from 
Rat Spinal Cord
Spinal cord cells were cultured according to the method outlined
by Digby et al (1985) with minor modifications. Pregnant rats (15
day) were killed by cervical dislocation and the embryos (13-15)
were removed under aseptic conditions. The spinal cords were
dissected from the embryos and minced with irridectomy scissors
in Puck’s BSS (0.5ml). The cell suspension was then transferred to
a round bottomed plastic test tube (12ml) by using the same buffer
(3ml). Deoxyribonuclease I (lmg/ml) in H-Eagles medium (200/il) was
added in order to prevent the cells becoming 'sticky* as a result
of the release of nucleic acids; this hinders the subsequent
o
formation of a single cell suspension. After 5 min at 20 C, 0.5#
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(w/v) trypsin in H-Eagles medium (200ul) was added. The cells were 
o
incubated at 37 C for 45 min with gentle mixing every 5 min then
centrifuged for 5 min at 400xg. The supernatant was discarded and
the spinal cord fragments were mechanically dissociated by
trituration with a plastic Pasteur pipette by using samples (2ml)
6
of SSM. The cell suspension (3~5 *10 /ml) was plated out on petri
5 2
dishes at a density of 10 cells/cm in culture medium. The
cultures were then maintained in a humidified atmosphere
o
containing 10% CO at 37 C. After 3 days the culture medium was 
2
changed to serum-free medium and renewed every 3 days. From days 
6-9 fluorodeoxyuridine (15ug/ml) and uridine (35ug/ml) were added 
daily. Addition of the inhibitor before this time led to excessive 
cell death.
2.2.6. Histochemical Staining
Coverslips were prepared as described in Section 2.2.5.1. and were
o
fixed in 5% (w/v) acetic acid/ ethanol for 10 min at -20 C, or in 
(4#) paraformaldehyde. They were then washed four times with PBS 
until the pH was neutral, and incubated with either methylene blue 
(MB) or Delafeld’s haematoxylin (HT) for 5"15 min (until the cells 
had stained slightly darker than desired) and washed with PBS. The 
coverslips were then incubated with 1% (w/v) eosin in water for 
2 min and washed with PBS. All the coverslips (MB+HT) were 
dehydrated by incubation for 10 min with each of a series of 
ethanol-water mixtures containing 70%, 80%, 30%, 35%* and 100#
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ethanol respectively. Finally the coverslips were incubated with 
xylene for 30 min and then mounted on a large microscope slide 
(2.5x8cm) with an organic solvent, DPX.
2.2.7. Immunocytochemical Identif ication of Cultured
Spinal Cord Cells
Rat spinal cord cells were cultured on collagen-coated cover slips
(13mm) in a similar manner to that described in section 2.2.5.1.
The slides were washed twice with PBS (5ml each wash) and then
o
fixed with 5% (v/v) acetic acid/ ethanol for 10 min at -20 C. The 
cover slips were rinsed with PBS until the pH was neutral,and then 
incubated with 10# (v/v) rabbit serum in PBS for 30 min at room 
temperature. Mouse antibodies (anti-neurofilament, a kind gift 
from Adrian Rodgers and anti-tetanus toxin a kind gift from Ahmed 
Jehanli) in 10# (v/v) rabbit serum/PBS were added to the cover 
slips (100pl). After 30 min at room temperature, they were then 
washed by dipping ten times in 10# (v/v) rabbit serum/PBS. Finally 
the fixed cultures were incubated for 30 min in the dark at room 
temperature with a fluorescent-labelled rabbit anti-mouse IgG, 
diluted in 10# (v/v) rabbit serum/PBS. The cover slips were then 
finally washed as before and mounted on a large microscope slide 
(2.5x8cm) with 5# (v/v) n-propyl gallate in glycerol/PBS (9:1 v/v) 
pH 8.0 solution.
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2.2.8, (a) Spinal Cord Membrane Preparation
The procedure of Snyder and Young (1973) was adapted to the
neuronal cultures. Spinal cord cell cultures (15-16 day) were
scraped by using a teflon-coated spatula from the petri dish
surface (3.5cm, 20 dishes) in 0.32 M sucrose (0.5ml) and the cell
suspension was then homogenised in a 1ml glass homogeniser for 10 
o
min at 0 C. The homogenate was centrifuged at lOOOxg for 10 min
and the resulting supernatant was then centrifuged at 15000xg for 
o
30 min at 4 C. The pellet was resuspended in ImM Tris/HCl buffer,
o
pH 8.0, (0.5^1) and homogenised for 10 min at 0 C. The suspension
o
was centrifuged at 9000xg for 20 min at 4 C to give a supernatant 
that contained membrane fragments (0.5~0.6 mg/ml). Protein was 
estimated by a modification of the method of Lowry (Markwell et 
al, 1978).
2.2.8. (b) Spinal Cord Membrane Preparation
This procedure is identical to the above method but instead of
cultured rat spinal cord cells, adult rat spinal cords were used.
Rat spinal cords (20) were homogenised in 0.32M sucrose (10ml) for 
o
10 min at 0 C. The resulting homogenate was then centrifuged at
1000 x g for 10 min and the resulting supernatant was centrifuged
o
at 15000 x g for 30 min at ^ C. The pellet was resuspended in ImM
o
Tris/HCl buffer, pH 8.0, (10ml) and homogenised for 10 min at 0 C.
o
The suspension was centrifuged at 9000 x g for 20 min at 4 C to 
give a supernatant that contained membrane fragments (3mg/ml).
115
This was referred to as a P3 membrane fraction. The protein 
content of the supernatant was estimated as described above.
2.2.9. Monoclonal Antibody Procedures
2.2.9.1. Myeloma Cell Line Maintenance
P3X63.Ag8-653. a mouse myeloma B-cell line, was kept under
continuous culture in cloning medium ( see section 2.1.6. (c) ).
6
The cells were maintained at a density of 0.2-0.8 xlO /ml, being 
supplemented with fresh medium every 3 days.
2.2.9.2 Macrophage Preparation
Balb-c mice (4 weeks old) were killed by cervical dislocation and
placed in 75# (v/v) ethanol in water. The mice were removed from
the liquid, the skin was dissected away from over the liver and
PBS (5rol) was injected into the peritoneal cavity by using a 5ml
syringe with an l8g needle. The mice were then rocked for 2 min.
The PBS was removed by drawing the liquid back into the 5™!
syringe with a 28g needle, and placed in a 5®1 Bijou bottle. The
45
cell suspension was irradiated with Co (400 rads, 4 min) and the
cells were then counted by using a haemocytometer. The macrophages
were centrifuged at 400xg for 10 min at room temperature and
6
resuspended in cloning medium at 1x10 /ml. They were then
distributed (50/nl) to each well of a 96 well flat bottomed
o
microtitre tray, and incubated for 24h at 37 C in a 5# humidified




Lymphocytes were separated from fresh venous blood (see Section
2.2.1.(a)) and mixed with the P3X63.Ag8-653 mouse myeloma cell
line in the ratio of 2:1. The lymphocytes and the Ag8 cells were
centrifuged to a common pellet at 200xg, for 10 min at room
temperature in a 50 ml siliconised glass centrifuge tube. The
supernatant was discarded and the pellet was resuspended in RPMI
1640 and centrifuged again at 200xg for 10 min at room
temperature. The supernatant was discarded and the pellet was
loosened by tapping the centrifuge tube gently. The centrifuge
o
tube was then placed in a water bath at 37 C. and 50% (w/v)
polyethylene glycol 6000 (1 ml) was added over a period of 1 min
after which the suspension was swirled for 90 sec in a water bath 
o
at 37 C. The centrifuge tube was then removed from the water bath
and RPMI 1640 (1 ml) was added over 1 min; this operation was then
o
repeated. RPMI 1640 (2 ml) at 37 C was then added over 30 sec, and 
this was repeated. Finally, RPMI 1640 (7 ml) was added over 2 min 
and the volume was made up to 20 ml. The cell suspension was then 
allowed to stand for 10 min at room temperature, after which the 
tube was centrifuged at 200xg, for 10 min at room temperature. The 
supernatant was discarded and the pellet carefully resuspended 
(1x10 6 Ag 8/ ml) in cloning medium containing HAT. The cells were 
then distributed at a density of 200,000 cells/well of a 96 well 
flat bottomed tray already preseeded with macrophages. The medium 
was changed by removing an aliquot (lOOpl) with a multipipetter
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o
and replenishing with fresh cloning medium plus HAT at 37 C for 4 
weeks . The medium was changed to cloning medium plus HT, for a 
period of 2 weeks after which cloning medium alone was added.
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FIGURE 2.1 General Procedures Followed for the
Production of Monoclonal Antibodies 
Mouse myeloma cells were fused with B-cells using polyethylene 
glycol and the hybrids plated out in culture wells. These hybrids 
were grown in HAT medium for 2 weeks, then HT medium and finally 
cloning medium. This procedure eliminates any unfused cells 
allowing hybrids to grow. The desired colonies were then selected, 
propagated and then cloned by limiting dilution. This procedure 
was repeated 3 times to obtain a monoclonal antibody.
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2.2.10. Epstein-Barr Virus Transformation
2.2.10.1. The Production of EBV-containing supernatant
The EBV-containing supernatant was prepared by using the method of
Haskard and Archer (1984). Marmoset blood leukocytes (B95"S) were
cultured in 10% FCS/RPMI 1640 containing 2mM pyruvate for 10 days
5
at a starting cell concentration of 10 cells /ml in T flask at 
o
37 C. The Epstein-Barr virus is released extracellularly into the
o
culture fluid, which is centrifuged at 400xg at 4 C for 10 min.
The supernatant was then filtered through a 0.4^|um filter and 
o
stored at -70 C.
2.2.10.2. EBV Trans formation of Human Lymphocytes
Peripheral blood lymphocytes were cultured initially in flasks
6
with Pokeweed Mitogen (20jig/ml/lxl0 cells) for 5 days. The cells
were counted, washed twice with RPMI 1640 and centrifuged at 200xg
for 10 min at room temperature in 30ml sterilin tubes. The pellet
was loosened by gentle tapping and the EBV supernatant was added 
6 o
at lml/3xl0 cells for 1 h, and the tubes were incubated at 37 C
in an atmosphere of 3% 00 in air.
2
After 1 h the cells were washed twice by centrifuging at
2OOxg for 10 min at room temperature in RPMI 1640. Finally the
pellet was resuspended in cloning medium at a concentration of 0.5
6
xlO cells/ml. The suspension was then dispensed (200jul) to each




The supernatant was replenished as previously described.
2.2.10.3. Cloning by Limiting Dilution
Antibody-secreting clones must be recloned as soon as possible
and in order to become stable must be recloned at least 3 times.
This was performed by plating out cells at 1, 2, and 5 cells/well
on 96 well flat bottomed microtitre tray, previously preseeded
o
with macrophages. The cells were then incubated at 37 C in an
atmosphere of 5% CO in air until clones appeared, the medium
2
being replenished every 7 days. Once clones appeared the 
supernatants were assayed for the desired antibody and the 
appropriate clone(s) were grown up in 24 well trays.
2.10.4 Storage of Clones in Liquid Nitrogen
The cells were centrifuged at 200xg for 10 min at room
temperature. The supernatant was discarded and the cells were
o
washed twice with RPMI 1640 at 37 C, counted and resuspended in
6
50# (v/v) Fetal Calf Serum-RPMI 1640 at 10x10 cells/ml. 20# (v/v)
DMS0-RPMI 1640 was added dropwise to bring the concentration to 
6 o
5x10 cells/ml. The cells were then put in a freezer at -70 C
o
overnight and then transferred to liquid nitrogen (-196 C) for 
storage.
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2.2.11 Partial Purification of Immunoglobulins by Salt 
Fractionation
o
Culture supernatant (50ml) was warmed to 25 C and sodium sulphate
(9g) was added with stirring to make an 18% (w/v) solution. The
o
solution was stirred at 25 C for 30 min, and centrifuged at 3000xg 
o
for 30 min at 25 C. The supernatant was discarded. The precipitate 
was then redissolved in distilled water up to a maximum of 25ml 
and the solution was dialysed against PBS.
2.2.12. Detection of Immunoglobulin Production 
2.2.12.12 Immuno-dot binding assay
All steps in the dot-immunobinding assay were done at room
temperature unless otherwise stated, and all incubations were done
on a shaking platform to provide gentle agitation.
Nitrocellulose membrane was cut into strips of convenient
size and labelled with waterproof ink for identification. After
soaking in 50 mM Tris/HCl, 0.15M NaCl, pH 7*4 buffer containing
0.01# thiomersal (TBS), the strips were dried (tweezers were used
at all times to handle the strips). Serial dilutions of anti-human
IgG, IgM, IgA, or anti-human light chains (l^ il) from l^g/ml -
50ng/ml in TBS were spotted on the sheet. The strips were then
allowed to dry, and were incubated for 1 h with 1% (w/v) casein in
TBS to block any unoccupied sites. The nitrocellulose sheet was
o
then incubated with human monoclonal supernatant overnight at 4 C. 
The nitrocellulose sheet was then washed three times with l#/w/v)
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casein in TBS, each for 5 min at room temperature. Horse-radish
peroxidase conjugated goat anti human IgG, IgM or IgA antisera
(diluted 1:1000) was then added and incubated for 2 h. The
nitrocellulose sheet was finally washed 3 times with 1% (w/v)
casein in TBS and incubated with the substrate, 0.02# (w/v) 3"
amino-9-ethyl carbazole and 0 .03# H O  in 50mM sodium acetate
2 2
buffer, pH 5*0, for 15 min. When "spots" appeared the substrate, 
was removed and the sheet was then washed five times with water 
and then dried by using filter paper. The control "spots" were 
normal human IgG, IgM, or IgA (l^ ug/ml).
2.2.12.2. Competitive Enzyme Linked Immunoassay (CELIA)
To determine immunoglobulin class and concentration in the human
monoclonal supernatants, a CELIA was established (see Fig 2.2).
o
Microtitre plates were coated overnight at k C with human IgG,
IgM, or IgA (2oong/ml) in 50mM sodium bicarbonate buffer, pH 9*6.
5
Serial dilutions of the standard immunoglobulins from 10 ng/ml to
lOng/ml or appropriately diluted culture
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FIGURE 2.2 Competitive Enzyme Linked Immunoassay
The specific antibody was attached to the solid phase and then 
washed. The solid phase was then blocked to fill any unoccupied 
antibody sites. During this procedure standard dilutions of the 
specific antibody or unkown antibody concentration were incubated 
with enzyme-conjugated anti-antibody in separate tubes. The solid 
phase was then washed and the solutions from the tubes added. 
Competition then takes place between the solid phase-coupled 
antibody and the free standard antibody or the unknown antibody 
for the enzyme-conjugated anti-antibody. The solid phase was then 
washed and the enzyme-labelled substrate added. The inhibition of 
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supernatants in 0.05% (v/v) tween-PBS were transferred to LP3
tubes containing an equal volume of the appropriate alkaline
phosphatase anti-immunoglobulin conjugate (diluted 1:1000 with
o
0.05# (v/v) PBS-tween) and incubated for 1 h at 37 C. Meanwhile,
the coated cuvettes were washed three times, each for 5 min with
PBS-tween and then incubated with 1% (w/v) casein in PBS for 30
min to block any unoccupied sites. Then the mixture (250)il) in the
LP3 tubes was transferred to the now blocked cuvettes and
o
incubated for 1 h at 37 C. The cuvettes were washed three times,
each for 5 win with 0.05# (v/v) tween-PBS and the appropriate
substrate added. Para nitro-phenyl phosphate (PNPP) (lmg/ml) was
the substrate used for alkaline phosphatase and was added in 0.1M
glycine buffer,pH 10.4, with ImM MgCl and ImM ZnCl for 1 h. The
2 2
reaction was stopped by adding 1M NaOH and the absorbance was read 
at 405 nm. The inhibition of the colour change being proportional 
to the amount of antibody . The assay is summarised in Fig. 2.2.
2.2.12.3. Double Antibody Sandwich Enzyme-Linked
Immunoabsorbent Assay
Microtitre plates were coated with sheep anti-human light chain
antibodies (supplied by Dr. A. Jehanli of this department),
(200ng/ml; 100/al) in 50mM sodium bicarbonate buffer, pH 9*6,
o
overnight at 4 C. The plates were then washed with 0.2# (w/v)
casein in 0.05# (v/v) tween-PBS (250pi) buffer three times for 5 
min each, and then incubated with the buffered casein for 30 min
125
at room temperature to block any unoccupied sites. The plates
were washed and the various dilutions of standard solutions of
IgG, IgM, or IgA in the 0.2% (w/v) casein buffer containing 2.5#
(v/v) normal goat serum (lOQul) were added and incubated overnight 
o
at 4 C. Again the plates were washed three times with the buffer
and the horse-radish peroxidase-goat anti human IgG, IgM, or IgA
was added (diluted 1:500 with casein buffer plus 2 .5% (v/v) normal
goat serum) (lOOjil) for 3 h at room temperature. This was then
removed and the trays washed three times for 5 min with the casein
buffer with one last wash with PBS. The wells were then incubated
with the substrate for the HRPO which is 3»3f“5“5,-tetramethyl
benzidine (TMB) at a final concentration 42mM made in 0.1M sodium
acetate / citric acid buffer, pH 6.0, containing 0.004# (v/v) H 0
2 2
(10(}ul) 30 min -lh at room temperature. An intense blue colour
developed E max ** 655 nm,and the reaction was stopped by the 
addition 2M sulphuric acid (20/liI) . The assay is sumarised in Fig 
2.3
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FIGURE 2.3 Double Antibody Sandwich ELISA
Antibodies were attached to the solid phase which was then washed. 
The test solution was then incubated with the solid phase and then 
washed. Enzyme-labelled specific antibody to the unknown antibody 
was then incubated with the solid phase followed by washing. The 
enzyme substrate was then added. The colour change being 
proportional to the amount of unknown antibody in the test 
solution.
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2.2.12,4. Substrates for horse radish peroxidase
(a) O-phenylenediamine (OPD): Hydrogen peroxide (0.012% v/v) was
added just before use to a freshly prepared solution of OPD (0.4 
mg/ml) in 0.1M citric acid/0.2M Disodium phosphate buffer, pH 5*0.
The reaction stopped by the addition of sulphuric acid (2M,100^il).
Optical density was read at 494nm.
(b) 3#31#5>51-tetramethylbenzidine (TMB) : The TMB was added at a
final concentration 42mM made in a sodium acetate/ citric acid
buffer, pH 6.0, containing 0.004# (v/v) H 0 (lOO/il) for 30 min-
2 2
lh at room temperature. The reaction was stopped by the addition 
of 2M sulphuric acid (20jil).
2.2.12.5« ELISA for Anti-Neuronal Membrane Antibodies
Microtitre plates were coated with neural membrane preparation P3
(see section 2.2.8. (b) ) (5jjg/ml) in 50mM sodium bicarbonate
o
buffer, pH 9*6, overnight at 4 C. The plates were then washed with 
0.2# (w/v) casein in 0.03# (v/v) tween-PBS buffer three times for 
5 min each, and then incubated with the buffered casein for 30 
min at room temperature to block any unoccupied sites. The plates 
were washed and the culture supernatants from the clones were 
added (lOC^ul) and allowed to stand for 2 h at room temperature.
Again the plates were washed three times with the buffer and the 
alkaline phosphatase anti-human whole immunoglobulin (contains 
IgG, IgM, and IgA) (lOOul) was added (diluted 1:500 with casein 
buffer plus 2.5# (v/v) normal goat serum) for 2 h at room temperature . T
128
removed and the trays were washed three times for 5 “in with
casein buffer and finally with PBS. The wells were then incubated
o
with the substrate PNPP for 1 h at 37 C. An intense colour 
developed and the reaction was stopped by adding 1M NaOH. The 
absorbance was read at 405nm. Fig 2.4 summarises this assay.
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FIGURE 2.4 ELISA for the Detection of Anti-Neuronal
Membrane Antibodies
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SECTION 3.1 1 LYMPHOCYTE STIMULATION STUDIES
3.1.1. Lymphocyte Preparation
The numbers of lymphocytes recovered after separation on a ficol-
hypaque gradient varied depending upon whether whole blood or
plasma-deficient blood was used, the age of the blood sample and
o
whether blood stored at room temperature or 4 C were used.
The blood samples were drawn from the patient in the
morning. The blood was stored overnight, either at room 
o
temperature or 4 C, or used fresh. Lymphocyte numbers from fresh
blood and from that held overnight at room temperature were
o
essentially the same. Storage of the blood for 24 h at 4 C
resulted in the number of lymphocytes being drastically reduced 
(by as much as 75#)* If the blood was stored at room temperature 
for longer than 24 h the numbers of lymphocytes steadily declined 
(~20#/day) until, after 4 days, very few lymphocytes could be 
recovered.
Larger numbers of lymphocytes from a ficol-hypaque gradient 
were consistently obtained from whole blood compared with blood 
from which the plasma had been removed ( ~50% less) by
centrifugation. Figure 3*1 shows a gradient before and after 
centrifuging at 400 x g for 35 min at room temperature. The
"fluffy” white band at the interface contains the lymphocytes. 
Using whole blood, this band is approximately twice as thick as 
the plasma deficient blood sample. Contamination of the band with
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red blood cells was also less when whole blood was used.
3.1.2. Blastogenic Activity of Fresh and Frozen 
Lymphocytes
Lymphocytes were separated from 5 samples (20 ml, each) of venous
blood. Each sample was divided into four equal aliquots, three of
o
which were kept in liquid nitrogen (-196 C). The fourth was 
stimulated with Concanavalin A (Con A) and with 
Phytohaemagglutinin (PHA) (7. 5/ig/ml) for 3 days. After one 
month, one aliquot of each frozen lymphocyte sample was chosen, 
rapidly thawed and stimulated with Con A and PHA. This was then 
repeated after two and three months.
The stimulation was measured by using five assays which
3 3 3
included [ H]-thymidine, [ H]-uridine, and [ H]-leucine 
incorporation into DNA, RNA, and protein respectively; glucose 
consumption, and lactate release. The latter assays were used as 
measures of metabolic activity. The results in Tables 3.1 (a) and 
3.1 (b) show that the ability of lymphocytes to undergo
blastogenesis was progressively reduced by freezing.
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TABLE 3*1 (a) The Blastogenic Activity by Concanavalin A of
Fresh and Frozen Lymphocytes
FRESH
STORAGE CONDITIONS 
1 MONTH : 2 MONTH 
FROZEN : FROZEN




























































Stimulation Index Mean +_ Standard Deviation 
Number of experiments = 4
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TABLE 3.1 (b) The Blastogenic Activity by Phytoheamagglutinin of
Fresh and Frozen Lymphocytes
FRESH
STORAGE CONDITIONS 
1 MONTH ; 2 MONTH 
FROZEN : FROZEN




























































Stimulation Index Mean +_ Standard Deviation 
No. of experiments =4
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3.1.3. Glucose Assay with Lymphocyte Culture Medium
The glucose assay was performed on lymphocyte culture medium 
(100-0# v/v PBS) which had been treated by exactly the same 
method as patient stimulation assays (see Section 2.2.4. (a)).
The medium was diluted with PBS.
The results shown in Fig. 3*2 indicate that the glucose 
assay accurately detects the amount of glucose in the medium. 
The theoretical value of the medium (100# v/v) was 2mg/ml.
3.1.4. Dose-Response Study of Blastogenesis 
6
Lymphocytes (1x10 ) separated as described in Section 2.2.3 from
5 normal controls ( age range 23-63 years : mean 52 yrs) were
stimulated with increasing concentrations of Con A, and PHA (0-
2CJ(ug/ml) for 3 days and incubated in a humidified atmosphere of
o
5# CO in air at 37 C.
2
Stimulation of lymphocytes was assayed by following the 
incorportion of radiolabelled thymidine, uridine, and leucine 
into DNA, RNA, and protein repectively. Lactate production and 
glucose consumed were also measured as indices of metabolic 
activity.
The results (Fig. 3*3) show that maximum response was 
observed in all 5 assays with 10-15jig/ml mitogen. In all 
following procedures 7*^ug/ml mitogen was used.
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3.1.5» Time-Response Study of Blastogenesis
Lymphocytes were separated from 5 normal donors (age range 23- 
65yr : mean 51 yr) and incubated for a period of from one to
seven days with Con A and PHA as described in Section 2.2.1. (a). 
The response was measured by the incorporation of radiolabelled 
precursors, thymidine, uridine, and leucine into DNA, RNA, and 
protein repectively. Lactate released and glucose consumed were 
also measured. The results, shown in Fig. 3*4, reveal that the 
optimum period was 2-4 days for incorporation of radiolabelled 
precursors. Lactate release also reached a peak between 2 and 4 
days. Glucose consumption increased rapidly for the first 3 days 
and then assumed a steady level.
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FIGURE 3»3 The Dose-Response Study of Blastogenesis by
Con A and PHA
The effect of concentration of PHA and Concanavalin A on the 
stimulation of normal human lymphocytes. Values, obtained after 3 
days in culture as described in the Materials and Methods Section 
2.2.4., are the means from 5 separate determinations using 
lymphocytes from different normal individuals and are expressed 
as the difference (in cpm or jag/ml) between test sample and that 
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FIGURE 3.4 The Time-Response Study of Blastogenesis
with Con A and PHA
The effect of time on the stimulation of normal human lymphocytes 
by PHA and Concanavalin A. Values obtained by using 7*5 
mitogen as described in the Materials and Methods Section 2.2.3*» 
are the means of five separate experiments using lymphocytes from 
different normal individuals and are expressed as the difference 
(in cpm or ^ ig/ml) between test sample and that incubated in the 
absence of mitogen.
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3.1.6. Stimulation by Con A and PHA of Lymphocytes from Motor
Neurone Diseased Patients and Normal Healthy Controls
Peripheral blood lymphocytes from 18 MND patients (age range 40-
80 yrs : mean 61.1 +_ S.D. 9*8 yr) and from 20 age and sex
matched controls ( age range 41-77 yr : mean 55*6 +_ 9 yr) were
stimulated by using sub-optimum concentrations of Con A and PHA
(7.5^g/ml) for the optimum period of incubation (3 days). The
results are shown in Table 3*2 and Figures 3*5 (a) and (b).
3 3
The incorporation of [ H]-thymidine, and [ H]-leucine and 
the consumption of glucose by MND lymphocytes was in each case 
significantly depressed compared with the age and sex -matched
3
controls (p<0.01) with both mitogens. In the case of [ H]-uridine 
incorporation and lactate release there was no significant 
difference between the MND lymphocytes and those from the age- 
matched controls.
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TABLE 3.2 Stimulation by Con A and PHA of Lymphocytes from 
Patients with MND and from Normal Controls
(A) Con A
• Normal : MND Patients : Significance:
«• Controls (20): (18) : (P = 0.01 :
J Mean +_ SD : Mean +_ SD *
3
[ H]-Thy : 4.13+ 0.19 : 3.69 ♦ 0.34 : S :
(log CPM)
3
[ H]-Uri : 3.83 + 0.31 : 3.78 + 0.33 : NS :
(log CPM)
3
[ H]-Leu : 3.91 + 0.30 : 3.36 + 0.67 : S :
(log CPM)
Lactate Prod: 200 + 94 : 191 + 142 : NS :
(^ ig/ml)







MND :Significance : 
Patients (18): (P=0.01)















3.93 +_ 0.32 3.57 +_ 0.39 S
Lactate Rel 
tyig/ml) 142 +_125 141 +_ 83
» • • •
NS :
Glucose Cons 
(^g/ml) : 579 +_ 224 382 +_ 212 S :
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3.1.7. Stimulation of MND Lymphocytes with Rat Spinal 
Cord Membranes Optimisation of Membrane Protein 
Concentration
Lymphocytes from MND patients were incubated with increasing 
concentrations of P3 membrane fragments (0-30(J)ug protein /ml) as 
determined by Lowry et al (1959)* This was prepared as described 
in Section 2.2.8. (a) from 15"17 day old cultures of rat spinal
cord cells which at this time consist predominantly of large 
clusters. Lymphocyte proliferation was assayed by the 
incorporation of labelled leucine and thymidine.
The results, shown in Fig. 3*6, indicate a maximum uptake
the uptake declined. For subsequent assays, a suboptimal dose of
of membrane protein, following which
FIGURE 3.5 (a) Stimulation By Con A of Lymphocytes from Motor
Neurone Diseased Patients and Normal Healthy Controls
Values, obtained as described in the Materials and Methods 
Section 2.2.4., are the means of triplicate assays of lymphocytes 
from each individual donor and are expressed as the difference 
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FIGURE 3.5 (b) Stimulation By PHA of Lymphocytes from Motor
Neurone Diseased Patients and Normal Healthy Controls
Values, obtained as described in the Materials and Methods 
Section 2.2.4., are the means of triplicate assays of lymphocytes 
from each individual donor and are expressed as the difference 
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FIGURE 3.6 The Dose-Response Study of MND Lymphocytes Incubated 
with Increasing Concentrations of Rat Spinal Cord 
Membrane Fragments
Values, obtained after 3 days in culture as described in the 
Materials and Methods Section 2.2.4., are the means from 3 
separate determinations using lymphocytes from different MND 
individuals and are expressed as the difference (in cpm or^ig/ml) 
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3.1.8. Stimulation by Rat Spinal Cord Membranes Fragments of
Lymphocytes from patients with Motor Neurone Disease
Lymphocytes from 14 MND patients (11 males, 3 females; age range 
44-80 yrs : mean 62.4 yr), and 9 normal healthy controls (7
males, 2 females; age range 35"65 yrs : mean 55*3 yr) were
cultured for 3 days in the presence of spinal cord membrane 
fragments at a sub-optimal concentration (59Mg/ml). It was found 
that the glucose consumption assay gave extremely variable 
results in these experiments and no reliable data could be 
obtained. All the other assays gave consistent results and are 
shown in Fig. 3*7.
Lymphocytes from normal age-matched controls were non­
reactive towards the membrane samples. However, even though MND 
lymphocytes responses were very variable, some patients showed 
stimulation greater than unity. For assays based upon the 
incorporation of radiolabelled ligand, a stimulation index
greater than 3 has been suggested to be significant (Urbaniak et 
al, 1978) and by this criterion 4 out of 14 MND patients showed 
significant stimulation in all such assays.
3.1.9. Stimulation By Con A and PHA of Lymphocytes From
Multiple Sclerosis Patients
Peripheral blood lymphocytes from 10 Multiple Sclerosis (MS)
148
patients (age range 18-41 yrs; mean 31*5 yr +_ S.D. 8 yr) and 
from 10 age-matched, healthy controls (age range 22-42 yrs; mean
31.8 yr +_ S.D. 7 yr) were stimulated with Con A and PHA for 3 
days as described in Section 2.2.3.
The results are shown in Tables 3*3 (a) and (b) and Fig.
3.8 (a) and (b). In response to Con A, the incorporation of 
radiolabelled leucine and thymidine, and glucose consumption were 
all significantly decreased in MS patients compared to normals. 
Whereas, with PHA, all the above assays, and also the lactate 
release assay were significantly decreased compared to the normal 
healthy controls.
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FIGURE 3.7 Stimulation by Rat Spinal Cord Membrane Fragments of
lymphocytes from patients with Motor Neurone Disease
Values, obtained as described in the Results Section 3.1.8., are 
the means from triplicate assays of lymphocytes from each
individual donor and are expressed either as the Stimulation 
Index (ratio of cpm from test sample to that from sample 
incubated in absence of spinal cord membranes) or as the 
difference between lactate released from test sample and that
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TABLE 3.3 (a) The Stimulation by Concanavalin A of Lymphocytes 
from Multiple Sclerosis
: NORMAL : MULTIPLE SIGNIFICANCE
: CONTROLS (10) : SCLEROSIS (10) P= 0.01 :
: MEAN = 31.8 yr : MEAN = 31 .5 yr























997+_l87 367+_l66 + :
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TABLE 3.3 (b) The Stimulation by Phytohaemagglutinin of
Lymphocytes from Multiple Sclerosis Patients
NORMAL : MULTIPLE : SIGNIFICANCE
CONTROLS (10) : SCLEROSIS :
MEAN =31.8 yr : MEAN =31.5 yr:
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FIGURE 3*8 (a) The Stimulation by Con A of Lymphocytes from
Multiple Sclerosis Patients and from Normal 
Healthy Controls
Values, obtained as described in the Results Section 3*1*9*tare 
the means from triplicate assays of lymphocytes from each
individual donor and are expressed as the difference (in cpm or
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FIGURE 3«8 (b) The Stimulation By PHA of Lymphocytes from
Multiple Sclerosis Patients and Normal Healthy 
Controls
Values, obtained as described in the Results Section are
the means of triplicate assays of lymphocytes from each 
individual donor and are expressed as the difference (in cpm or 
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3.1.10. Stimulation of Normal Lymphocytes by Pokeweed Mitogen 
Optimisation of Conditions
The investigation of Pokeweed mitogen was undertaken 
because PWM is a polyclonal B cell activator and so enables the 
number of B-cells to be increased. The raising of human 
monoclonal antibodies was to be performed by fusing the mouse 
myeloma cells X63~Ag8.653 to human peripheral blood lymphocytes. 
The numbers of lymphocytes obtained from the peripheral blood are 
in the order of 30 million/20ml, of which only 30# are B-cells. 
Therefore the use of PWM increases the numbers of cells which 
could be potentially fused (Campbell, 1985).
3.1.10. (a) Time-Response Study
Peripheral blood lymphocytes from 5 normal healthy individuals 
(age range 22-44 yr : mean 29 yr) were incubated with Pokeweed
mitogen for periods of upto 8 days. Lymphocyte proliferation was 
assayed by all five assays previously described.
The results, shown in Figure 3*9 show maximum stimulation 
after J2 h for all five assays.
3.1.10. (b) Dose-Response Study
Lymphocytes from five healthy controls (age range 23-28 yr : mean 
25 +_ S.D. 2 yr) were stimulated with increasing concentrations 
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FIGURE 3.9 The Time-Response Study for PWM
o
atmosphere of 5# CO in air at 37 C.
2
Lymphocyte stimulation was assayed by all five methods 
previously described and the results are shown in Figure 3*10. 
The concentration of 20 ^ ig/ml gave maximal proliferation in all 
cases.
3.1.11. Stimulation of Normal Lymphocytes by Phytohaemagglutinin, 
Concanavalin A and Pokeweed Mitogen in Serum-Free Medium
The use of serum-free medium was investigated because the serum 
(fetal calf serum) used to supplement the lymphocyte culture 
medium is very expensive and it would be convenient to remove 
this.
Lymphocytes from 5 normal healthy individuals (age range 23“ 
28 yr : mean 25 +_ S.D. 2.9 yr) were resuspended in two different 
media. One medium was the lymphocyte culture medium containing 
10% (v/v) fetal calf serum (FCS), and the second was medium
supplemented with insulin 0.2U/ml; human transferrin 5 ^g/ml; 
progesterone 20 nM; putresceine 100 ^ iM; sodium selenite 30 nM; 
hydrocortisone 0.5^M; biotin 1 jig/ml; thyroxine 3 jug/ml and 
bovine serum albumin 1 mg/ml but without any FCS. Each control 
sample was divided into two aliquiots so that half was in the 
Serum-Supplemented Medium (SSM), and the other half in Serum-Free 
Medium (SFM). The samples were then stimulated in the usual way 
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FIGURE 3.10 The Dose—Response Study for PWM
proliferation was measured by all five previously described 
assays.
The results are shown in Table 3*^. In SFM stimulation with 
PHA and Con A was virtually absent but the stimulation indices 
obtained with PWM are comparable with those shown in SSM.
3*1.12 Stimulation of Motor Neurone Diseased Lymphocytes 
by Direct Culture in the Presence of Foetal Rat Spinal 
Cord Neurones
An initial study was carried out to investigate the possibility
that the peripheral blood lymphocytes from MND patients could be
sensitized to spinal cords cells.
Trays (2^ well) of 15 day old rat spinal cord cells cultured
as described in Section 2.2.8. (a) were treated with mitomycin C
for 1 h. Control preparations included wells with spinal cord
cells but no lymphocytes and vice versa. Lymphocytes from MND
6
patients were cultured in the spinal cord cell wells (0.1 xlO /ml 
6
- 1 xlO /ml) in a humidified atmosphere containing 10# CO at 
o 2
37 C for 3 days. Lymphocyte proliferation was assayed by the
incorporation of radiolabbelled thymidine, uridine and leucine.
The results, shown in Table 3*5. indicate that cultured rat
spinal cord neurones cause stimulation of MND lymphocytes but not
of normal controls.
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TABLE 3.4 The Stimulation of Normal Lymphocytes by Con A, PHA, 
and Pokeweed Mitogen in Serum-Supplemented and 
Serum-Free Medium
: Concanavalin A : PHA :Pokeweed Mitogen :
SFM : SSM : SFM : SSM : SFM : SSM :
3
[ H]-Thy : 0.77 !: 3.7 : 1.31 ! 3.78 : 3.30 : 3.73 .
Log CPM : +_0.12 : +_0.22 : +_0.12 : +_0.l4 : +_0.13 : +_0.15
!
3
[ H]-Uri : 0.47 !: 3.32 : 0.99 : 3.49 : 3-26 : 3.32 •
Log CPM : +_0.13 : +_0.24 : +_0.21 : +_0.l4 : +_0.23 : +_0.14 *
3
[ H]-Leu : 1.09 j: 4.28 : 1.54 : 4.64 : 3.25 !: 3.38 •
Log CPM : +_0.11 : +_0.23 : +_0.19 : +_0.24 : +_0.21 : +_0.15 ••
Lactate Rel : 228 : 826 : 250 : 1454 : 710 : 887 ••
ug/ml : +JL17 : +_129 : +_105 : +_138 : +_213 :; +_156 •
Glucose Cons: 32 : 1135 : 387 : 1245 : 1172 : 1124 •
ug/ml : +_11 : +_121 : +_125 :• +.135 : +_154 : +_149 ••
SFM = Serum-Free Medium
SSM = Serum-Supplemented Medium
+_ Standard Deviation
Number of Experiments = 5
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3 3 3
LYMPHOCYTE : [ H]-Thymidine : [ H]-Uridine : [ H]-Leucine 
NUMBER INCORPORATION INCORPORATION INCORPORATION
Log CPM Log CPM Log CPM
100,000 :
MND : NS NS : 3*3+_ 0.2:
NORMAL : NS NS : NS :
500,000 :
MND : 2.5+_0.21 2.7+_0.26 : 3.4+_0.3 :
NORMAL : NS NS : NS :
1,000,000 :
MND : 3.5+_0.30 3.8l+_0.21 : 3.7+_0.12 :
NORMAL : 0.8l+_0.11 0.56+_0.32 : 0.39+_0.43:
NS= no stimulation 
Number of experiments = 3
Log CPM = (CPM of stimulated cells/ CPM of control cells)
Control cells
TABLE 3-5
Incorporation of Radiolabelled Isotopes into MND and Normal 
Lymphocytes Cultured with 15 Day Old Cultured Rat Spinal Cord 
Cells
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SECTION 3.2 j_ RAT SPINAL CORD CELL CULTURE STUDIES
3.2.1. Cell Culture Conditions
Digestion of spinal cords with trypsin and DNAse gave 3*5“4.5 x 
6
10 cells/ foetal spinal cord. The viability was > 90% with very 
good reproducibility.
When the cells were dissociated and plated out immediately 
in SFM, they failed to attach to the dishes and the few cells 
that did bind died after a few days. Cells which were kept in 
serum supplemented medium for the first three days showed 
attachment of the cells : serum free medium could then be used
for subsequent growth (Digby et al, 1985)•
3.2.2 Histochemical staining
Figures 3.11 (a)“(f) show cultures at various stages of maturity 
stained with Dalofeld's haematoxylin. Day 1 (Figure 3*11
(a))shows that, after 2k h, the majority of cells attach to the 
dishes. At this stage, it is possible to see flat cells on top of 
which are small oval neurone-like cells with some processes. By 
Day 3 (figure 3*11 (c)) the size and number of the processes have 
increased. The neurone-like cells have migrated to form clusters. 
However the flat cells also grow rapidly and can hinder the 
growth of the neurone-like cells (figure 3.11 (f))» This problem 
can be reduced by the addition of fluorodeoxyuridine and uridine
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from day 6 to day 8. By day 12 (figure 3»H W )  the clusters 
have acheived maximum size and can be maintained for a further 
10-12 days. Figure 3*11 (e) shows that some of the clusters are 
joined by processes which can become very thick.
3.2.4. Immunocytochemical Identification of the Cells
Mouse monoclonal antibodies were used in the identification of 
the cultured cells. A mouse monoclonal antineurofilament antibody 
confirms the neuronal identity of the clustered cells and their 
processes. This is shown in Figure 3*12. In no case were the 
underlying cells shown to be labelled with the anti-neurofilament 
antibody.
Tetanus toxin is a specific cell surface marker for 
neurones in culture ( Mirskey et al, 1978). Figure 3*13 shows the 
labelling of the surface of the neurone-like clusters and their 
processes.
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FIGURES 3»11 (a)-(f) Rat Spinal Cord Cells in Culture
Figure 3*H (a) Photomicrographs of 1 day old rat spinal cord
cells cultures stained with haematoxylin-eosin (a) low power (bar 
= 10pm) (b) high power (bar = 4Qpm)
Figure 3*11 (b) Photomicrographs of 2 day old rat spinal cord
cells cultures stained with haematoxylin-eosin (a) low power (bar 
=10pm) (b) high power (bar = 40pm)
Figure 3*11 (c) Photomicrographs of 3 day old rat spinal cord
cell cultures stained with haematoxylin-eosin (a) low power (bar 
= 10pm) (b) high power (bar = 4(^ um)
Figure 3*11 (d) Photomicrographs of 12 day old rat spinal cord
cell cultures stained with haematoxylin-eosin (a) low power (bar= 
lC^ um) (b) high power (bar = 40pm)
Figure 3*11 (e) Photomicrographs of 16 day old rat spinal cord
cell cultures stained with haematoxylin-eosin (a) low power (bar 
= lC^ um ) (b) high power (bar = 4(^ um)
Figure 3-H (f) Photomicrograph of a 3 day old rat spinal cord












Rat spinal cord cells cultured for 12 days were fixed with 
acid alcohol and labeled with mouse antineurofilament antibody 
followed by fluorescein-labeled rabbit anti-mouse immunoglobulin 
and viewed with fluorescence optics. (a) low power (Bar =10|im)




Rat spinal cord cells cultured for 12 days and labeled with 
tetanus toxin followed by mouse anti-tetanus toxin and finally by 
fluorescein-labelled rabbit anti-mouse immunoglobulin viewed 
under fluorescence optics high power (bar = 40um)
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3-3 HUMAN MONOCLONAL ANTIBODY PRODUCTION
3.3.1. Detection of Immunoglobulin Production
3.3.1. (a) Immunodot Assay
The assay was performed as described in Section 2.2.12. (a) and
used to detect whether colonies were actually secreting 
immunoglobulin. It was a very sensitive system detecting levels 
at 500 ng/ml. However, when the class of immunoglobulin being 
secreted was investigated, the culture supernatants often gave 
positive results for more than one class of immunoglobulin. This 
could have been due to the assay system being too sensitive and 
detecting left over immunoglobulin when there was more than one 
colony in a particular well.
The assay was not a very quantitative procedure as it was 
extremely difficult to distinguish between the intensity of colour 
of one "spot” from another. However a first screening procedure it 
was quick and easy to perform.
3.3*1. (b) CELIA
For the CELIA, standard curves for IgG, IgM, and IgA
were constructed. This enabled the class and quantity of the
immunoglobulin to be determined from each colony.
The procedure is complex and takes a long time to perform,
especially if there are many culture
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Immunoabsorbent Assay with Horse Radish
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supernatants to be assayed. The results obtained by this 
procedure were very variable from day to day and not at all easy 
to optimise. However the procedure decided upon is described in 
section 2.2.12.(b). The standard curves are shown in Figure 3*1^* 
A standard curve was run with each assay to account for 
variability.
3.3.1. (c) Double Antibody Sandwich ELISA
The assay was performed as described in Section 2.2.12.(c), and 
was developed because of the increase in sensitivity compared with 
the CELIA. Standard curves were established for IgG, IgM, and IgA 
and are shown in Figures 3*15 and 3*16. The coating solution was 
found to give the best results at 100 ng/ml Sheep Anti-Light chain 
antibodies (SAL) in sodium carbonate buffer 50 mM, pH 9.6. The 
standard curves were used to determine the amount and class of 
immunoglobulin secreted by the colonies.
This method was more convenient than the CELIA to use and 
gave consistently reliable results. The variation of the standard 
deviation was less than 2 % from day to day on the same sample 
culture supernatant. Two different enzyme conjugates were used, 
alkaline phosphatase and horse radish peroxidase. Horse radish 
peroxidase was found to be the more sensitive of the two as can 
be easily seen from the two sets of standard curves (Figs 3*15 and 
3.16).
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3.3.1 * (d) ELISA with Rat Spinal Cord Membranes 
Culture supernatants were tested on rat spinal cord membrane 
fractions (prepared as described in Section 2.2.8. (b)). A
number of different coating antigen concentrations were tried to 
find the optimum concentration. Table 3*6 summarises the results.
: COATING ANTIGEN : OPTICAL 405 nm :
: n=5 (^S/ml) : DENSITY :
• • •
: 0.5 : 0.010 :
• • •
• • •
: 1.0 : 0.798 :
• • •
• • •
: 5-0 : 0.625 :
• • •
• • •
: 10.0 : 0.652 :
TABLE 3.6. Optimisation of coating antigen concentration with the 
culture supernatant from a positive clone obtained from a MNP 
patient
Maximum reaction of antibody was with antigen coated at 1 /ig/ml 
in 50 mM sodium carbonate buffer pH 9 .6. These conditions were 
then used for any subsequent reactions.
This assay system was used to detect any anti-rat spinal 
cord membrane antibodies secreted by clones obtained after
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peripheral blood lymphocytes from MND patients, MS patients, and 
normal healthy controls were either fused with a mouse myeloma 
cell line X63“Ag8.653 or transformed with Epstein-Barr virus. 
Positive results were those wells that gave 50# more colour than 
the control wells which contained culture supernatants from 
colonies formed from healthy normal individuals and reagent 
blanks. Colonies whose supernatant was 50# greater than control 
wells using the ELISA, tested twice were expanded in flasks and 
then recloned by limiting dilution at cell concentrations of 0.5* 
5, and 50 cells/well. The cell concentration of 5 cells/well gave 
the best results; 0.5 cells/well yielded no colonies and 50 
cells/well yielded 90# of wells with colonies. The supernatant 
from the expanded clones was stored and concentrated for future 
use. Samples of each positive clone obtained were frozen and 
stored in liquid nitrogen.
3.3.2. Human Monoclonal Antibody Production
Three separate methods were used for the production of human 
monoclonal antibodies. These were the fusion of peripheral blood 
lymphocytes (PBL) with a mouse myeloma cell line X63~Ag8.653 in 
the ratio 1:1. The second method was the prior stimulation of the 
PBL with Pokeweed mitogen at the optimal concentration (20 ug/ml) 
followed by fusion as described above. The final procedure used 
was the intial stimulation of the PBL with the Pokeweed mitogen 
and then the transformation of the cells with Epstein-Barr virus.
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The growth and number of colonies obtained by each method 
will be discussed separately. When the colonies were visible by 
eye, screening was carried out with all the previously described 
detection assays.
3.3.2. (a) Fusion of PBL with X63-Ag8.653 
The fusion of the mouse myeloma X63~Ag8.653 cell line with human 
peripheral blood lymphocytes results in slower growth, fewer 
clones and lower immunoglobulin levels secreted than is the case 
with mouse-mouse, rat-rat, or even human-human hybridomas. The 
clones began to appear after 3 weeks, but even after 6 weeks some 
further clones started to appear. The early assaying of the 
clones is essential in order to obtain the required hybrid as 
they are easily lost; mouse-human hybrids have been reported to 
be unstable and need recloning immediately. Fusions were 
performed with PBL from MND, MS and normal healthy controls. 
Previous results had indicated that lymphocytes from the MND 
patients could be stimulated by rat spinal cord membrane 
fragments suggesting that the lymphocytes are sensitized to these 
fragments. The results are summarised in Table 3.7*
The immunoglobulin production ranged from 7 ng/ml to 1 jug/ml 
with an average of 200 ng/ml. The wells that produced colonies 
were mainly IgG secretors with a few IgM secretors. From the 3 
fusions performed on PBL from the MND patients a total of 20 
wells were positive of which 50# were frozen and the remainder
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were recloned by limiting dilution. After recloning, only 6 wells 
remained positive, these were expanded in flasks and some of each 
of the cells frozen whilst the remainder were kept in culture. 
The immunoglobulin production of the 6 wells was low averaging 
200 ng/ml. However 4 started to lose their immunoglobulin 
production until, after a couple of months, in culture nothing 
could be detected. The 2 remaining producers were IgG secretors 
and remained stable.
The MS fusions produced 4 positive clones all of which were 
IgG secretors (300-750 ng/ml). Two of the clones were recloned 
whilst the other two were frozen. Upon recloning by limiting 
dilution a further 4 positive clones were also detected. These 
were IgG secretors (250-750 ng/ml) and were expanded in flasks so 
that some of the cells could be frozen while the remainder were 
kept in culture. Their immunoglobulin secretion was very stable.
The fused normal samples gave many colonies of which 8 were 
selected and 4 were subsequently frozen. The remaining 4 were
recloned by limiting dilution and 4 colonies were chosen for
their immunoglobulin production ( around 0.8 jig/ml). Of these, 2
gave IgG; 1, IgM; and 1, IgA. These were kept in culture as
controls, their immunoglobulin production was fairly stable.
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TABLE 3-7
FUSED :N0. Of CELLS:% WELLS:* WELLS:* WELLS: #IgG: #IgM:RECLONED: 
6
SAMPLE:FUSED(10 ) :GROWTH : R.S.C.: : : :
MND 1 26 4 0 70 20 : + :
2 22 40-50# 6 0 78 16 : + :
3 18 8 0 85 12 : + :
MS 1 31 10 0 2 75 20 : + :
2 33 12 0 2 77 21 : F :
NORM. 1 36 30 0 0 90 8 : + :
2 41 50 0 0 95 3 : F s
F = FROZEN IN LIQUID NITROGEN
+ = RECLONED BY LIMITING DILUTION
NORM. = NORMAL BLOOD SAMPLE
MND = MOTOR NEURONE DISEASE BLOOD SAMPLE
MS = MULTIPLE SCLEROSIS BLOOD SAMPLE
R.S.C. = RAT SPINAL CORD MEMBRANES
M.B.P. = MYELIN BASIC PROTEIN
3-3-2. ibl Pokeweed Mitogen Stimulation of PBL and 
then Fusion with a mouse myeloma cell Line
PBL from 2 MND patients, 2 MS patients and 2 normal healthy 
controls were first stimulated with optimal concentrations of PWM 
and then fused with X63“Ag8.653* The results were similar to the 
above except that after the stimulation for 5 days with PWM the 
numbers of lymphocytes increased, enabling more cells to be 
fused. This was very advantageous as the numbers of lymphocytes 
recovered from diseased patients’ blood is often low.
The same percentage of wells yielded colonies, with a 
similar percentage of IgG and IgM secretors. The immunoglobulin 
production was still low with an average of 250 ng/ml. From the 
18 MND clones positive for rat spinal cord membrane fragments, 9 
were frozen and 9 recloned by limiting dilution. Of the 9 
positives recloned only 10 wells were positive of which all 
stayed positive for at least a month. However, these were 
subsequently lost because of a fungal infection. The 6 positive 
MS clones were all recloned by limiting dilution and yielded 4 
positives which were expanded. Cells from each clone were frozen 
and the rest were maintained in culture. The immunoglobulin 
levels stayed the same for 3 months. The normal fusions gave many 
colonies of which 4 (2 IgG and 2 IgM secretors) were also
recloned and 4 colonies (2 IgG and 2 IgM secretors) were then 


















23 10 0 86 11 + :
2 21 24
40-50
8 0 81 13 F :
MS 1 25 29 0 6 92 4 + :
2 32 36
30-50
0 2 95 2 F :
NORM.1 35 41 0 0 89 4 F :
2 36 42
40-50
0 0 93 4 + ;
F = FROZEN
+ = RECLONED BY LIMITING DILUTION 
R.S.C. = RAT SPINAL CORD MEMBRANE 
M.B.P. = MYELIN BASIC PROTEIN 
B = BEFORE STIMULATION WITH PWM 
A = AFTER 5 DAY STIMULATION WITH PWM
3.3.2. (c) Epstein-Barr Trans formation of Human PBL 
The Epstein-Barr transformation of PBL enables the B-cells to 
proliferate and secrete immunoglobulin without having to fuse the 
cells with a myeloma cell line. The fusion of cells causes cell 
death if not performed correctly so this method only allows 
minimal handling of the cells. The EBV transforms the majority of 
B-cells in each blood sample. However, here the lymphocytes were 
separated and then initially stimulated with Pokeweed mitogen (20 
ug/ml) for 5 days to increase the number of B-cells. They were 
then transformed with EBV for 1 h and finally plated out, as for 
any other fusion.
The cell growth was quick, the plates being covered with 
colonies after only 2 weeks. Samples were 4 MND, 1 MS and 1 
normal. The total number of positive wells was 21, of which half 
were IgG secretors, and the other half IgM secretors. The level of 
immunoglobulin production was still found to be low, averaging 
0.50 ug/ml. Seven of the positives were recloned by limiting 
dilution. These were chosen because of their greater 
immunoglobulin production. The remainder were frozen. From these 7 
came 14 positives of which half were producing IgG and half 
producing IgM. These were expanded in flasks and some of each 
frozen, the rest were kept in culture and their levels of 
immunoglobulin stayed stable (0.75 ug/ml).
The MS transformation gave only 2 positives and they were
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IgM secretors having values of 0.50 jug/ml, and 0.70/ig/ml. These 
were recloned by limiting dilution and 4 positives were selected 
2 of which were frozen and the other 2 were kept in cuture. They 
remained stable for 4 months.
The transformation of normal cells gave many colonies none 
of which was positive in the MS or MND ELISA. However, 2 strong 
secretors of IgG (0.45 ^ lg/ml) and IgM (0.30 jug/ml) were selected 
and maintained in culture. These, even without recloning, still 
continued to secrete immunoglobulin. The results are summarised 
in Table 3.9
3.3.3 Immunocytochemical Identification
All the positive clones described above and culture supernatants 
from normal clones were tested on fixed and unfixed cultures of 
rat spinal cord neurones (15 day) by immunofluorescence.
The MS supernatants did not give any labelling with the 
antibody. This could be expected as the cultures may not be 
myelinated. The normal supernatants gave the same labelling as 
the reagent blanks.
The MND supernatants showed no noticable difference from the 
background controls. These results could be explained if the 
affinities of the antibodies in the supernatants are low or if, 
even after concentrating by salt fractionation, the amount of 
immunoglobulin present was still too low to be detectable.
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TABLE 3.9
:FUSED :NO. OF CELLS: % WELLS:+ WELLS:+ WELLS: %IgG #IgM: RECLONED:
6
:SAMPLE: FUSED(10 )• GROWTH : R.S.C : M.B.P.: ••
MND 1: 20 : 5 : 0 : 55 40 + :
2: 23 : 4 : 0 : 56 42 + :
3: 26 90-70 : 6 : 0 : 54 41 + :
4: 27 : 6 : 0 : 55 42 + :
MS 1: 30 90-70 : 0 : 6 : 56 42 + :
2: 32 : 0 : 7 : 53 45 F :
NORM 1: 35 75-60 : 0 : 0 : 55 41 + :
F = FROZEN
+ = RECLONED BY LIMITING DILUTION 
R.S.C. = RAT SPINAL CORD MEMBRANE 
M.B.P. = MYELIN BASIC PROTEIN
CHAPTER 4 DISCUSSION
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4,1. Stimulation of Lymphocytes by Mitogens
Over the past two decades there has been a significant increase 
in studies relating to the function of the immune system. The 
continued popularity of research in this area reflects the 
awareness by the medical and scientific professions of the 
importance of immune function in the maintenance of disease-free 
homeostasis and technological advances in the field of 
immunological research.
Human lymphocyte transformation response to mitogen is one 
of the most widely used assays of cell-mediated immune function, 
and has proved to be an excellent immunodiagnostic tool. 
Lymphocytes are cells which can be stimulated to proliferate and 
undergo biastic transformation by a variety of biological and 
non-biological agents (see Introduction Section 4). This 
blastogenic responsiveness of peripheral blood lymphocytes has 
been used to gauge the immune response in a variety of diseases 
and is generally used to assess the responsiveness of groups of 
people rather than the repeated testing of one indivdual which 
tends to show large variations (Buckley, 1976; Oppenheim and 
Schecter, 1976). Cancer patients are kept under constant 
observation as their immune function ranges from normal or near 
normal to profound depression depending on the type and stage of 
the disease (Levy, 1978). Immunodeficiency states frequently show 
defective lymphocyte reactivity in vitro eg. in Di-George's
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syndrome, T-cells are deficient but there are B-cells capable of 
making an antibody response (Roitt et al, 1985). Autoimmune 
diseases often are associated with abnormalities in cellular 
immunity with reduced lymphoproliferative reactions in vitro to 
T-cell mitogens as in Rheumatoid Arthritis (RA)(Yamana, 1978) and 
Multiple sclerosis (MS)(Tosato,1985). There are defective 
lymphocyte subpopulations in a variety of diseases (Bach and 
Bach, 1981; Nowinski et al, 1983). In a number of liver diseases 
the T-cell subsets are abnormal, in MS the subsets are also 
altered. In parasitic diseases evaluation of human T suppressor 
lymphocyte subpopulation may indicate how chronic the infection 
actually is e.g. in the case of leprosy which is a chronic 
bacterial disease depending upon cell mediated immunity entirely 
for protection. The role of T-cells is important and lymphocyte 
transformation using whole or sonicated mycobacterium leprae as 
antigen is used to assess the immune status of the individual 
(Mshana et al, 1982; Bloom, 1983).
The stimulation of B-cells in vitro with mitogens causes 
them to secrete immunoglobulin and provides valuble information 
about various aspects of B-cell function, e. g., antibody 
response repertoire.
The purpose of the present investigation was to study, 
under optimal conditions, lymphoproliferative responses, from 
diseased (largely MND) patients and normal controls, to a variety 
of mitogens.
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The measurement of lymphocyte stimulation indices relies 
upon a variety of factors such as the dose of mitogens used, the
incubation time with the mitogens, the way of expressing the
stimulation indices and the overall assay systems selected.
In this study, to increase the chances of detecting
abnormality, 5 assays were employed. Three of which relied on the
measurement of radiolabelled ligand incorporation into 
macromolecules, namely, DNA, RNA, and protein. The other two 
methods measured glycolysis in stimulated cells. The methods 
used for the incorporation of radio-labelled precursors rely on 
pulse labelling for 18 h. Hence these methods only look at the 
events at the time of and during pulse labelling and do not 
measure changes taking place during the whole time of incubation 
with the mitogen under study. Therefore, glucose consumption and 
lactate released were also measured as they give an overall 
estimation of changes in energy (De Cock et al, 1980; Cordiali- 
fei et al, I98O).
Another reason for using five different assays was the fact 
that even with the strongest lymphocyte stimulants, the response 
of the cells was heterogeneous. With PHA, for instance, a high 
proportion of cells respond by increased RNA and protein 
synthesis but only about half the cells initiate DNA synthesis 
(Ling and Kay, 1975)• Hence, thymidine uptake would not detect 
changes in those cells that do not replicate.
These 5 assays were used to investigate peripheral blood
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lymphocytes from MND and MS patients compared to age-matched 
controls. As the abnormality in autoimmune disorders is often in 
T-cell control of the immune regulation, two mitogens 
Concanavalin A and Phytohaemagluttinin both of which are reported 
to be T-cell specific (Ramagnani, 1977) were utilised. PWM 
stimulation was also investigated.
Dose-response and time -response curves were determined for 
normal lymphocytes in order to establish the best conditions for 
measuring stimulation indices. With both mitogens Con A and PHA 
maximum response was obtained with 10 ug/ml. Most laboratories 
standardise assay conditions to produce maximum responses 
according to the idea that, under such conditions, maximum 
differences will be seen between patients and controls (Oppenheim 
et al, 197*0* However, in this study sub-optimum doses were 
employed for subsequent work because sub-optimum mitogen 
concentrations give maximum differences between normal and 
impaired lymphocyte responses (Fitzgerald, 1971; Malave et al, 
1975* Waller and Maclennan, 1977; Bernhard et al, 1980).
The time-response curves for all mitogens showed a maximum
3 3
response by day 3 for [ H]-thymidine and [ H]-leucine uptake.
3
While [ H]-uridine uptake peaked after ^8 h. Glucose consumption 
also reached a steady level after 3 days. Hence for the 
convenience of assaying day 3 was chosen as the incubation 
period for all subsequent assay. Others (Bernard et al, 1980) 
also found that this gives the greatest discrimination between
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normal and diseased lymphocytes.
The responses of the 18 MND patients' peripheral blood
lymphocytes (PBL) were found to be significantly depressed (p <
0.01) in response to Con A and PHA relative to the controls as 
3 3
measured by the [ H]-thymidine, [ H]-leucine incorporation and by
3
the amount of glucose consumed. The [ H]-uridine incorporation and 
the lactate release assays gave similar results to those of normal 
healthy controls.
3
Although the [ H]-uridine and the lactate release assays
failed to show a significantly depressed response, there is no
reason to expect a correlation between uridine incorporation and
that of thymidine or leucine nor between lactate release and the
glucose uptake assays.
As mentioned earlier the mitogenic response of cells is very
heterogeneous even with the strongest lymphocyte stimulants. The
incorporation of uridine into RNA is greatly increased upon
stimulation with mitogens and becomes prominent well before DNA
synthesis. The time-response curves (Section Results 3*1*5*) show
3
that the incorporation of [ H]-uridine into RNA was maximum after
3
2 days while for the incorporation of [ H]-thymidine was maximum 
after 3 days. The optimum time of incubation used for all 5 assays 
was 3 days for convenience of assaying, if however, 2 days had 
been used for the uridine assay then there may have been 
correlation. Also even though uridine uptake is increased in 
stimulated cells, it is, however not
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essential for proliferation and may be blocked with inhibitors 
without affecting DNA synthesis (Peters and Hausen, 1971)* In 
contrast the inhibition of DNA or protein synthesis, or absence 
of glucose from the medium all prevent stimulation. Another 
explanation for the uridine results is that stimulated cells 
synthesise a high proportion of both ribosomal and non-ribosomal 
RNA which is metabolically unstable and cannot be recovered (Ling 
and Kay, 1975).
Glucose is very crucial to activated cells and no 
stimulation occurs in media devoid of glucose. The lack of 
correlation between the glucose uptake test and lactate release 
was most likely due to experimental differences inherent to the 
assays employed. In the glucose consumption test the amount of 
glucose removed from the medium by stimulated cells was measured. 
This will not only include glucose used up in glycolysis (lactate 
release) but also, glucose stored in the cells as glycogen. In 
addition, glucose provides many of the intermediates needed for 
nucleic acids, carbohydrates and protein synthesis (Fodge and 
Rubin, 1973). In the lactate assay the amount of lactate released 
into the medium by stimulated cells is measured. This is not 
necessarily equivilant to the glucose removed from the medium. 
However, in the lactate release assay, lactate was released into 
the medium initially, but at later times there is re-uptake of 
lactate by the cells which was more significant as time increased 
(Wang et al, 1976). This was the most likely reason for the lack
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of correlation. This point was well illustrated by the time-
response profiles (Section 3«1«5«)« Glucose consumption increases
steadily with time till day three then increases slowly. While
lactate released into the medium increases sharply reaching a
maximum between day 2-3 then declines afterwards. Similar results
were found by Wang et al (1976) in their system.
In retrospect it would have been better to measure the
ability of stimulated lymphocytes to convert glucose into lactate 
14
by using C-glucose as a function of time rather than actually 
measuring the amount of lactate released.
It is difficult to compare the results of this study with 
reports by other groups of researchers as the details of the 
assays are often not reported or vary from the ones used here. 
Hoffman et al (1978) found that, in response to PHA and Con A, 2 
out of 11 Guamanian MND patients had decreased responses, as
3
measured by [ H]-thymidine incorporation, and in the same study 3 
out of 3 non-Guamanian MND patients showed a normal response. A 
significantly depressed mean response by lymphocytes of 9 MND
3
patients to PHA was reported by Behan (1979) as measured by [ H]-
3
leucine incorporation but not with [ H]-thymidine incorporation.
More recently, Bartfeld et al (1982) found that the mean 
responses of PBL from 96 MND patients, tested with PHA or PWM,
3
were comparable to those of age-matched controls; [ H]-thymidine 
uptake was followed. Antel et al (1982) found similar results 
with the Con A and PHA reponses of 11 MND patients.
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However, the results of this study with non-specific 
mitogens give evidence for immune cell abnormalities in MND 
patients.
The investigation into MS was undertaken to study the 
response of MS PBL to mitogens under the previously stated 
conditions to observe if a depressed response would be measured 
as in the case of MND PBLs. MS is a disease with a possible 
autoimmune cause. The nature of the MS peripheral blood response 
to various mitogens is still unclear. Many reports found it not 
to differ from that of normal control populations, or of other 
patients with neurological diseases. The mitogens investigated 
were Con A, PHA, PWM, and purified protein derivative (from 
tuberculin mycobacteria) and the clinical disease activity was 
also found not to affect the lymphocyte response .
Some studies have, however, shown a decrease in the PBL 
response to mitogens in MS. A few of these studies were confined 
to older patients who had had the disease for many years. In 
other studies the decrease was found when the MS patients were 
compared to healthy normals but not with neurological diseases 
(See Introduction Section 2 for more details).
The response observed in this study was compared to normal 
healthy controls, age and sex matched, as there were no available
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samples of the correct age with neurological disease. The 
stimulation by Con A and PHA of lymphocytes from 10 MS patients
3
was found to be significantly depressed as measured by the [ H]-
3
thymidine, [ H]-leucine, glucose and lactate assays. The 
decreases probably result from a defect in the T-cell immune 
functions, possibly the T-cell suppressor subset, which has been 
reported to be decreased when the disease is active (Huddleston 
et al, 1979; Huddleston et al, 1982).
4.2. Neuronal Membranes j_ Stimulation of Lymphocytes
4.2.1. The Morphology and Characteristion of Rat Spinal Cord 
Cells
The conditions used for the rat spinal cord cell cultures 
enable the cells to grow and remain viable for 3 weeks. The 
cultures contained low numbers of contaminating non-neuronal 
cells as shown in Figure 3*11 (d); a result attributable to the 
use of serum-free medium from day 3 onwards. The serum-free 
medium used here was based on that of Bottenstein and Sato (1979) 
and as modified by Digby et al (1985).
The prior addition of serum-supplemented medium to the 
tissue plates for 1 h and its use for the first 3 days of culture 
was essential for cell attachment. Similar requirements for serum 
have been reported by others (Faivre-Bauman et al, 1961; 
Bottenstein et al, 1980; Messer et al, 1981) for successful cell 
culture. This initial period of culture in serum-supplemented
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medium was also essential for the long term culture of the cells. 
The lack of serum in the early days results in early cell death. 
The growth and migration of cells was rapid and neuronal clusters 
were seen, rather than individual neurones.
Confirmation of the identity of neurones was achieved by
their specific labeling with mouse antineurofilament antibodies
and tetanus toxin. Tetanus toxin is a marker for neurones (Mirsky 
et al, 1978; Vulliamy et al, 1981). Although the neuronal class 
could not be specified. The presence of cholinergic neurones in 
such cultures was confirmed by Digby et al (1985) with the 
measurement of the activity of enzymes choline acetyltransferase 
and cholinesterase of which the former is believed to be a marker 
for cholinergic neurones (Gombos et al, 1982) and is present in
the motor neurones of the anterior horns (Weil et al, 1977)* The
levels of both of these enzymes reached maximum values between 
days 15-20 of culture. Glycine receptors has also been reported 
(Digby et al, 1984) to increase in parallel with the maturation 
of these cultures providing further evidence for the presence of 
neuronal cells.
4.2.2. Stimulation of MND Lymphocytes with membranes from Rat 
Spinal Cord Cell Cultures
The direct stimulation of lymphocytes with membrane 
fragments from these cultures resulted in the lymphocytes from 4 
out of 14 MND patients showing stimulation indices of greater
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than 3. in contrast to 0 out of 9 age-matched controls. These
3 3
results were obtained with the [ H]-thymidine, [ H]-leucine,
3
[ H]-uridine and lactate assays.
These results indicate that some MND lymphocytes are 
sensitized to neural membrane components. Bartfeld et al (1982) 
found that the LMIF responses of MND leucocytes to subcellular 
brain antigens were significantly inhibited for MND cells exposed 
to either frontal lobe fraction PI (nuclei, cell debris and 
membrane fragments) or fraction P2 (synaptosomes).
These MND-specific responses, together with the reported 
anti-nuclear antibodies in sera are suggestive of a specific 
immune response in the disease.
4.2.3* Use of Serum-Free Medium for Peripheral Blood Lymphocytes
The use of serum-free medium for lymphocyte stimulation 
studies was investigated as a preliminary study to the culture of 
lymphocytes in Petri dishes already covered with a monolayer of 
rat spinal cord cells (15 day old). Lymphocyte tissue culture 
media are commonly supplemented with serum (Forsdyke, 1973; 
Hirsberg and Thorsby, 1975)• However the use of serum introduces 
many variables such as different serum lots, sources (Hayry and 
Defendi, 1970) and concentrations (Melchers and Andersson, 1974). 
Serum can even inhibit growth of lymphocytes (Ivanyi et al,1973) 
and components of the serum can react with substances whose 
effects on lymphocytes have been studied (Yachnin et al,1980;
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Needleman et al, 1981).
The rat spinal cord cells are only cultured in serum- 
supplemented medium (SSM) for the initial 3 days. After that 
period the medium is changed to serum-free medium (SFM). 
Otherwise the rat spinal cord cells become overgrown with 
fibroblasts (Digby et al, 1985).
Several serum-free tissue culture media have been reported 
for culturing lymphocytes from human (Spieker-Polet, 1976; Arai
et al, 1977; Hsia et al, 1979; Needleman and Weiler, 1981) mouse 
(Iscove and Melchers, 1978) and chicken (Kirchner and Oppenheim, 
1972) and hybridoma cell lines (Chang et al,1980; Farrant et al, 
1981). There have, however, been only two reports of culture of 
B-cells in serum-free medium; one was in the mouse (Iscove and 
Melchers, 1978) and the other (Tanno et al, 1982) in human 
peripheral blood lymphocytes surviving and maturing to IgG and 
IgM secretion. The latter group replaced fetal calf serum with 
albumin, transferrin, insulin and fibronectin and this was 
sufficient for extensive B-cell growth.
The serum-free medium used in the present study was the 
lymphocyte culture medium without fetal calf serum but 
supplemented with bovine serum albumin; human transferrin; 
insulin; biotin; thyroxine; hydrocortisone; sodium selanite; 
putresceine and progesterone. This medium was very similar to 
that used by Digby et al (1986).
Whereas neither Con A nor PHA gave reasonable stimulation,
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PWM gave a stimulation comparable to that with medium containing 
fetal calf serum. These results can be explained if serum-free 
medium supports B-cell growth rather than T-cell growth (Tanno et 
al,1982).
4.2.4. Coculture of MND Lymphocytes with Rat Spinal Cord Cell 
Cultures
The sensitisation of PBL from MND lymphocytes to rat spinal 
cord membrane fragments indicated that there may be some 
component on the membrane that was responsible for an immune 
response. The suggestion that the membranes might be contaminated 
and responsible for this sensitisation prompted the investigation 
into the co-culture of the rat spinal cord cells and the MND PBL. 
Serum-free medium was used for the co-culture of MND lymphocytes 
with rat spinal cord cells. The stimulation was measured by the
3 3 3
incorporation of [ H]-thymidine, [ H]-uridine and [ H]-leucine
into DNA, RNA and protein respectively. When the lymphocyte 
6
number was 1 x 10 /ml the stimulation was significant in the case 
of MND patients when compared to age and sex matched healthy 
controls. This was the case with all the MND patients 
investigated indicating that only these lymphocytes had become 
sensitised to a particular component on the rat spinal cord cell 
surface. The serum-free medium was not favourable for T-cell 
responses, and this observation indicates that the sensitisation
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is as a result of B-cells.
4.3. Monoclonal Antibody Studies
The study of the MND lymphocyte response to rat spinal cord 
membrane fragments showed that lymphocytes from 4 out of 14 MND 
patients gave stimulation indices of greater than 3* This was in 
contrast to 0 out of 9 age-matched controls, as measured by 
uptake of thymidine, uridine, leucine or lactate release and that 
3 out of 3 MND patients lymphocytes showed stimulation indices of 
greater than 3 when directly cultured with rat spinal cord cells 
in culture (see Results Section 3.1.12). In view of these 
findings and those previously reported by Digby et al (1984, 
1985) in our department that serum from MND patients was shown to 
contain antibodies that bind specifically to rat spinal cord 
cells in culture seems to suggest that there may be an immune 
response to neural component(s) in MND patients.
The maintenance and development of many autoimmune disorders 
relies an autoantibodies. There are many examples of this, such 
as the acetyl choline receptor in myasthenia gravis, IgG in 
rheumatoid arthritis and nuclear components in systemic lupus 
erythematosus. The majority of these autoreactive antibodies are 
polyclonal, which hinders investigation into their structure, 
specificity, and pathogenic role. In the present investigation
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into MND as a possible autoimmune disorder, autoantibodies could 
provide the key to the precise nature of the antigen or antigens. 
In myasthenia gravis, the identification of the acetyl choline 
receptor as the autoantigen was a very important finding, 
enabling increased understanding of its aetiology and 
pathogenesis (Harrison and Behan, 1986). If one could 
characterise the autoantibodies in MND then the auto reactive 
antigen may be revealed, giving valuable information about the 
nature of the disease.
This induced the investigation into human monoclonal 
antibody production from MND patients and the hybridoma 
technique of Kohler and Milstein (1976) gave the opportunity to 
study antibody production in MND.
This procedure would provide monoclonal antibodies instead 
of polyclonal, with no problems of heterogeneity yielding large 
and inexhaustive supplies. Also when investigating the immune 
response the availability of a battery of monoclonal antibodies 
would enable the primary antigen to be distinguished from the 
secondary in the disease. The detection of the antigen would be 
made easier hence enabling its possible purification by 
immunoaffinity. Once the antibody responsible for the disease is 
detected and purified then there may be a possible diagnostic 
value in the production and use of anti-idiotypic antibodies.
Human hybridomas are harder to make than rodent ones. Only a 
few papers have reported the production of human-human hybridomas
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and relatively few deal with technical details (see Introduction 
Section 5)* The human cell lines used in human-human fusions are 
usually Epstein-Barr virus negative. This is because the Epstein- 
Barr antigen transforms B-cells and it is not desirable to have 
fused and transformed cells together because one cannot 
differentiate between the two. There are no commercially 
available non-secreting human myeloma or lymphoblastoid cell 
lines.
There are many technical aspects to be taken into 
consideration, including the myeloma cell line used, the fusion 
method, selection of hybrids and the identification of antigen- 
reactive hybrids, subcloning and finally large scale production.
Several different procedures were investigated for the 
production of human monoclonal antibodies with PBL from MND 
patients, MS patients and normal healthy controls. The first of 
which was the direct fusion of human lymphocytes with a non­
immunoglobulin secreting mouse myeloma cell line due to the lack 
of a reliable non-secreting human myeloma cell line. The 
production of human-human hybridomas was not attempted.
The choice of myeloma cell line was straight forward. The 
mouse myeloma X63“Ag8.653 was chosen as it does not secrete 
immunoglobulin and is easily maintained in culture with a 
doubling time of 18-20 hours (Kearney et al, 1979)* The use of a 
secreting myeloma cell line would result in hybrids producing
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mixed immunoglobulins and would only hinder the investigation.
The fusion protocol has been outlined in the Methods Section
2.2.9. However the best results were obtained when the media were 
o
warmed to 37 C and all the steps of the fusion were carried out 
o
at 37 C. Human peripheral blood lymphocytes are very susceptible 
to cell death when not kept at this temperature. A ratio of 1:1 
human peripheral blood lymphocytes to mouse myeloma was found to 
give good results (Olsson et al, 1983)• Many different PEGs are 
used in fusions, all with different molecular weights. The 
toxicity of PEG 4000 was tested and this was subsequently used.
The MND fusions produced 50# of wells with growth and 18# of these 
were antigen-reactive secreting 80# IgG and 18# IgM. The MS 
fusions produced 11# of wells with growth of which 4# were 
antigen-reactive secreting J5% IgG and 15# IgM. The normal 
fusions produced 50# of wells with growth, secreting 80# IgG and
15% IgM.
The second method was the prior stimulation of the 
peripheral blood lymphocytes in vitro with PWM before fusion. 
Astaldi et al, (1981) and Olsson et al, (1983) reported that this 
gave optimal recovery of antibody producing cells, increasing the 
numbers of B-cells actively dividing when the cells were 
stimulated over 5 days. This protocol was undertaken because of 
the low numbers of B-cells recovered from peripheral blood about 
30# of the total number of cells and even lower numbers due to 
the age of the MND patients and finally to compare with the
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direct fusion of the cells. The blood samples used came again 
from MND, MS patients and normal healthy controls. On the whole 
the results were comparable, to the fusions performed without 
prior stimulation with PWM. There were similar numbers of wells 
producing colonies (50%) and similar numbers secreting IgG (80#) 
and IgM (15%). The number of antigen-reactive clones seemed 
greater in the PWM stimulated fusion but not significantly so. 
The MND produced lQ% antigen-reactive clones; MS, h% antigen- 
reactive clones and the normal samples gave no antigen-reactive 
clones with either assay yet the majority secreted 
immunoglobulin. The stability and immunoglobulin secretion were 
also very similar, so, on the whole, the stimulation with 
pokeweed mitogen did little except increase the number of cells.
The third method employed for the production of monoclonal 
antibodies was using Epstein-Barr virus (EBV). The greatest 
advantage of using this system are that it is possible to 
immortalise a high percentage of antibody-producing cells, with 
no chemical selection. The main disadvantages are the so-called 
unstability of the transformed cells. However, many such reports 
concern bulk cultures and even mouse-mouse hybrids lose their 
immunoglobulin production under such conditions. Many reports 
suggest preselection of B-cells with the appropriate, antigen- 
binding specificity as one of the major steps in the 
transformation. This is to avoid the possibility that non­
antibody producing cells would transform and outgrow the required
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cells (Steintz et al, 1978; Steintz et al, 1980; Kozbor and 
Roder, 1981; Steintz, 1981; Campbell, 1985)•
MND, MS and normal peripheral blood lymphocytes were 
cultured with the Epstein-Barr virus after stimulation with PWM 
for 5 days as suggested by Olsson et al (1983), to increase the 
number of B-cells. This was advantageous as the number of PBL 
isolated from MND patients was often very low because of the age 
of the patient.
The transformed cells grew more quickly than did the
hybridisation clones; growth was observed after only a matter of
days and after 2 weeks there were over 90# of wells with growth 
for MND, MS and normal peripheral blood lymphocytes. There was no 
preselection as the possible auto-antigen in MND is unknown so 
the screening of the transformed cells was carried out as quickly 
as possible before overgrowth could take place. The 
immmunoglobulin secretion was still low (around 250 ng/ml). This 
has been shown to be increased when preselection was performed 
(Steintz et al,198l). There were 50# secreting IgG and 50#
secreted IgM. This was different from the mouse-human fusions
described above where the majority of hybrids secrete IgG. The 
number of clones secreting the desired antibody detected was 
about 5# of the colonies formed for MND and MS. The majority were 
recloned by limiting dilution rather than by cloning in agar 
(Goding, 1980) because agar gives lower cloning efficiency and 
the resulting colonies are not always pure clones. The cells were
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recloned at cell concentrations of 50, 5. and 0.5 cells/well of
which the 5 cells /well gave about 50% of wells with colonies and 
these were rescreened for positives which were kept in culture in 
flasks and remained stable for 3 months. The procedure of prior 
stimulation with PWM increased the number of B-cells but whether 
the cells should be transformed or fused needs further 
investigation.
Many of the human secreting cells made immortal by 
transformation are ’back fused’ (Campbell, A.,1985; Thompson et 
al, 1986). This may only be a safeguard as the reports of loss of 
secretion are worrying and it is better to be safe than sorry. 
The back fusion involves the fusion of the desired transformed 
cell line with either a mouse or human myeloma cell line. 
Transformed cells fuse exceptionally well as they are growing and 
replicating fast. These ideas indicate there is still much work 
to do with the cell lines produced in this research project.
The antibody screening methods employed were mainly enzyme 
immunoassays. These are safer to use than radioimmunoassays and 
are more suitable if many screenings are required. The immuno 
’dot’ assay measured immunoglobulin secretion and gave reasonable 
results for sensitivity but often it was too sensitive detecting 
more than one immunoglobulin secreted/well indicating that more 
than one colony started to grow. This then led to the use of the 
CELIA which was also sensitve but the results were often
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inconsistent from day to day. Finally, the double antibody 
sandwich ELISA gave the most consistent and sensitive results for 
measuring antibody class and concentration.
An ELISA was developed for the detection of antigen-reactive 
colonies in MND and MS. The assay only differed in the coating of 
the wells. For the MND, membrane fragments prepared from rat 
spinal cords were used to detect any antibodies directed against 
spinal cord components. This was chosen because of our finding 
that MND lymphocytes showed an immune response to rat spinal cord 
cell cultures and Digby et al (1984, 1985) showed immunoglobulin
binding to such cells. The use of actual cultured cells for an 
ELISA presented too many technical difficulties with the 
availability of material being limited so the use of adult rat 
spinal cord membrane fragments was undertaken. This ELISA was 
rapid and could allow the partial identification of the antigen 
through absorption assays, i.e., using glycolipids or 
glycopeptides. In the MS assay the coating was myelin basic 
protein which is steadily destroyed in MS patients. The results 
from the clones produced when human peripheral blood lymphocytes 
were fused directly with the mouse myeloma cell line indicated 
that the screening methods worked and that there was no cross­
reactivity between MS immunoglobulins and MND immunoglobulins. 
The membrane fragments used in the MND clone screen was purified 
and probably contained very little myelin basic protein. None of 
the immunoglobulins produced by the normal clones reacted in
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either of the screening methods for colonies reactive with 
membrane fragments or myelin basic protein. None of these wells 
were antigen-reactive in each of the screening assays.
The use of florescein-labeled antibodies enabled one to 
visualise the antibodies under fluorescence optics and the part 
of the cultured rat spinal cord cells labeled. This method was 
employed with the antibodies produced by all three previously 
described methods and from MND, MS and normal healthy controls. 
There was no clear labeling of the cells by any of the antibodies 
produced even after the antibodies were concentrated. This may 
have been due to the antibodies being of low affinity or even 
after concentrating the amount of relevant antibody was still at 
too low a concentration.
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4.4. Is MND an Autoimmune Disorder?
The etiology in MND is still unknown. There has been 
intensive research into the disease over the past decade and this 
has revealed many possibilities as stated in the Introduction. 
However, because Motor Neurone Disease is a highly specific 
disorder causing the degeneration predominantly of the motor 
neurones this makes MND an attractive model an autoimmune 
disorder. Therefore, the possibility has been investigated for 
years but many workers report conflicting results when 
investigating cell-mediated immunity, immune factors, and viral 
involvement.
The usual indices of abnormality in the immune system, the 
serum immunoglobulin and complement levels, and peripheral 
blood cell counts have all been reported normal. The CSF however, 
is usually normal in these cases but there have been reports of 
increased protein levels indicative of blood brain barrier 
damage. Immune involvement in MND is implicated by the detection 
of immune complexes in sera, spinal tissues and renal tissues. 
However, the in vitro responses to non-specific mitogens are 
conflicting as various groups of workers find diferent results. 
The peripheral blood MND B-cell and T-cell counts have been 
reported to be normal. There have been many reports of potential 
auto-antibodies but many are controversial. These vary from 
myelintoxic antibodies, antibodies to neurofilament antigens, and
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neurotoxic factors in MND sera, immunoglobulin binding from MND 
sera to rat spinal cord cells and that these sera recognise a 
muscle derived protein.
This may take place by attack on the membrane of neurones by 
antibodies of receptor(s), glycolipids, or glycoproteins. There 
may even be antibodies to a trophic factor preventing the 
maintenence and development of the motor neurones.
The results from this study show a depressed response of MND 
lymphocytes to PHA and Concanavalin A as compared with normal 
healthy controls. The controls were age and sex matched 
indicating the response was not related to age. However, the lack 
of neurological controls led to the study being compared to 
normality. Other workers have compared there results with MND PBL 
to other neurological diseases and no depressed response was 
observed indicating that the response seen in this study may be 
a general phenomenon of all neurological diseases and not 
specific for MND.
The responses of the MND lymphocytes to rat spinal cord cell 
culture membrane fragments, indicates that they were sensitised 
to the cells. Also, when the cells were co-cultured sensitisation 
was indicated suggesting an immune response to neural cells. 
Whether this immune response is the cause of the disease or just 
secondary, resulting from the breakdown of the motor neurones 
releasing neural material is questionable. Possible ways of 
investigating the auto-antigen was through the production of
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monoclonal antibodies. This study was however, inconclusive, 
monoclonals could be produced and detected against spinal cord 
membrane fragments but when trying to visualise the cells by 
immunofluorscence to determine which part of the cells these 
antibodies were directed, nothing could be observed. This study 
is worthwhile as the autoantigen once detected could allow the 
use of experimental animal models for future work.
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SUGGESTIONS FOR FUTURE WORK
The two main findings of this study are that MND lymphocytes 
have a depressed blastogenic response to the mitogens Con A and 
PHA and that there is significant stimulation of such cells with 
rat spinal cord membranes compared to normals. The stimulation of 
MND lymphocytes when cultured with rat spinal cord cells 
indicates that these cells .may be sensitised to neural 
components. Digby et al (1984, 1985) also reported that there is 
specific binding of immunoglobulin from MND sera. These results 
suggest that there is a specific immune response in this disease. 
This may be primary or secondary to immune attack of another 
target.
The major way forward is to characterise the target 
antigens(s) responsible for both the antibody binding and the 
lymphocyte activation. The antigen(s) may be glycoprotein, 
glycolipid or even receptors on either the membrane surface or 
intracellular. The neural membranes used for lymphocyte 
activation studies should be of human origin rather than rat. 
Further investigation into the antigen responsible could result 
from the neural membranes being fractionated into their various 
membrane consituents e.g. glycolipid or glycoprotein. This being 
subsequently used in lymphocyte activation of MND patients PBL or 
antibody binding of MND sera yielding a certain component 
responsible.
The lipids could be extracted from the membrane fragment 
preparation by chloroform-methanol mixtures or by ethanol, and
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then partitioned in a biphasic chloroform-methanol-water system. 
Most of the lipids are contained in the lower chloroform-methanol 
layer whereas the gangliosides and larger neutral 
glycosphingolipids remain in the upper water-methanol layer. 
Gangliosides can be separated from uncharged glycolipids on 
columns of DEAE-cellulose, while further purification of all 
glycolipids is usually performed on column and thin-layer 
chromatography.
Membrane glycoproteins can be difficult to obtain in a 
soluble form free from solubilizing agent without denaturation or 
aggregation. Some however, can be obtained in water soluble 
forms e.g. glycophorins. When like glycophorins membrane 
glycoproteins can be extracted into aqueous solution, then 
further purification can be carried out by standard techniques of 
protein chemistry. Many glycoproteins can only be extracted in 
the presence of detergent (triton, sodium dodecyl sulphate), 
organic solvents, or chaotrophic agents. Therefore procedures 
have been developed for further fractionation in the presence of 
the solubilising agents such as affinity chromatography using 
lectins and ion-exchange.
The production of human monoclonals from MND patients could 
enable one to identifiy the target antigen(s). The fractions of 
membrane fragments could be used when screening. The use of 
Epstein-Barr virus transformation of the cells with the prior
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stimulation with PWM would allow for a greater number of colonies 
being produced and growth would be quicker than fusing with a 
mouse myeloma where growth can take up to 6 weeks. The increase 
in the production of colonies by this method compared to mouse- 
human fusions gives a greater chance of obtaining the required 
clone. After the desired clone has been detected and recloned by 
limiting dilution then ’back* fusion with a mouse myeloma non­
secreting cell line would safeguard against the loss of 
secretion.
The production of monoclonal antibodies by in vitro methods 
could be undertaken. The MND peripheral blood lymphocytes would 
be incubated with the human neural membranes prior to the fusion 
with a non-secreting mouse myeloma cell line. This would allows 
the number of antigen-sensitised cells to proliferate prior to 
the fusion hence increasing the number of cells secreting the 
desired antibody being fused.
The use of serum-free media could be investigated for 
raising monoclonals. Serum-supplemented media are expensive and 
large quantities of medium are used from the initial fusion to 
the completion of recloning when raising monoclonals. It would be 
extremely benefical if serum-free media could be used. Peripheral 
blood lymphocytes have been shown in this study to proliferate in 
culture without serum. Therefore in principle, monoclonals (B- 
cell) could be established in serum-free media if the myeloma 
cell line could also be maintained in such media.
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The antibody produced by the immortalised, sensitised B- 
cells from MND patients could then be purified by protein A 
affinity chromatography and then affinity columns could be made 
with the relevant monoclonal and enable large quantities of the 
target antigen to be purified. Once the antigen is produced in 
reasonable amounts then this could be used to induce an 
experimental model of the disease.
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Summary
Stimulation of lymphocytes from m otor neurone disease patients by either 
concanavalin A or PHA was shown to be significantly depressed relative to that 
from normal controls, as assayed by incorporation of [3H]thymidine or [2H]leucine 
or by glucose uptake. Corresponding significant differences were not shown by 
assays based upon incorporation of [2H]uridine or of lactate release. Lymphocytes 
from 4 out of 14 motor neurone disease patients showed a blastogenic reponse to 
membranes from rat spinal cord cells, compared with those from 0 out of 9 normal 
controls. These results not only suggest the possibility of an impaired cellular 
immune control in M ND patients but also indicate the presence of lymphocytes 
sensitised specifically to neuronal membrane components.
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Introduction
M otor neurone disease (M N D) is a chronic progressive disorder characterised by 
degeneration of the anterior horn cells in the spinal cord and, in some cases, of the 
pyram idal cells of the cerebral cortex. The pathogenesis and aetiology of the disease 
are unknown. One aspect that is currently receiving renewed attention is a possible 
involvement of the immune system; an area in which both clinical and laboratory 
studies have produced many equivocal findings (for reviews see Rowland 1982; 
Clifford Rose 1984). However, early reports of a serum-borne neurotoxic factor in 
M N D  patients (Wolfgram and Myers 1973) have recently been confirmed by Roisen 
et al. (1982) and we have shown that M N D  sera contain immunoglobulins that bind 
to spinal cord cells in culture (Digby et al. 1984, 1985). Very recently G urney and his 
colleagues (Gurney and Apatoff 1984; G urney et al. 1984) have dem onstrated the 
presence in M ND sera of autoantibodies directed against a muscle-derived growth 
factor for spinal neurones.
Investigations of immune cells in m otor neurone disease have produced conflict­
ing data. Thus total T cell count and T cell subsets (suppressor/helper ratios) have 
been reported unchanged in M N D  patients (Antel et al. 1982; Bartfeld et al. 1982) 
compared to normal controls whereas T cell subsets as determined by the expression 
of receptors for Fey and Fqu were found by Westall et al. (1983) to be significantly 
different in such patients. Depressed responses to non-specific mitogens have been 
reported by some workers (Hoffman et al. 1978; Behan 1979) but other groups 
found no such effects (Antel et al. 1982; Bartfeld et al. 1982). In initial studies, we 
observed a decreased response of total peripheral blood lymphocytes from M ND 
patients compared with matched controls in assays using non-specific mitogens 
(Digby et al. 1984). The present study confirms these findings and extends our 
investigation to an examination of lymphocyte responses to m embrane preparations 
from cultured spinal cord cells.
Materials and Methods
Patients
Eighteen patients (14 males, 4 females) were investigated in this study. The age 
range was from 40 to 80 years with a mean ±  SD of 61.1 ±  9.8 years. Diagnosis of 
M N D  was based on a combination of both upper and lower motor neurone findings 
coupled with EM G changes characteristic of denervation. Normal controls (20) were 
age- and sex-matched as far as possible; the age range was 41-77 years with a mean 
+  SD of 55.6 +  9 years.
Lymphocyte preparation
Fresh heparinized venous blood was mixed with an equal volume of Dulbecco’s 
Ca2+- and M g2+-free phosphate-buffered saline (PBS) (Flow Labs., Irvine, U.K.) 
and carefully layered onto a Ficoll-Hypaque gradient (Flow Labs.). After centrifuga­
tion at 400 X g for 40 min, the mononuclear cell layer at the interface was carefully
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removed and washed 3 times with PBS (20 ml). Cells were resuspended at 1 X 106 
cells/m l in RPMI 1640 medium (Flow Labs.), supplemented with 100 un its/m l 
penicillin; 100 jag/ml streptomycin; 2 mM L-glutamine and 10% heat-inactivated 
foetal calf serum (Gibco, Uxbridge, U.K.). Cells used for [3H]leucine incorporation 
studies were resuspended in leucine-free Eagle’s minimum essential medium (Gibco) 
supplemented as above.
Mitogen stimulation
Samples (100 jal; 1 X 10s cells) of the lymphocyte cell suspension were placed in 
the wells of U-bottomed microtitre tissue culture plates (Nunc, Gibco, Uxbridge, 
U.K.). An equal volume of the complete medium containing the appropriate 
concentration of concanavalin A, phytohaemagglutinin (PHA) (both from Pharmacia, 
Hounslow, U.K.) or membrane fragments (see below) was added. Control cultures 
received complete medium only. Cultures were incubated in a humidified atm o­
sphere of 5% C 0 2 in air at 37°C for 72 h. Experiments were performed in triplicate 
for each preparation.
Glucose consumption assay
This was carried out according to De Cock et al. (1980). At the termination of the 
culture period, samples (100 jal) of the supernatant were removed from both 
stimulated and control cultures. The amount of glucose present was measured by 
using a glucose oxidase assay kit (Boehringer, Mannheim, F.R.G.). Lymphocyte 
stimulation was expressed as the difference between glucose used by control and 
stimulated cells.
Lactate assay
This procedure is similar to that described for the glucose assay. The lactate 
content of samples of supernatant from both control and stimulated cultures was 
assayed by using a lactate test combination kit (Boehringer, Mannheim). Stimulation 
was expressed as the difference in the lactate content of the supernatant from the 
stimulated and control cells.
Incorporation o f [ ^H]thymidine, [ 'H] uridine and [ H]leucine
At the appropriate time, cultures were exposed to radiolabelled precursor for 18 
h. The precursors (0.2 jitCi) were added in RPMI 1640 medium (10 jul). Cells were 
harvested and the acid-precipitable radioactivity was measured in a liquid scintilla­
tion spectrometer (Packard Tri-Carb, Packard Instruments, Reading, U.K.).
Lymphocyte stimulation was expressed as log (cpm slimulated — cpm contro, ) or as the 
stimulation index (cpm stimulated/c p m control), where control refers to the test sample 
incubated in the absence of mitogen.
Rat spinal cord cell culture
14- to 16-day-old rat embryo spinal cord cells were cultured as described earlier 
(Digby et al. 1985). Briefly, a single cell suspension of spinal cords was prepared by 
mincing and trypsinization. 1.5 X 106 cells were seeded on collagen-coated 3.5-cm
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Petri dishes (Nunc, Gibco) in Dulbecco’s modified minimum essential medium 
(DM EM ) supplemented with 10% heat-inactivated foetal calf serum (Gibco), 10% 
heat-inactivated donor horse serum (Flow Labs.), penicillin (100 un its/m l), strep­
tomycin (100 jiig/ml), 2 mM L-glutamine and glucose (1.5 m g/m l). The cultures 
were incubated in 10% C 0 2/a i r  at 37°C. After 3 days the medium was replaced with 
a serum-free medium which lacked the serum supplement but contained the follow­
ing reagents: insulin (0.2 units/m l), transferrin (5 jug/ml), 20 nM progesterone, 100 
juM putrescein, 30 nM sodium selenite, 0.5 juM hydrocortisone, biotin (1 jug/m l) and 
thyroxine (3 jug/ml). All reagents were from Sigma Co., Poole, U.K. This medium 
(SFM) was subsequently changed every 3 days.
The preparation o f crude membrane fractions from spinal cord cultures
Cells from 15- to 17-day-old cultures were scraped from the surface of the Petri 
dishes using a Teflon-coated spatula and 2 aliquots (50 jul) per dish of 0.3 M sucrose 
in 5 mM T ris /H C l buffer, pH 8.0. The mixture was homogenised by using a glass 
homogeniser and centrifuged at 1000 X g for 10 min. The nuclear pellet was 
discarded and the supernatant was centrifuged at 15 000 X g for 30 min at 4°C. The 
supernatant was discarded and the pellet homogenised in 5 mM T ris /H C l buffer, 
pH 7.4 (20 vols.) by using a glass homogeniser. The mixture was centrifuged at 
9000 X g for 20 min at 4°C. The pellet was discarded and the supernatant centri­
fuged at 48 000 X g for 20 min. The pellet was resuspended in RPMI 1640 medium 
at a final concentration of 2 m g/m l and aliquots were frozen at — 70°C.
Results
Effects of mitogen concentration and culture time on lymphocyte stimulation
Dose- and time-response curves were measured in order to establish optimum 
mitogen concentrations and culture times. Stimulation of lymphocytes was assayed 
in terms of DNA, RNA and protein synthesis by incorporation of radiolabelled 
thymidine, uridine and leucine, respectively. Lactate production and glucose uptake 
were also measured as indices of metabolic activity. Lymphocytes from 5 normal 
controls (age range 30-65 years, mean 52 years) were stimulated with increasing 
concentrations of concanavalin A and PHA and the stimulation was measured by 
each of the 5 methods after 3 days in culture. The results showed that the maximum 
response was observed in all cases with concentrations of mitogen of 10-15 p g/m l. 
In all subsequent studies 7.5 g g /m l mitogen was used.
In time-response experiments, DNA, RNA and protein synthesis, as measured by 
the incorporation of the relevant precursor, increased rapidly, reaching maximum 
values after 2, 3 and 4 days, respectively. The rate of glycolysis, measured by lactate 
release, was maximal after 3 days in culture. Glucose uptake increased rapidly up to 
3 days of culture and thereafter increased slowly. From these experiments, an 
incubation period of 3 days was chosen for subsequent studies.
M ND  lymphocytes: effects of concanavalin A and PHA
Peripheral blood lymphocytes from M ND patients and from matched controls 
were stimulated with concanavalin A and with PHA, and the results are shown in
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Fig. 1. Stimulation, by concanavalin A (a )  and PHA ( b ), of lymphocytes from patients with motor 
neurone disease and from normal controls. Values, obtained as described in the Materials and Methods 
section, are the means from triplicate assays o f lymphocytes from each individual donor and are expressed 
as the difference (in cpm or jug/m l) between test sample and that incubated in the absence of mitogen.
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TABLE 1
STIM ULATION BY C O NC ANA VALIN A A N D  PHA OF LYM PHOCYTES FROM  PATIENTS 
W ITH MOTOR N E U R O N E  DISEASE A N D  FROM NO RM AL CONTROLS
Values, obtained as described in the Materials and M ethods section, are derived from the means of 
triplicate assays of lymphocytes from each individual donor, and are expressed as the difference (in cpm  
or jug/m l) between test sample and that incubated in the absence of mitogen. There were no significant 



















(mean +  SD) 4.13 +  0.19 3.83 +  0.31 3 .9 1 + 0 .3 0 2 0 0 +  94 453 +  221
M N D
patients (18) 
(mean +  SD) 3.69 +  0.34 3.78 +  0.33 3.36 +  0.67 191 +  142 286 +  148
Significance 




(m ea n ± S D ) 3.94 +  0.23 3.74 +  0.32 3.93 +  0.32 142 +  125 579 +  224
M N D
patients (18) 
(mean +  SD) 3.35 +  0.38 3.56 +  0.32 3.57 +  0.39 1 4 1 +  83 382 +  212
Significance 
(P  =  0.01) S NS S NS S
S =  significant, NS =  not significant (Student r-test).
Fig. 1 and Table 1. The responses ot the M ND lymphocytes to both mitogens, 
measured by the incorporation of [3H]thymidine and [3H]leucine and by the 
consumption of glucose, were significantly depressed compared with the control 
group ( / ><0.01). In the case of [3H]uridine incorporation and the production of 
lactate, the values obtained for the M ND lymphocytes were not significantly 
different from those of the control group.
M ND  lymphocytes: effects o f spinal cord membranes
A membrane fraction was prepared from 15- to 17-day-old cultures of rat spinal 
cord cells. At this time the cultures consist predominantly of large clusters of 
neurones with many branching processes (Digby et al. 1985).
Preliminary experiments indicated that membrane preparations added to the 
cultures at a concentration of 50-100 jug pro tein /m l gave the maximum response 
and a concentration of 50 pg p ro tein /m l was accordingly used for all subsequent 
experiments.
Lymphocytes from 14 M ND patients (11 males, 3 females; age range 44-80 years.
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Fig. 2. Stimulation by rat spinal cord membranes of lym phocytes from patients with m otor neurone 
disease and from normal controls. Values, obtained as described in the Materials and M ethods section, 
are the means from triplicate assays of lym phocytes from each individual donor and are expressed either 
as the stimulation index (SI, ratio of cpm from test sample to that from sample incubated in absence of 
spinal cord membranes) or as the difference between lactate released from test sample and that from the 
non-stim ulated control. Patients showing SI >  3 are individually identified by letters.
mean 62.4 years) and 9 controls (7 males, 2 females; age range 35-65 years, mean 
55.3 years) were cultured for 3 days in the presence of the spinal cord membranes. It 
was found that the glucose consum ption assay gave extremely variable results in 
these experiments and no reliable data could be obtained. The other assays all gave 
consistent data which are shown in Fig. 2. Lymphocytes from normal controls were 
essentially non-reactive to the mem brane samples. The responses of the M N D  
lymphocytes were variable but samples from several patients showed stim ulation 
indices greater than unity. For assays that are based on the incorporation of a 
radiolabelled ligand, a stimulation index greater than 3 has been suggested to be 
significant (U rbaniak et al. 1978) and, by this criterion, 4 out of 14 M N D  showed 
significant stim ulation in all such assays. Lymphocytes were prepared from 2 of 
these 4 patients, 6 months later, and in both cases stimulation by the m em brane 
preparation was significantly higher than the initial value.
Discussion
The response of peripheral blood lymphocytes to non-specific mitogens is com ­
monly used as a measure of cellular immune capability. Blastogenesis is usually
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quantified in terms of incorporation of [?H]thymidine, taken as an indicator of 
DNA synthesis, but other parameters have also been used. Thus, incorporation of 
[3H]leucine (Adkinson et al. 1974; Levy and Kaplan 1974) can be taken to reflect 
protein synthesis, while early metabolic changes, particularly glycolysis, can be 
monitored by assays of glucose consumption (De Cock et al. 1980) or of lactate 
production (Cordiali-Fei et al. 1980). Various advantages have been claimed for 
these alternative assays, but that involving [3H]leucine incorporation, in particular, 
has been recommended as a more sensitive indicator of lymphocyte abnormality 
than the more common [3H]thymidine uptake assay (Levy and Kaplan 1974; Behan 
1979). In order to increase the chances of detecting abnormal responses in lympho­
cytes from M ND patients we have used all four of the above-mentioned methods, 
together with a [3H]uridine incorporation assay of RNA synthesis, to compare 
results from such patients with those from normal controls. Following a similar 
reasoning, we have examined lymphocyte stimulation in response to both PHA and 
to concanavalin A, known to activate preferentially suppressor T cells (Shou et al. 
1976). In view of the findings, in several laboratories (Malave et al. 1975; Waller and 
M acLennan 1977; Bernhard et al. 1980), that maximum differences between re­
sponses of normal and impaired lymphocytes are observed at suboptimal mitogen 
concentrations, we have employed such conditions in each assay. Time courses 
indicated that, for all assays, response to mitogen had achieved near maximum 
values at 3 days, a period which was shown to lead to greatest discrimination 
between normal and impaired lymphocytes in the studies of Bernhard et al. (1980). 
This incubation period was consequently chosen for all subsequent comparisons.
The response, to both PHA and concanavalin A, of lymphocytes from 18 M ND 
patients was significantly depressed (R cO .O l), relative to normal controls, as 
measured by incorporation of [3H]thymidine or of [3H]leucine and by glucose 
consumption.
N o significant differences between M ND lymphocytes and controls were ob­
served in the cases of [3H]uridine incorporation or lactate production. While the 
reasons for these latter results are not clear, they are not necessarily inconsistent 
with our other findings. RNA and DNA synthesis are shown by different propor­
tions of a given population of lymphocytes stimulated by PHA (Ling and Kay 1975) 
and inhibition of uridine uptake need not affect DNA synthesis (Peters and Hausen 
1971), nor is there any reason to expect that uridine incorporation should parallel 
protein synthesis. A further complicating factor is that a high proportion of RNA 
synthesised in stimulated cells is metabolically unstable and cannot be recovered 
(Ling and Kay 1975). Similar arguments apply to the assays based on glucose uptake 
and lactate production, which need not be closely linked. Whereas uptake of glucose 
reflects its utilisation in a range of both anabolic and catabolic pathways, lactate 
production might be expected to indicate specifically glycolytic activity. Moreover, 
conclusions based on lactate production are complicated by a time-dependent 
increase in lactate utilisation in stimulated cells.
Comparison with previously reported findings is difficult in that details of the 
assays vary, or are not reported. Behan (1979) reported a significantly depressed 
mean response to PHA by lymphocytes from 9 M ND patients, as assayed by
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[3H]leucine incorporation, but not by [3H]thymidine uptake. H offm an et al. (1978) 
found that 2 out of 11 G uam anian M N D  patients tested had lymphocytes hypo- 
responsive to both PHA and concanavalin A as judged by [?H]thymidine uptake; 3 
out of 3 non-G uam anian patients showed normal lymphocyte responses in these 
studies. In more recently reported findings, Antel et al. (1982) found that the mean 
responses to PHA and concanavalin A of m ononuclear cells from 11 M N D  patients 
were com parable to those of age-matched healthy controls, while Bartfeld et al. 
(1982) drew similar conclusions for lymphocytes from 96 M N D  patients tested with 
PH A or with pokeweed mitogen; in both of these latter studies [3H]thymidine 
uptake was followed. Overall, our present findings with non-specific mitogens 
provide evidence for imm une cell abnorm alities in M N D  patients that may be 
relevant to the presence of circulating autoantibodies in this disease (Digby et al. 
1985).
In view of the above and previously reported (Digby et al. 1984, 1985) results in 
which serum from M N D  patients was shown to contain antibodies that bind 
specifically to spinal cord cells in culture, we examined the effect of membranes 
from such cultures on lymphocytes from M N D  patients. Lymphocytes from 4 out of 
14 M N D  patients showed stim ulation indices greater than 3, in contrast to 0 out of 9 
age-m atched controls, as m easured by uptake of thymidine, uridine or leucine or by 
lactate release. These results are consistent with the sensitisation of M N D  lym pho­
cytes to neuronal m em brane com ponents. Bartfeld et al. (1982) com pared the 
responses of M N D  and control leycocytes to subcellular brain antigens by means of 
the leucocyte migration inhibition factor (LM IF) and found significantly greater 
inhibition for M N D  cells exposed to either frontal lobe fraction PI (nuclei, cell 
debris and m em brane fragm ents) or fraction P2B (synaptosomes). These M ND- 
specific responses to neuronal m em branes are supported by our present lymphocyte 
stim ulation data which, together with the dem onstration of anti-neuronal m em brane 
antibodies in M N D  sera, combine to indicate a specific im m une response in the 
disease. W hether an immune response to neuronal m em branes is secondary to 
imm une attack at another target, e.g. nerve growth factor (G urney and Apatoff 
1984; G urney et al. 1984) or incidental to neuronal degenerations caused by other 
m eans remains unclear.
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